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The genetic networks that regulate bacterial phenotypes are highly complex and 
incompletely understood in many cases. One such example of this is virulence, 
which is dependent on a variety of contributors including genetic, environmental 
and host factors. If we are to continue to develop new treatments and 
preventative measures against bacterial disease, it will become increasingly 
important to understand how different pathogens cause disease, and genome 
sequencing information can be of considerable use in doing so. A key aspect of 
bacterial virulence is toxicity, which is the production of proteins toxic to host cells 
that actively damage them to the benefit of the bacteria. This work uses 
functional genomics to further elucidate the genetic basis for toxicity in two 
medically important pathogens; Staphylococcus aureus and Streptococcus 
pneumoniae. Following identification of the cyoE locus as a novel effector of 
toxicity in S. aureus using a genome-wide association study (GWAS), this gene is 
shown to be involved in processing haem for incorporation into the electron 
transport chain during aerobic respiration. In its absence S. aureus respires as if 
growing in microaerobic conditions and down-regulates toxin production. The 
functional genomics approach is then extended further in S. pneumoniae, using 
three different GWAS methods in combination to aid identification of novel 
effectors of the toxic phenotype. From this, the SPN23F12470 gene is identified 
as a novel effector of toxicity in the pneumococcus, which encodes a UvrD-like 
protein with helicase and nuclease domains. Data presented here shows a 
physical interaction between this protein and regions of the genome either side of 
the pneumococcal toxin pneumolysin which may be interfering with expression of 
the toxin gene. Functional genomics is therefore shown to be a useful approach 
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Bacterial virulence is a highly complex and multi-faceted phenotype which 
encompasses the many aspects of a bacterium’s ability to cause disease. Here, 
the term ‘virulence’ is used to refer to factors which can be broadly classified into 
three groups based on their functions in different stages of disease, namely: 
factors associated with colonisation and invasion of host tissues; factors involved 
in evasion of the host immune system; and toxic factors involved in actively 
damaging host cells.  
The work presented in this thesis builds on previous research by our group to 
contribute to a better understanding of the genetic basis for a key aspect of 
bacterial virulence; toxicity. In previous work by Laabei et al. (2014; 2015), a 
genome-wide association study (GWAS) was conducted on large collections of 
clinical Staphylococcus aureus isolates which led to the identification of novel 
genetic loci that contribute to toxin production in this species. The work presented 
here follows on from this project with the detailed characterisation of one of these 
loci, extension of the approach to the bacterium Streptococcus pneumoniae, and 
finally with the characterisation of a novel toxicity-affecting locus identified in S. 
pneumoniae. 
This approach, starting with whole genome sequence data and ending with the 
characterisation of a toxicity-affecting gene, is referred to as functional genomics. 
The results presented here demonstrate how this approach has been 
successfully used in two bacterial species to identify novel toxicity-affecting 
genetic loci, starting with characterisation of the GWAS-identified locus cyoE in S. 
aureus, which has not previously been reported to be involved in bacterial 
toxicity. In S. pneumoniae, the approach was extended to include a range of 
GWAS methods which were used in combination to pinpoint more accurately 
those loci which are associated with the toxic phenotype. This resulted in 
identification of the uvrD-like gene SPN23F12470, which showed a reduction in 
toxicity when knocked out, and is subsequently characterised to elucidate its 
effect on toxin production in S. pneumoniae.   
Staphylococcus aureus and Streptococcus pneumoniae are medically important 
pathogens, both of which can survive as harmless commensals in the human 
11 
 
host, but which can also transition to opportunistic pathogens in certain 
circumstances. Both species occupy a similar niche within the host, living in the 
nasopharynx in their commensal state (Bogaert, de Groot & Hermans, 2004; 
Wertheim et al., 2005), and are known to compete for colonisation of this area 
(Park et al., 2008). There is a substantial difference in toxin production between 
the two species, with Staphylococcus aureus possessing fifteen known toxins 
employed in different types of disease, while Streptococcus pneumoniae has only 
one known toxin. However, the work presented here demonstrates that toxin 
production in both species relies on a complex network of genetic contributors 
outside of the well-characterised toxin genes, which is not yet fully understood. 
1.1.0 From commensal to virulent pathogen 
A characteristic feature of both S. aureus and S. pneumoniae is their ability to 
transition from commensal to opportunistic pathogen within the human host. S. 
aureus can be commonly found in the nasal passages of around 20-30% of the 
population (Gordon & Lowy, 2008) as a commensal, but can become the cause 
of opportunistic infections within the host when the immune system becomes 
compromised through illness, injury or surgery. Staphylococcal infections can 
range from mild skin and soft tissue infections, to serious invasive disease 
including pneumonia, meningitis and septicaemia. Likewise, S. pneumoniae is 
commonly carried in up to 60% of young children (Henriques-Normark & 
Normark, 2010) and 2-20% of adults (Regev-Yochay et al., 2003; Hussein et al., 
2005; Henriques-Normark & Normark, 2010), but can cause a range of diseases 
including sinusitis, otitis media and the more invasive pneumonia, meningitis and 
septicaemia. Both can also be responsible for device-associated infections due to 
their ability to form biofilms on surgical implants, ventilators and catheters, for 
example (Rosenthal et al., 2006; Liu et al., 2012; Haque et al., 2018).  
As commensals, these bacteria form part of the normal nasopharyngeal 
microflora which can act as barriers to other species of potentially pathogenic 
bacteria attempting to colonise the host. A stable balance is maintained through 
interactions between commensal bacteria, viruses and the host immune system, 
and its constituents vary greatly between individuals (Shak et al., 2013). Selective 
pressures such as the use of antibiotics and vaccines can also heavily influence 
the make-up of this ecosystem (Vergison, 2008). Competition for colonisation of 
this niche takes place predominantly between species of the families 
Moraxellaceae, Streptococcaceae, Corynebacteriaceae, Pasteurellaceae and 
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Staphylococcaceae (Shak et al., 2013). A number of studies have revealed an 
inverse correlation between carriage of S. pneumoniae and S. aureus (Chien et 
al., 2013; Regev-Yochay et al., 2004; Bogaert et al., 2004), with the 
pneumococcus inhibiting growth of staphylococci through production of hydrogen 
peroxide, to which S. aureus are sensitive (Regev-Yochay et al., 2006).   
In a healthy host, these interactions usually prevent one bacterial species 
dominating the ecosystem and invading host tissues. On occasion, normally 
commensal bacteria cause infection in an otherwise healthy host, however, it is 
immunocompromised patients and people at the extremes of age who are most 
at risk of infection by species such as S. aureus and S. pneumoniae. In these 
cases, depression of the immune system can disturb the fine balance of the 
commensal bacterial community. As a result, one species outcompetes its rivals 
for space and nutrients within the ecosystem and becomes the dominant 
population. This species proliferates, taking advantage of a weakened host 
immune system, and as nutrients become increasingly scarce it invades host 
tissues, damaging host cells and consequently causing the symptoms of disease.  
At this point, the invading species has transitioned from commensal to 
opportunistic pathogen and research has shown that in around 80% of cases of 
staphylococcal bacteraemia, the infecting strain in fact originated from the 
anterior nares of the patient (von Eiff et al., 2001). This transition requires an 
extensive array of virulence factors, including adhesins for initial colonisation of 
the host, immune evasion proteins for proliferation and persistence throughout 
infection, and toxins to destroy host cells for nutrient acquisition. This army of 
virulence factors available to breach host defences and establish infection is a 
key factor that differentiates obligate commensals from opportunistic pathogens 
(Casadevall & Pirofski, 1999). 
Toxins in particular contribute greatly to the presentation of symptoms during 
infectious disease. For example, action of the toxin pneumolysin in the upper 
respiratory tract of pneumonia patients is responsible for the strong inflammatory 
response in the lung and the resulting fever and cough which are symptomatic of 
this disease (Boulnois, 1992). Increasingly, the role of toxins in different stages of 
pathogenesis is being highlighted, with recent research demonstrating that toxins 
are important throughout disease development, from colonisation through to 
presentation of symptoms (Rudkin et al., 2017). The biology of staphylococcal 
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and pneumococcal toxins is discussed in more detail in sections 1.3.2.3 and 
1.4.2.4 respectively.  
With ever-increasing levels of antibiotic resistance among bacterial pathogens, it 
is becoming increasingly important to understand exactly how species such as S. 
aureus and S. pneumoniae cause disease, such that we can work towards 
development of better prevention and treatment of disease. This encompasses a 
variety of factors which contribute to the onset of disease in a patient, from social 
factors such as hygiene procedures in hospitals, to individual factors such as 
underlying co-morbidities which may predispose someone to infection, and to the 
virulence potential of the infecting pathogen. This project focuses on the 
virulence potential of infecting pathogens, looking specifically to elucidate the 
genetic factors which contribute to toxin production and secretion in two 
prominent causes of opportunistic infection.  
1.2.0 A genomic approach to studying virulence 
The genetic basis for bacterial virulence is highly complex, and in an era where 
genome sequencing information is being obtained quickly and accurately, and 
used to track disease outbreaks and genetic changes in pathogens in real-time 
(Gardy et al., 2015; Quick et al., 2016), there is an increasing need to work 
towards a more complete understanding of the genetic basis of virulence.  
Simply knowing the genome sequence of an isolate is of little use in the context 
of disease treatment unless we can fully understand the function of genes which 
contribute to the pathogenic phenotype. This point is highlighted by Viney (2014), 
where the importance is stressed of understanding individual gene function in an 
era when it is becoming increasingly common to compare similarities between 
genomes instead of focussing on the function of specific genes. If whole genome 
sequencing is to be used in the future to improve disease treatment, it is 
necessary to study individual gene function in relation to pathogenesis so that 
pathogenic genomes can be sequenced and interpreted in a way which will be 
clinically relevant. In particular, it is hoped that through an improved ability to 
accurately interpret genome sequencing information, it will one day be possible to 
diagnose and treat infections on an individual and personal basis, such that the 
most appropriate and effective treatment can be given as early as possible in the 
course of an infection.  
14 
 
This work takes a small step towards this aim by characterising the individual 
function of two genes which contribute to bacterial disease, one in S. aureus and 
one in S. pneumoniae. In doing so, this contributes to the long-term goal of being 
able to interpret genome sequencing information on a personalised basis to 
determine the potential severity of disease caused by a patient’s individual 
bacterial isolate. 
A recent genome-wide association study (GWAS) by Tunjungputri et al. (2017) 
took a further step towards this goal, demonstrating how sequencing data can be 
used to identify novel associations between genotype and phenotype in the 
context of bacterial disease. Specifically, the authors identified that presence of 
the pblB gene on the pneumococcal chromosome correlated with increased 
mortality in patients suffering from invasive pneumococcal disease, and that this 
was mediated by an increase in activation of platelets. Platelets have been 
shown to be important in patients suffering from sepsis, in that excessive platelet 
activation causes over-stimulation of the innate immune system, subsequently 
leading to organ failure and mortality. Identification of strains harbouring this gene 
during the course of an infection would give clinicians some indication of the 
potential severity of invasive pneumococcal disease which a patient may 
develop, and allow them to tailor treatment accordingly to the needs of the 
individual.  
The need to determine the most appropriate treatment for infection is becoming 
ever more pressing considering the increased prevalence of antibiotic resistance 
observed in numerous bacterial pathogens over the past few decades (Gross, 
2013; Levy, 1998; Neu, 1992); the rise of methicillin resistance in Staphylococcus 
aureus being one of the best examples of this. Investment into early-stage 
research for development of novel antibiotics has improved over recent years, 
however, investment into clinical development and commercialisation of novel 
antimicrobial compounds is lacking, with very few antibiotics currently in the later 
stages of clinical trials, and several large pharmaceutical companies terminating 
their antibiotic development programmes (Blaskovich et al., 2017; Simpkin et al., 
2017). This lack of funding for the later stages of novel antibiotic development 
creates a barrier to new antibiotics entering the pharmaceutical market, 
exacerbating the long-term threat posed by antibiotic-resistant infections.  
Given these challenges, it is essential that we work towards a better 
understanding of bacterial virulence, and in turn that this knowledge is used to 
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find alternative ways of treating the wide range of diseases caused by pathogens 
such as S. aureus. Potential alternative treatments include trying to boost host 
immunity to naturally fight off infection (Finlay & Hancock, 2004; Kyme et al., 
2012), identifying potential new drug targets (Lee et al., 2009; Payne et al., 2007; 
Gotoh et al., 2010), and ensuring that the antibiotic treatments that are still 
effective are used efficiently and appropriately to minimise the further spread of 
resistance, and maintain a reserve of these antibiotics for last resort treatment. 
Our lab group has previously studied the genetic basis for toxicity in the 
opportunistic pathogen Staphylococcus aureus, which used a genome-wide 
association study (GWAS) to identify potential genetic loci which may be 
associated with the toxic phenotype. This work revealed several novel genes 
which when disrupted caused a significant loss in toxicity in S. aureus, helping to 
further our understanding of the highly complex genetic regulation of virulence 
factors in this bacterium (Laabei et al., 2014; Laabei et al., 2015).  
1.2.1 Genome-wide association studies (GWAS) 
A genome-wide association study is conducted using a large dataset of genomic 
data, traditionally consisting of single-nucleotide polymorphisms (SNPs) present 
throughout the whole genome of an organism, and a corresponding set of 
quantifiable phenotypic data. In its most basic form, GWAS is a simple statistical 
test for association between particular loci in the genome and the phenotype of 
interest. It is important to note that GWAS can only identify statistical associations 
between genotype and phenotype, and causal relationships have to be verified 
through further investigation. It is well known that GWAS produces a high number 
of false associations with the phenotype (false positives) and can also wrongly 
exclude significant associations (false negatives), therefore functional verification 
is a crucial aspect of this research if meaningful results are to be obtained. 
Nonetheless, using this top-down approach can be a useful tool for identification 
of what would otherwise remain unknown effectors of a phenotype.  
GWAS was originally designed to identify genetic polymorphisms associated with 
human disease, with the first published study looking to identify single nucleotide 
polymorphisms (SNPs) associated with myocardial infarction (Ozaki et al., 2002). 
This study identified a single SNP which was statistically associated with this 
condition and further experimental testing confirmed the finding. Another well-
known example of GWAS in studies of human disease was the discovery of a 
common breast cancer risk allele among carriers of the BRCA1 gene (Antoniou 
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et al., 2010; Kraft & Haiman, 2010). As a result of this research, screening tests 
now look for the BRCA1 mutation in patients which is associated with a higher 
risk of developing breast cancer. The success of these studies demonstrates the 
potential impact this GWAS method can have on medical research, and so more 
recent research has looked to apply this approach to the study of bacterial 
phenotypes relevant to disease such as host specificity (Sheppard et al., 2013), 
toxicity (Laabei et al., 2014) and antibiotic resistance (Farhat et al., 2013; Alam et 
al., 2014).  
1.2.1.1 Units of genetic variation used in GWAS 
GWAS has traditionally used single nucleotide polymorphisms (SNPs) as the unit 
of genetic variation to investigate a phenotype (Bush & Moore, 2012). These are 
single base changes that can be either synonymous (do not cause a change in 
the resulting amino acid) or non-synonymous (cause a change in the resulting 
amino acid). As described above this has yielded some important discoveries in 
genetic contributors to human disease. With genome sequencing data becoming 
more readily available and bioinformatics techniques continue to advance, 
researchers are beginning to use a variety of different measures of genetic 
variation, especially in bacterial GWAS, in an effort to increase the accuracy of 
GWAS predictions. For example, Sheppard et al. (2013) developed a method of 
dividing the genome into short segments of around 30bp in length for use as the 
unit of genetic variation; Laabei et al (2014) used both SNPs and indels in their 
GWAS method; and a number of studies have instead used presence or absence 
of whole genes (van Hemert et al., 2010; Chaston et al., 2014; Salipante et al., 
2015).  
1.2.1.2 Linkage disequilibrium 
One of the major criticisms of GWAS is the high number of false positive and 
false negative associations this method identifies. The identification of false 
positive results is in part due to linkage disequilibrium, referring to the degree to 
which SNPs are inherited together during recombination in non-random 
proportions (Slatkin, 2008; Bush & Moore, 2012; Sved & Hill, 2018). Highly clonal 
populations of bacteria, in comparison to human populations, have high levels of 
genome-wide linkage disequilibrium because recombination does not take place 
as frequently (Read & Massey, 2014). For example, Mycobacterium tuberculosis 
is a highly clonal species, and in bacterial GWAS this increases the difficulty of 
identifying a causative SNP among a high number of statistically significant 
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associations (Chen & Shapiro, 2015). Bacteria with high levels of recombination 
are much more desirable for GWAS, because this effect of linkage disequilibrium 
is reduced, although not eliminated. Streptococcus pneumoniae is one such 
species of highly recombining bacteria, with shorter, more localised regions of 
linkage disequilibrium across the genome (Chen & Shapiro, 2015).  
1.2.1.3 Direct and indirect associations 
Due to this effect of linkage disequilibrium, it is essential to distinguish direct from 
indirect associations in GWAS results. Direct associations refer to the specific 
causative loci which directly affect the phenotype. Indirect associations are loci 
which are identified as being statistically significantly associated with the 
phenotype but are in fact in linkage disequilibrium with the causative SNP and 
therefore not an effector of the phenotype. Distinguishing these two types of 
associations requires functional verification of the effect a significantly associated 
loci has on the phenotype of interest. In bacteria, this can be done by genetic 
manipulation of associated loci and subsequent assaying of the phenotype. 
Though potentially labour and time intensive, with the introduction of mutant 
libraries such as the Nebraska Transposon Mutant Library for Staphylococcus 
aureus (Fey et al., 2013), functional verification is becoming increasingly feasible 
in a high-throughput manner.  
1.2.1.4 Population stratification 
Population stratification is another influence on statistical associations made 
through GWAS which can be responsible for identification of false associations 
with the phenotype – both false positives and false negatives. The problem of 
population stratification refers to the nature of bacterial populations to be strongly 
segregated into distinct genetic lineages that are highly influenced and 
maintained through the action of natural selection (Earle et al., 2016). Natural 
selection can be a strong driver of the propagation of antibiotic resistance and 
virulence phenotypes, for example, through a bacterial population (Chen & 
Shapiro, 2015). Such differences between genetically distinct populations can 
confound GWAS results if not considered in the analysis because they account 
for the observed variability in a phenotype (Earle et al., 2016).  
For example, genetic variant A may be causative of phenotype B in one 
genetically distinct subset of a bacterial population; if the GWAS analysis is 
conducted on the population as a whole, it will not pick up this causative 
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association because the effect of variant A on the phenotype in this subset will be 
masked by the wider population in which it does not affect the phenotype (it wil 
be a false negative). However, if population structure is accounted for in the 
analysis it will become clear that in a specific subset of the population, variant A 
has a strong association with the phenotype.  
On the other hand, if population stratification is too tightly controlled, genetic 
variants that are unrelated to the phenotype but only present in distinct subsets of 
the population that exhibit the phenotype may be falsely identified as causative 
loci (they will be false positive associations). As with many aspects of GWAS, 
controlling for population stratification relies on a balance between excluding loci 
that are likely to confound the analysis and including loci that are present only in 
a subset of the population but may be directly causative of a change in the 
phenotype. 
Work by Maury et al. (2016) is a good example of the increased power of 
association studies which appropriately controls for population stratification. In 
this work, focussing on population structure in an association study of the 
foodborne pathogen Listeria monocytogenes led to identification of virulence 
attributes which were specifically relevant to either central nervous system 
listeriosis or maternal-neonatal listeriosis, both of which are clinically important. 
Listeriosis is a serious and sometimes deadly disease, so understanding the 
virulence factors which specifically contribute to different types of disease caused 
by clinical L. monocytogenes isolates could prove to be extremely useful in the 
development of better treatments. Here, accounting for population structure was 
shown to be important in increasing the power of GWAS analysis. 
1.2.1.5 Corrections for multiple testing 
A further aspect of GWAS to consider is the effect of multiple testing. The 
threshold of significance for an individual statistical test is usually set at p=0.05, 
meaning that the probability of an association being incorrectly observed if the 
null hypothesis is true is 5%. The null hypothesis here would be that there is no 
association between an individual genetic locus and the observed phenotype, 
and results where this hypothesis is rejected when it is true are referred to as 
type I errors, or false positive results. In a small dataset, for example of 20 
results, this would mean only 1 result would be false positive. However, as the 
dataset increases in size, the number of false positive results increases 
simultaneously, so in a dataset of 100, 5 results will be false positive, in a dataset 
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of 1000, 50 will be false positive, and so on. GWAS can involve potentially 
millions of statistical tests for association in a single dataset, resulting in a huge 
number of results for which the null hypothesis is incorrectly rejected under a 
significance threshold of p=0.05. One way to overcome this effect is to apply 
corrections for multiple testing, examples of which include the Bonferroni 
correction, the false discovery rate and permutation of the dataset.  
The Bonferroni correction is a well-known method of correcting for multiple tests; 
it is a simple calculation designated ‘α/n’ where ‘α’ refers to the threshold at which 
a p-value is considered significant (eg. 0.05) and ‘n’ refers to the number of tests 
conducted. This adjusts the significance level for each individual test to a much 
more stringent threshold but maintains the study-wide error rate at 0.05, or 5% 
(Perneger, 1998). However, this type of correction is not always valid in biological 
science; for example, the Bonferroni correction assumes that each test for 
association is independent of the others, but due to linkage disequilibrium, 
particularly in highly clonal populations, this is not always the case (Bush & 
Moore, 2012). In some cases, this type of correction can be too stringent and 
result in an increase in type II errors, also known as false negative results, 
whereby the null hypothesis is accepted when it should be rejected (Perneger, 
1998; Armstrong, 2014).  
An alternative to the Bonferroni correction is the false discovery rate, first 
proposed by Benjamini & Hochberg (1990; 1995). Instead of adjusting the 
significance threshold to reduce the likelihood of producing false positive results, 
the false discovery rate estimates the proportion of false positive results within 
the dataset, correcting for this to determine the number of true results among 
those which are statistically significant (Bush & Moore, 2012). Control of the false 
discovery rate has proved a useful tool in the analysis of GWAS data to adjust for 
the high number of statistical comparisons and in turn reduce the incidence of 
false positive results (van den Oord, 2007; Brzyski et al., 2017).  
A third approach to correcting for multiple tests is permutation of the dataset. A 
permutation test involves scrambling the original dataset to remove the 
relationship between genotype and phenotype, creating a situation whereby the 
null hypothesis is true and there is no biological basis for the alignment between 
genotype and phenotype. Following permutation, the GWAS analysis is 
conducted again on the scrambled dataset (note this is not a secondary 
analysis), and this is repeated thousands of times so that any association found 
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between genotype and phenotype is purely due to chance. The p-value for each 
locus is then recalculated after all permutations have been completed to 
determine the likelihood of an association being made by chance alone, taking 
into account the average p-value under the null hypothesis (permutation) and the 
number of permutations conducted. This strengthens the findings of GWAS by 
providing empirically-derived p-values and demonstrating that significance is not 
an artefact of chance. Permutation of the dataset and subsequent calculation of 
empirically derived p-values can be done in numerous ways depending on the 
hypothesis being tested. For example, permutation could be applied to SNP data, 
to whole genes or to the phenotypic data, or to a combination of these (Guo et 
al., 2009; Cantor et al., 2010; Backes et al., 2014; Davenport et al., 2015; 
Brynildsrud et al., 2016). While permutation in principle is a straightforward 
approach to correcting for multiple tests, the number of permutations required to 
obtain statistically meaningful results can be computationally intensive, which is a 
potential drawback to this approach.  
1.2.1.6 Filtering of genotypic data 
Like permutation, GWAS analysis itself can be a computationally intensive 
process. One method to reduce the number of comparisons which are made in 
the first place is to filter genotypic data to eliminate loci with high frequencies of 
missing data and low frequencies of genetic polymorphisms. As has been 
discussed with many other aspects of GWAS, filtering of the dataset could lead to 
exclusion of potentially important loci from the analysis, so it is important that 
reasonable thresholds are set for exclusion of data. A threshold referred to as the 
genotype frequency can be set to eliminate loci with, for example 90% missing 
data, and a threshold referred to as the minor allele frequency can be set to 
eliminate loci with, for example, less than 5% polymorphisms. These thresholds 
can be manipulated to the needs of the researcher and can add power to the 
analysis by reducing the overall number of comparisons made.  
Other approaches could include removing loci which cause only synonymous 
mutations, or grouping all mutations within a genetic feature, such as a gene or 
intergenic region, and treating each group as one statistical comparison (Read & 
Massey, 2014). However, eliminating loci from the genotypic dataset could 
potentially lead to the elimination of biologically important loci from the analysis, 
resulting in an increase in false negative results. Highly conserved loci, for 
example, will have very few SNP changes, and may be eliminated from the 
21 
 
analysis by the minor allele frequency threshold, as would rare mutations that 
may have a strong effect on the phenotype. This step must therefore be a trade-
off between increasing statistical power of the analysis, and potentially losing 
biologically meaningful results.  
1.2.1.7 Visualisation of GWAS results 
Despite statistical correction for multiple testing and prior filtering of genomic 
data, false positive and negative results cannot be completely eliminated from 
GWAS analysis. To some degree, it is therefore important to judge GWAS results 
in terms of their biological relevance as well as statistical significance. One way 
to do this is to graph the results to visualise where the peaks and clusters of 
significant associations are along the genome; this is usually done using the 
Manhattan scatterplot format (see figure 1.1), where the -log10 of each p-value is 
plotted and statistically significant loci appear as peaks along the X-axis, 
comparable to the Manhattan skyline from which the graph gets its name (Zhang 
et al., 2014). Visualising the data in this way does not allow discrimination 
between direct and indirect associations, but it does allow identification of 
clusters of significant associations which are likely to contain a causative SNP.  
 
Figure 1.1. Example of a Manhattan scatterplot. Position of the locus on the 
chromosome is plotted on the X axis, against the -log10 of the p-value, indicating 
significance on the Y axis. The horizontal grey line represents the threshold for statistical 
significance. Clusters of statistically significant loci associated with the phenotype, in this 
case body mass index in east Asian populations, are seen as peaks on the plot. From 
Okada et al. (2012), reused with permission from Springer Nature. 
 
Recent work has led to the development of interactive applications such as 
Phandango (Hadfield et al., 2017) for the visualisation of GWAS data beyond the 
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static Manhattan plot. Phandango allows researchers to visualise the output from 
multiple different genomic analysis methods and explore regions of significance 
in a more intuitive way, combining GWAS results with the reference sequence, 
phylogenetic data and genome annotations, all of which can be tailored to the 
needs of the user. From this, inferences can be made regarding the likely 
biological function of a genetic locus of interest in relation to the phenotype, 
allowing prioritisation of significant GWAS results based on both biological 
relevance and statistical significance.  
1.2.1.8 Investigating bacterial phenotypes using GWAS 
GWAS is increasingly being applied to studies of bacterial phenotypes, 
particularly in relation to antibiotic resistance and pathogenesis. The first 
published bacterial GWAS was conducted by Sheppard et al. in 2013 and 
investigated genetic factors in Campylobacter jejuni that are associated with 
adaptation to a specific host. The authors found a region of seven genes which 
were specifically associated with adaptation to cattle and frequently absent in 
strains which were isolated from chickens and wild birds. Three of these genes 
were found to be involved in vitamin B5 biosynthesis, and the authors 
hypothesise that they may contribute to specific adaptation to the cattle diet. Host 
adaptation is an important aspect of bacterial pathogenicity, as transmission 
dynamics between hosts can influence the survival and persistence of a 
pathogen (Dobson, 2004), and this research presents GWAS as a useful tool for 
investigation of bacterial pathogenicity using a genome-wide approach. 
A number of studies since then have focussed on identifying specific genetic loci 
in bacteria which contribute to antibiotic resistance (Farhat et al., 2013; Alam et 
al., 2014; Chewapreecha et al., 2014). For example, Chewapreecha et al. (2014) 
used GWAS to pinpoint specific polymorphisms within pneumococcal ‘mosaic 
genes’ which contribute to resistance to β-lactam antibiotics. Mosaic genes are 
regions of DNA containing polymorphisms from the cell’s original DNA in 
combination with those from donor DNA obtained through recombination (Boc & 
Makarenkov, 2011). While previous studies had identified these blocks of 
recombination as associated with β-lactam resistance, Chewapreecha et al. used 
GWAS to refine smaller loci of discrete or linked SNPs which contribute to the 
phenotype.  
The GWAS approach has also been expanded from identifying effector 
polymorphisms in isolation to identifying epistatically interacting loci; these being 
23 
 
loci that alone are not significantly associated with a change in the phenotype but 
do become significantly associated when interacting with other loci, whereby one 
gene masks or modifies the effects of another (Laabei et al., 2014; Yokoyama et 
al., 2018; Schubert et al., 2019). For example, work by Laabei et al. (2014) 
identified SNPs in several genes including ileS and mreC which were found to be 
epistatically interacting with other loci to affect toxicity in S. aureus with high 
statistical significance. Follow-up work by Yokoyama et al. (2018) to functionally 
verify the role of the ileS gene in relation to toxicity demonstrated that mupirocin 
resistance, which is conferred by a mutation in the ileS gene, affects toxin 
production when in combination with specific polymorphisms at other loci. In turn 
this was found to affect the fitness of S. aureus to the extent that this mutation 
has not spread through the population as much as would be expected for one 
which confers antibiotic resistance.  
All the examples given above demonstrate the broadening application of GWAS 
in expanding our understanding of the genetic factors which contribute to 
bacterial pathogenesis. Traditionally this line of investigation has taken a bottom-
up approach, whereby the function of individual genes is disrupted and the 
resulting phenotype is studied to determine the role of the gene. With the 
increasing availability of genome sequences and improvements in bioinformatic 
methods, it is becoming increasingly possible to take a top-down approach to this 
research. Despite its flaws in terms of the generation of false positive and false 
negative results, and the extensive amount of quality control which must be 
performed on the dataset, GWAS has been shown to be a useful tool in this top-
down approach, allowing researchers to start with a large dataset of whole 
genome sequences, and narrow down regions of interest for targeted 
investigation of specific loci in relation to a phenotype of interest.  
1.3.0 Introduction to Staphylococcus aureus 
Strains of methicillin-resistant Staphylococcus aureus (MRSA) are perhaps best-
known among the S. aureus species, having been a persistent cause of hospital- 
and community-acquired infections in the UK over recent decades and has been 
identified as a public health priority within the European Union (Köck et al., 2010). 
Gould (2006) describes MRSA as “by far the most significant antibiotic-resistant 
pathogen we have ever encountered” and following a dramatic rise in MRSA 
bacteraemia over the turn of the century surveillance of MRSA bacteraemia was 
made mandatory (Johnson et al., 2012). A concerted effort has since been made 
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to improve hygiene practices in hospitals for the prevention of MRSA and as a 
result the prevalence of MRSA bacteraemia has substantially declined over 
recent years (see figure 1.2). 
 
Figure 1.2. Trends in the rate of MRSA bacteraemia in England. Illustration of the 
reduction in prevalence of MRSA bacteraemia from 2007-2018. Figure from Public Health 
England (2018a), reused under the Open Government Licence v3.0.  
 
While MRSA bacteraemia is shown to be in decline, cases of methicillin-
susceptible Staphylococcus aureus (MSSA) bacteraemia have been on the rise 
since surveillance was made mandatory in 2011 (see figure 1.3).  
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Figure 1.3. Trends in the rate of MSSA bacteraemia in England. Illustration of the 
increase in prevalence of MSSA bacteraemia from 2011-2018. Figure from Public Health 
England (2018a), reused under the Open Government Licence v3.0. 
 
It is interesting from an evolutionary and epidemiological perspective that MSSA 
is on the rise while MRSA is in decline. It seems there is a reversal of roles 
between methicillin-resistant and -sensitive strains, with MSSA shown to replace 
MRSA as the predominant cause of nosocomial infections. Furthermore, in 
America for example, MRSA has become a prevalent cause of S. aureus 
infection in the community (David et al., 2011). Community-acquired disease 
caused by S. aureus was first reported in injecting drug users in 1981 (Saravolatz 
et al., 1982) and this was later followed by the deaths of four young children from 
MRSA infection, despite having no apparent risk factors for disease (Centers for 
Disease Control and Prevention, 1999). Since these early reports, the incidence 
of community-acquired S. aureus infections has risen worldwide, with methicillin-
resistant isolates emerging as the predominant cause of staphylococcal disease 




It was noted by David et al. (2011) that MSSA isolates causing clinical infections 
in hospitals rarely carried genes for the Panton-Valentine leukocidin (PVL) toxin, 
which contributes to increased virulence in isolates that carry it (although it is not 
the singular determinant of increased virulence [Voyich et al., 2006]). In contrast, 
most of the community-acquired MRSA (CA-MRSA) isolates identified by David 
et al. were PVL-positive. The authors imply based on these findings that 
nosocomial MSSA strains are less virulent than the PVL-positive CA-MRSA 
isolates, which have to invade an otherwise healthy host with a fully functional 
immune system in most cases. MSSA isolates, on the other hand, have access in 
the hospital environment to immune-compromised patients who are less 
competent to resist the onset of staphylococcal disease and therefore do not 
need such high levels of virulence in order to colonise and invade a vulnerable 
host. This, in combination with the intense effort to reduce the prevalence of 
MRSA in hospitals over recent decades, could explain the increase in cases of 
MSSA infections.  
Interestingly, however, high levels of toxicity do not necessarily correlate to more 
severe disease. This principle was demonstrated in work by Laabei et al. (2015), 
in which it was shown that there is an inverse correlation between bacterial 
toxicity and disease severity. These results are consistent with the work of David 
et al. (2011), which demonstrated that the supposedly more virulent CA-MRSA 
strains were predominantly responsible for less severe skin and soft tissue 
infections, while patients infected with MSSA were more likely to develop invasive 
disease, although this data represents a static time point and disease outcomes 
are not reported. 
Laabei et al. explain this observed trade-off between bacterial toxicity and 
disease severity by demonstrating that low-toxic S. aureus isolates have higher 
relative fitness in human serum than high-toxic isolates, and showed that high-
toxic isolates have a competitive advantage at the population level and are more 
likely to transmit successfully between hosts. Isolates of lower toxicity, on the 
other hand, are more consistently found in bacteraemia patients, which is an 
evolutionary dead end for S. aureus in the event the disease is fatal to the host. 
Nonetheless, follow-up work by Recker et al. (2017) demonstrated that once in 
the bloodstream a low-toxic isolate is less likely to lead to mortality than a high-
toxic isolate, as would be expected.  
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MRSA remains a huge concern for clinicians in this era of antibiotic resistance, 
and other drug-resistant variants such as glycopeptide-intermediate S. aureus 
(GISA) and vancomycin-resistant S. aureus (VRSA) are also a particular threat 
should they become more prevalent causes of staphylococcal disease (Gould, 
2006). However, the rise in cases of MSSA infection should not be ignored, and 
epidemiological monitoring of the fluctuations in disease prevalence of both 
methicillin-resistant and -sensitive S. aureus will be important in designing future 
prevention strategies against staphylococcal disease. 
1.3.2 S. aureus virulence factors 
In causing a range of diseases from milder skin and soft tissue infections, to the 
more invasive diseases such as pneumonia, meningitis and septicaemia, 
Staphylococcus aureus employs an army of virulence factors (see figure 1.4 
below for examples). Bacterial virulence is highly dependent on genetic and 
environmental determinants for both host and pathogen, but S. aureus 
nonetheless is well equipped to cause disease in the human host due to this 
extensive array of virulence factors. 
Figure 1.4. Virulence factors of Staphylococcus aureus. (A) Surface and secreted 
proteins. (B) and (C) Cross-sections of the cell envelope. TSST-1 – toxic shock syndrome 






S. aureus produces a wide array of adhesive proteins that contribute to its ability 
to colonise host cells and tissues in the early stages of infection (Gordon & Lowy, 
2008). A number of these adhesins belong to a large group of surface proteins 
that are collectively referred to as ‘microbial surface components recognizing 
adhesive matrix molecules’ or MSCRAMMs. MSCRAMMs are a key part of the 
colonization stage of infection and while most are adhesive proteins, some also 
play a role in evasion of host immunity (Foster et al., 2014). MSCRAMMs are 
more specifically defined by Foster et al. as a family of proteins with a common 
mechanism of ligand binding mediated by two adjacent subdomains containing 
IgG-like folds. Examples of adhesins within this group include clumping factors A 
and B (ClfA/ClfB), fibronectin-binding proteins A and B (FnBPA and FnBPB) and 
the collagen adhesin Cna.  
ClfA specifically adheres to fibrinogen in the extracellular matrix of host tissues to 
facilitate colonisation (O’Connell et al., 1997), and promotes clumping of S. 
aureus cells in the bloodstream by binding fibrinogen within the plasma (Ganesh 
et al., 2008). ClfB is similar in structure to ClfA but binds a different region of host 
fibrinogen; Eidhin et al. (1998) propose that the two clumping factor proteins act 
together to enhance binding to fibrinogen within the blood stream. A role has also 
been proposed for ClfB in adherence to the squamous epithelial cells of host 
nasal passages to promote specific colonisation of this niche (Mulcahy et al., 
2012) and it has been demonstrated that this can be mediated by the structural 
protein cytokeratin 10 (Walsh et al., 2004; Ganesh et al., 2011) and the cell 
envelope protein loricrin of squamous epithelial cells (Mulcahy et al., 2012). 
Clumping factor mutants have been shown to be attenuated in adherence to host 
cell components and tissues (Eidhin et al., 1998; Mulcahy et al., 2012), and 
further roles have also been demonstrated for clumping factors in evading 
phagocytosis (Higgins et al., 2006), in binding to platelets to initiate infective 
endocarditis (Siboo et al., 2001) and in binding to biomaterials used in surgical 
implants (Vaudaux et al., 1995). 
The fibronectin-binding proteins FnBPA and FnBPB, as their name suggests, 
bind fibronectin within the blood plasma and the extracellular matrix of host 
tissues, and also contribute to adherence to surgical implants (Foster & Höök, 
1998; Foster et al., 2014). Work by Peacock et al. (1999) demonstrated that the 
FnBPs are the dominant adhesins involved in binding of S. aureus to human 
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endothelial cells and are also key to internalisation of S. aureus into endothelial 
cells to promote invasion during disease. Massey et al. (2001) extended this work 
to elucidate the fibronectin-binding regions of FnBPA, which are described as 
forming a bridge between bacterial cells and endothelial cells that is connected 
via fibronectin. This work also demonstrated that FnBPA is the most important 
factor responsible for internalisation of S. aureus into endothelial cells. 
Collagen adhesin Cna adheres specifically to collagen-rich tissue (Foster et al., 
2014) and has been shown to contribute to virulence in models of bone infection, 
endocarditis and septic arthritis (Patti et al., 1994; Hienz et al., 1996; Elasri et al., 
2002). For example, Patti et al. (1994) demonstrated that mutants lacking the cna 
gene were unable to bind collagen or express a collagen adhesin and were 
reduced in ability to adhere to cartilage. In a subsequent animal model of septic 
arthritis only 27% of mice treated with cna-deficient mutants developed 
symptoms of disease compared to 70% of mice treated with cna-positive strains.  
Adhesins such as those described above have been identified as potential 
candidates for development of a staphylococcal vaccine, and work has shown 
that immunisation in mouse models with MSCRAMM proteins including ClfB and 
fibrinogen binding proteins can protect against initial colonisation, thereby 
protecting against onset of disease (Mamo et al., 1994; Schaffer et al., 2006). 
Recombinant ClfA and Cna fragments have also been shown to reduce the 
severity of septic arthritis in mouse models, with mortality significantly reduced in 
vaccinated hosts (Nilsson et al., 1998; Josefsson et al., 2001).  
A further critical role of adhesins in virulence is their contribution to formation of 
biofilms in the initial stages of infection (Rohde et al., 2007; O’Neill et al., 2008; 
Heilmann, 2011), a process usually associated with indwelling medical devices 
such as catheters or surgical implants (Otto, 2008). Biofilms have been shown to 
aid resistance to antibiotic action by both providing a physical barrier to cells in 
the centre of the biofilm and because cells in a biofilm typically grow slowly with 
reduced metabolism which facilitates tolerance of antibiotic treatment (Marrie et 
al., 1982; Archer et al., 2011). These principles also apply to resistance against 
action of the host immune system (Costerton et al., 1999). Due to the persistence 
of biofilms within the host once established, they can become a reservoir for 
dissemination of S. aureus to other sites within the body (Otto, 2008).  
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1.3.2.2 Immune evasion 
Once staphylococci have colonised the host, they must evade the action of the 
host immune system if they are to persist and spread. Infection with 
staphylococci stimulates a strong inflammatory response, so S. aureus must be 
prepared to actively evade host immunity, which it does through the deployment 
of several virulence factors dedicated to immune evasion. Examples of some of 
these immune evasion proteins are shown in figure 1.5 below. 
Figure 1.5. Mechanisms by which S. aureus avoids opsonophagocytosis. (A) 
Capsular polysaccharide compromises neutrophil access to bound complement and 
antibody. (B) Extracellular staphylokinase (Sak) activates cell-bound plasminogen and 
cleaves IgG and C3b. (C) Protein A binds the Fc region of IgG. (D) Fibrinogen-binding 
protein Efb binds complement factor C3 and blocks its deposition on the bacterial cell 
surface, thereby preventing complement activation beyond C3b attachment and inhibiting 
opsonisation. (E) Clumping factor A (ClfA) binds the γ-chain of fibrinogen. Figure taken 
from Foster (2005), reproduced with permission from Springer Nature. 
 
The polysaccharide capsule provides a physical barrier to components of host 
immunity. For example, it prevents access of neutrophils to serum opsonins such 
as C3b which bind to the cell surface beneath the polysaccharide layer (Verbrugh 
et al., 1982), reducing uptake of staphylococcal cells by neutrophils and thereby 
interfering with opsonophagocytosis. In doing so, it has been shown that this 
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increases staphylococcal virulence, and in turn disease severity, in mouse 
models of infection (Nilsson et al., 1997; Thakker et al., 1998). Most clinical S. 
aureus isolates are found to express one of either serotypes 5, 8 or 336 capsular 
polysaccharide, which forms a thin ‘microcapsular’ layer around the cell (Foster, 
2005). Out of a total of 11 serotypes identified thus far, serotypes 5 and 8 have 
been specifically associated with increased virulence in mouse models of 
infection (Nilsson, 1997; Luong & Lee, 2002). For example, work by Nilsson et al. 
(1997) showed that strains positive for capsular serotype 5 (CP5+) caused a 
higher frequency and severity of arthritis in a murine model, while in vitro assays 
suggested that CP5+ strains were phagocytosed less by macrophages and once 
phagocytosed were killed less efficiently than their isogenic capsule-deficient 
mutants. A number of studies have also shown that S. aureus strains of capsular 
serotypes 5 and 8 are able to resist phagocytosis by human polymorphonuclear 
leukocytes (Peterson et al., 1978; Verbrugh et al., 1982; Karakawa et al., 1988).  
Along with the polysaccharide capsule, another well-characterised contributor to 
immune evasion is staphylococcal protein A (SpA), a cell wall-anchored protein 
which binds to the Fc region of host immunoglobulin IgG. Binding of the Fc region 
renders the antibody unrecognisable to host neutrophils because it is in the 
incorrect orientation. As the bacterial cell becomes covered in these incorrectly 
oriented IgG molecules it is concealed from neutrophils, and in this manner 
evades opsonophagocytosis (Foster, 2005). Furthermore, this protein A-IgG 
complex then goes on to bind components of the complement system which are 
usually involved in opsonisation, as the variable region of IgG to which 
complement would normally bind remains exposed. Mutants deficient in protein A 
are phagocytosed much more efficiently than protein A-rich strains and exhibit 
reduced virulence in animal models of infection (Patel et al., 1987; Gemmell et 
al., 1991; Palmqvist et al., 2002). The importance of IgG in the action of protein A 
was demonstrated by Peterson et al. (1977), who showed that protein A-rich 
strains were phagocytosed quicker in IgG-deficient serum compared to isogenic 
protein A-deficient strains. 
Important roles have also been demonstrated for protein A in binding to tumour 
necrosis factor receptor 1 (TNFR1) on host epithelial cells, and in causing 
depletion of B lymphocytes. Binding of protein A to TNFR1 induces a strong 
inflammatory response in the respiratory tract and a signalling cascade that leads 
to recruitment of high numbers of neutrophils (Gómez et al., 2004). The rapid 
increase in inflammation causes increased tissue damage which is detrimental to 
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the host and can ultimately be responsible for the induction of staphylococcal 
pneumonia. Interference of protein A with B cells via binding to B cell receptors 
(BCRs) leads to rapid down-regulation of BCRs culminating in apoptosis 
(Goodyear and Silverman, 2003). Protein A can therefore promote the 
pathogenesis of S. aureus by evading the action of host immunity, directly 
interacting with host immune cells to inhibit their function and over-stimulating the 
immune response, depending on the stage of infection. 
Several other virulence factors produced by S. aureus also interfere with 
phagocytosis by interacting directly with components of the human complement 
system. Examples include Staphylococcus complement inhibitor (SCIN), the 
extracellular fibrinogen-binding protein Efb, and the plasminogen activator protein 
staphylokinase (Sak). SCIN interacts directly with the C3 convertases C4b2a and 
C3bBb to stabilise the C3 convertase complex, inhibiting C3b deposition on the 
cell surface and thus preventing complement activation. This early intervention 
with complement ultimately prevents the formation of membrane attack 
complexes that would otherwise lead to lysis of the bacterial cell (Rooijakkers et 
al., 2005). Efb has been shown to bind the C3d fragment of C3b, inhibiting 
opsonophagocytosis, while simultaneously binding fibrinogen to interfere with 
platelet aggregation and wound healing (Palma et al., 1998; Lee et al., 2004). 
Staphylokinase binds host plasminogen that attaches to the bacterial cell surface, 
causing the formation of active plasmin that then goes on to cleave surface 
bound C3b and IgG, subsequently interfering with opsonophagocytosis (Foster, 
2005; Bokarewa et al., 2006). It is also found to interact with the bactericidal 
peptide α-defensin produced by neutrophils to resist neutrophil killing (Bokarewa 
et al., 2006). 
Other immune evasion proteins can act to indirectly protect the bacteria from the 
action of host immune cells. Coagulase, for example, binds prothrombin to clot 
the blood and mask the bacteria from the action of macrophages, indirectly 
protecting the pathogen from phagocytosis (McAdow et al., 2012). Interestingly, 
the golden pigment which is characteristic of S. aureus has also been identified 
as a virulence factor that contributes to immune evasion by protecting the 
bacteria from oxidative stress (Liu et al., 2005; Clauditz et al., 2006). Clauditz et 
al. demonstrated this through deletion of the crtM gene encoding the carotenoid 
pigment staphyloxanthin, which rendered the bacteria susceptible to oxidative 




The third group of virulence factors produced by S. aureus are the toxins; 
proteins secreted by the bacterial cell that actively damage the host. Generally, 
S. aureus toxins can be divided into three distinct groups: 
1) Membrane-damaging toxins 
2) Toxins that interfere with receptor function only 
3) Secreted enzymes that degrade host molecules and affect host defences 
The army of staphylococcal toxins is extensive; the membrane-damaging toxins 
include α-toxin, Panton-Valentine leukocidin (PVL), the leukocidins LukDE and 
LukAB, γ-toxin and phenol-soluble modulins (PSMs). Toxins that interfere with 
receptor function include the enterotoxins, staphylococcal enterotoxin B and C 
(SEB/SEC), the superantigen toxic shock syndrome toxin-1 (TSST-1) and finally, 
the secreted, degradative enzymes include aureolysin, glutamyl endopeptidase 
SspA, β-toxin and lipase and nuclease enzymes. There is some crossover in the 
definition of a toxin here, with immune evasion proteins such as staphylokinase 
also being classified in the third group of secreted enzymes that degrade host 
molecules and defences.  
α-toxin is one of the major cytolytic toxins of S. aureus and has been extensively 
studied over the years as a model for pore-forming toxins (Bhakdi & Tranum-
Jensen, 1991; Dinges et al., 2000; Vandenesch et al., 2012). It exerts its toxic 
effect on host cells by binding as monomers to ADAM10 receptors on host cell 
membranes (Inoshima et al., 2011), which then oligomerise to form a heptameric 
complex and create a pore (Gouaux et al., 1997). Interestingly, binding of alpha-
toxin to ADAM10 activates metalloprotease activity in epithelial cells, resulting in 
the cleavage of E-cadherin to which opportunistic S. pneumoniae can bind during 
infection (Devaux et al., 2019). The pore ultimately formed through the action of 
alpha-toxin allows indiscriminate passage of ions and small molecules up to a 
molecular weight of 4,000 daltons through the channel, causing osmotic swelling, 
and ultimately lysis of the target cell (Bhakdi & Tranum-Jensen, 1991). At sublytic 
concentrations, however, it was observed that α-toxin can act to influence a 
variety of host cells in the capacity of immune evasion (see figure 1.6 below), and 
it is becoming increasingly clear that the function of this and other toxins in 
relation to different stages of the bacterial life cycle is complex and incompletely 
understood (Berube & Wardenburg, 2013). 
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Figure 1.6. Cellular responses to intoxication by α-toxin. Multiple cell types are 
targeted by α-toxin, each displaying unique effects that are dependent on the relative 
concentration of toxin to which the cell is exposed. Figure taken from Berube & 
Wardenburg (2013) reused under the Creative Commons Licence 3.0. 
 
The β-barrel family of pore-forming toxins to which α-toxin belongs also includes 
the Panton-Valentine leucocidin (PVL), the leukocidins LukDE and LukAB, and γ-
toxin (Otto, 2014). PVL, like α-toxin, is also a receptor-mediated membrane 
damaging toxin which interacts with host C5aR and C5L2 receptors to form a 
pore in host cells (Spaan et al., 2013). PVL is of particular interest to researchers 
due to its apparent prevalence in community-acquired MRSA isolates, despite 
only being present in around 2-3% of S. aureus isolates overall (Dinges et al., 
2000). The PVL locus is encoded on a bacteriophage and has been shown to be 
generally associated with skin infections, but in extreme cases can also be 
responsible for the development of necrotising pneumonia (Gillet et al., 2002). 
Whilst it has been suggested that PVL could be a stable genetic marker for CA-
MRSA infection, and that it may have driven the CA-MRSA epidemic of clones 
such as USA300 (Vandenesch et al., 2003), more recent in vitro analyses of the 
contribution of PVL to S. aureus pathogenesis suggests only a minor role in 
pathogenesis (Badiou et al., 2010; Graves et al., 2010). Work by Voyich et al. 
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(2006) provides further convincing evidence that PVL is not a major contributor to 
virulence in CA-MRSA isolates; here the authors compared the virulence of PVL-
positive and -negative CA-MRSA strains in mouse models of infection and found 
that strains deficient in PVL remained as virulent as PVL-positive strains. This 
finding was also supported by experiments using PVL knockout strains of 
USA300 and USA400, which caused comparable skin disease to the isogenic 
wild type strains. PVL may therefore be a potentially useful epidemiological 
marker for CA-MRSA strains in some cases but appears not to be the major 
determinant of virulence in these strains.  
α-toxin and PVL are just two examples of well-characterised toxins of S. aureus. 
A variety of toxins are produced by this bacterium, as listed above, and whilst 
there are differences in the mechanisms by which they damage host cells, all 
have the potential to be potent effectors of virulence during staphylococcal 
disease. 
Interestingly, work by Laabei et al. (2014) demonstrated that a greater amount of 
phenotypic variation is seen among the toxins of S. aureus when compared to 
adhesive proteins, which may account for the wide variety of diseases this 
bacterium can cause. Expanding on this, work by Laabei et al. in 2015 
demonstrated that isolates extracted from skin and soft tissue infections are more 
often caused by high-toxic S. aureus strains, while isolates extracted from 
patients with life-threatening bacteraemia and septicaemia had comparatively low 
levels of toxicity, although among isolates causing bacteraemia, those with higher 
toxicity were more likely to cause mortality (Recker et al., 2017). Once a strain 
has gained access to the bloodstream it is not known whether it is capable of 
switching its level of toxicity, and strains are grouped into high- and low-toxic on 
the basis of in vitro assays. This inverse correlation between toxicity and disease 
severity was also observed by Nozohoor et al. in their work of 1998, in which 
lower levels of α-toxin were observed in strains causative of endocarditis 
compared to wound infection and nasopharyngeal carriage strains.  
This difference between surface infections and invasive disease could be 
explained by the concept that the skin is a difficult physical barrier to break 
through and in which to maintain an infection, requiring higher virulence in the 
infecting isolate during the initial stages of colonisation and disease, whilst an 
isolate which has gained entry to the blood does not need to be highly virulent to 
cause potentially fatal disease. Importantly, this work by Laabei et al. (2014; 
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2015) suggests that staphylococcal toxicity may be tightly linked to disease 
severity, even if this link is an inverse relationship between the two. If we can 
better understand this phenotype, we may be better able both to predict the 
severity of disease and provide appropriate, personalised treatment. The work 
presented in chapter 3 of this thesis contributes to a better understanding of the 
genetic factors that contribute to toxicity in S. aureus. Furthermore, it is becoming 
increasingly clear that toxins are not just offensive tools used solely in the 
destruction of host cells, but that they contribute to various stages of the bacterial 
life cycle, including colonisation and asymptomatic carriage. 
1.3.2.4 Changing perspectives on toxin function 
Whilst much research has focused on the damaging effects of toxins in relation to 
their impact on host cells, Rudkin et al. (2017) emphasise that if we are to fully 
understand the role of toxins in the bacterial life cycle we must move away from a 
disease-centric perspective. While toxins are clearly advantageous to a 
bacterium in contributing to nutrient acquisition and transmission, from an 
evolutionary point of view, a highly toxic staphylococcal strain that causes fatal 
disease could find itself at an evolutionary dead-end upon the death of its host. 
So, what evolutionary advantage do such toxins provide? 
Recent work has started to shift from a host perspective to the bacterial 
perspective, particularly focusing on the adaptable role of toxins in colonisation 
and asymptomatic carriage, alongside pathogenesis within a host. For example, it 
is now acknowledged that bloodstream staphylococcal isolates exhibit reduced 
toxicity compared to carriage and skin infection isolates (Nozohoor et al., 1998; 
Laabei et al., 2015), and that bacteraemia in a patient often stems from their own 
originally asymptomatic carriage isolate which transitions to cause invasive 
bloodstream infection (von Eiff et al., 2001). To understand why this happens, we 
must look further into the role of toxins in the initial stages of infection and into the 
evolutionary changes that occur within a population over a short space of time to 
effect changes in the infectious state.  
Work by Das et al. (2016) has demonstrated that staphylococci undergo evolution 
within the human body, mutating the transcription factor repressor of surface 
proteins (rsp) to attenuate toxin production and transition from an asymptomatic, 
high-toxic carriage isolate to an attenuated-cytotoxicity, non-haemolytic 
phenotype capable of causing serious bloodstream infection. This ability of 
staphylococci to transition within the host based on the manipulation of toxin 
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expression demonstrates the important contribution of toxins at different stages of 
the bacterial life cycle, something we must work to understand if we are to gain a 
complete picture of the progression of staphylococcal pathogenesis.  
It is important to note that host factors should not be forgotten in contributing to 
changes in the state of staphylococcal carriage isolates, as changes in immune 
status may be the initial trigger which allows changes in the bacterial phenotype 
to facilitate invasive infection. Nonetheless, further investigation of the genetic 
contributors to virulence, and specifically toxicity, in pathogens such as S. aureus 
will be useful in improving this understanding of the progression of staphylococcal 
pathogenesis during infection and disease, elucidating how toxicity is regulated 
throughout the bacterial life cycle to the detriment of the host. 
1.3.3 Regulation of virulence determinants in S. aureus 
The individual contribution of certain virulence regulators, such as the accessory 
gene regulator (agr) and the staphylococcal accessory regulator (sarA) have 
been extensively studied in S. aureus to characterise their role in virulence. 
However, the epistatic interactions between the broad range of genes which can 
influence virulence in S. aureus are less well characterised, and as yet it is not 
possible to produce a generalised model of the virulence regulatory network of 
this bacterium that is applicable to all strains. Furthermore, we do not yet have a 
complete picture of the network of genes which contribute individually to 
staphylococcal pathogenesis. Priest et al. (2012) demonstrate the complexity of 




Figure 1.7. The known virulence regulatory network in S. aureus. This figure is taken 
from Priest et al. (2012), reused with permission from the corresponding author. Inside 
the circle are all the regulatory genes shown to affect each other and virulence. Outside 
the circle, the known effects of each regulator on adhesion (A), toxicity (T) and evasion 
(E) are indicated. Question marks indicate either no information is available regarding the 
direct activity of the regulator, or that available information is conflicting. The authors note 
that much of the data used to generate this image is qualitative. 
 
Work by Peacock et al. (2002) further demonstrates the effect individual 
virulence-related genes can have in combination on the virulence phenotype of 
an isolate. Here, the authors studied the contributions of a variety of adhesins 
and toxins to invasive staphylococcal disease and found seven virulence factor 
genes which were significantly more common in invasive S. aureus isolates 
compared to carriage isolates. Interestingly, no single factor emerged as a 
predominant effector of virulence, but each appeared to have a cumulative effect 
on the virulent phenotype. 
Production of virulence factors by S. aureus is affected by environmental signals 
and growth conditions, and changes in virulence factor expression in response to 
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these signals is predominantly regulated at the transcriptional level by two-
component regulatory systems such as agr, saeRS, srrAB, arlSR and lytRS 
(Bronner et al., 2004). The most well-known of these is the global regulator agr.  
1.3.3.1 The Agr quorum sensing system 
The accessory gene regulator (agr) system is a two-component quorum sensing 
system and a global regulator of virulence in S. aureus. The operon consists of 
the genes agrABCD, two promoters P2 and P3 and the small regulatory RNA 
(srRNA) gene RNAIII, which also encodes the phenol soluble modulin δ-toxin 
(see figure 1.8).  
AgrA is an intracellular regulatory protein which is phosphorylated by the 
membrane-bound histidine kinase AgrC (Wang et al., 2014; Rajasree et al., 
2016). Phosphorylated AgrA then interacts with the divergent P2 and P3 
promoters, stimulating expression of the agr operon via the P2 promoter, and 
expression of the global virulence regulator RNAIII via the P3 promoter (Koenig 
et al., 2004, Reyes et al., 2011). The first gene downstream of P2 is AgrB; a 
transmembrane protein that modifies the AgrD propeptide post-translationally and 
transports the modified AgrD, referred to as autoinducing peptide (AIP), through 
the membrane to the extracellular space (Ji et al., 1997; Otto et al., 1998; Zhang 
et al., 2002). AIP binds the protein histidine kinase receptor AgrC, stimulating 
autophosphorylation of the receptor which then transfers the phosphoryl group to 
AgrA (Lina et al., 1998; Wang et al., 2014), and the cycle continues.  
 
Figure 1.8. The agr operon in S. aureus. Diagram of the agr operon illustrating the role 
of each component in this two-component quorum sensing system.  
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From the P3 promoter, phosphorylated AgrA stimulates expression of the small 
regulatory RNAIII (sRNA), which regulates expression of several virulence genes; 
expression of adhesive proteins is downregulated, including those involved in 
biofilm production, as are immune evasion proteins such as protein A (Cheung et 
al., 1997; Vuong et al., 2000; Boles & Horswill, 2008), whilst expression of toxins 
and other virulence factors is simultaneously upregulated, for example α-, β- and 
δ-haemolysins, staphylokinase and nuclease (Recsei et al., 1986; Morfeldt et al., 
1988). Adhesins and immune evasion proteins are downregulated at this stage 
as the bacterium transitions from colonisation of the host, for which both will be 
required, to invasion and persistence within the host, for which actively damaging 
toxic proteins are required.  
RNAIII regulates gene expression by base pairing with target mRNA sequences 
to mediate translation, which is achieved through interactions with the Shine-
Dalgarno sequence of the target mRNA (Gupta et al., 2015). This interaction can 
either lead to inhibition of translation in which RNAIII binds the Shine-Dalgarno 
sequence (as in the case of adhesive proteins) or facilitation of translation 
whereby RNAIII unmasks the Shine-Dalgarno sequence (as in the case of alpha-
toxin). S. aureus mutants deficient in Agr activity have been shown on several 
occasions to be severely attenuated in virulence (Janzon & Arvidson, 1990; 
Abdelnour et al., 1993; Gillaspy et al., 1995), demonstrating the importance of 
this system in pathogenic S. aureus isolates.  
As cell density increases, AIP levels increase concomitantly, stimulating further 
phosphorylation of AgrA in cells within the population, and in this manner creating 
a positive feedback loop. Toxin production and secretion therefore increases with 
Agr activity and decreases with its repression; effects on this system are usually 





1.3.3.2 The TCA cycle 
 
Figure 1.9. The Tricarboxylic Acid (TCA) Cycle in S. aureus. Diagram of the TCA 
cycle in S. aureus illustrating each intermediate involved in the cycle, the enzymes which 
catabolise each step, the energy, reduced dinucleotides and CO2 that are produced and 
the H2O that is used throughout the cycle.  
 
The tricarboxylic acid (TCA) cycle is a key part of metabolism in S. aureus. 
During aerobic growth of S. aureus in vitro, in the presence of a catabolisable 
carbon source and glutamate, the TCA cycle is repressed throughout the 
exponential growth phase (Somerville et al., 2003a). Pyruvate is metabolised via 
glycolysis producing acetyl-coenzyme A, which is converted to acetylphosphate 
before being used to generate ATP (Somerville et al., 2002; Somerville et al., 
2003a). A by-product of this reaction is acetate, which accumulates exogenously 
in the cell medium (Somerville et al., 2002). Once the bacteria enter stationary 
phase, and the supply of external amino acids becomes growth limiting (Zhu et 
al., 2009), the TCA cycle is derepressed such that the accumulated acetate in the 
culture medium is catabolised in place of pyruvate (Somerville et al., 2003a). This 




Figure 1.10. Glucose catabolism by S. aureus. Illustration of the reactions which take 
place during the exponential phase (green arrows) and reactions which take place during 
the post-exponential phase (red arrows) in S. aureus. Black arrows indicate reactions for 
which there are insufficient data to determine whether they occur. Figure from Somerville 
et al. (2003a) reproduced with permission, copyright American Society for Microbiology. 
 
When the TCA cycle is active, reduced dinucleotides (eg. NADH, FADH2) 
produced from the cycle donate electrons to membrane-bound electron acceptors 
in the electron transport chain, producing energy in the form of ATP, as shown in 
figure 1.11 (Dickerson et al., 1976; Schaetzle et al., 2008).  
 
Figure 1.11. Donations of electrons from reduced dinucleotides to the electron 
transport chain. Reduced dinucleotides produced from the TCA cycle donate electrons 
to the electron transport chain, where they are used to fuel ATP production. Figure from 
Schaetzle et al., 2008, reproduced with permission from the Royal Society of Chemistry.  
 
There is therefore a close link between electron transport and TCA cycle activity; 
in the absence of a functional electron transport chain, the TCA cycle can be 
repressed through a process of feedback inhibition, possibly mediated through 
the action of the transcriptional regulator ArcA. For example, in E. coli it has been 
shown that ArcA, part of a two-component system, represses expression of 
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genes involved in respiratory metabolism under anaerobic or microaerobic 
conditions, including enzymes of the TCA cycle (Georgellis et al., 2001; Malpica 
et al., 2004; Perrenoud & Sauer, 2005). ArcA also simultaneously upregulates 
expression of genes involved in fermentation, allowing energy production to 
continue in the absence of aerobic respiration (Georgellis et al., 2001).  
1.3.3.3 Metabolism, Agr activity and toxin production 
Changes in cell metabolism can have important consequences for production of 
virulence factors including toxins, which are energetically costly to produce, and 
mutants deficient in TCA cycle activity have been shown many times to exhibit 
attenuated virulence (Somerville et al., 2002; Somerville et al., 2003b; Zhu et al., 
2009; Sadykov et al., 2010), as have mutants in electron transport (McNamara & 
Proctor, 2000; Kohler et al., 2003). Work by Proctor & Peters (1998) discusses 
how decreasing ATP levels can activate the stress sigma factor σB. This is 
thought to interact with the global regulator sar, which in turn interacts with the 
agr system, and in the absence of sufficient levels of ATP this chain of 
interactions results in downregulation of agr and a subsequent reduction in toxin 
production.  
Evidence for this chain of interactions is corroborated in work by Chan & Foster 
(1998), who demonstrate that the global virulence regulator SarA responds to 
changes in aeration during growth to influence expression of the toxin α-
haemolysin and a number of staphylococcal proteases. Further work by Chan et 
al. (1998) investigates the interactions between SarA and σB and demonstrates a 
close relationship between environmental, and therefore metabolic stresses, and 
subsequent regulation of virulence factor production. Cell metabolism is therefore 
tightly linked to pathogenicity in S. aureus. 
1.3.5 Prior research into S. aureus toxicity  
Interestingly, community-acquired isolates have been shown to be more toxic to 
the host than hospital-acquired isolates (Rudkin et al, 2012). This is thought to be 
because healthy people in the community will present more of a challenge to the 
pathogen, and as such it must be more virulent to colonise and cause disease in 
an otherwise healthy host. Whereas in patients who are already vulnerable to 
infection, even isolates of low virulence will be able to colonise the host and 
cause disease.  
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Following on from this, work by Laabei et al (2015) has shown that S. aureus 
isolates which cause severe bacteraemia (infection of the blood) are less toxic 
than isolates which cause relatively mild skin and soft tissue infections. This is 
thought to result from a trade-off between virulence and disease severity, 
because toxin production is an energetically expensive activity, and as the 
bloodstream is quite a hostile environment for the bacteria it acts as an extreme 
bottleneck. As such only the fittest bacteria (i.e. those not expending 
unnecessary energy on toxin production at this specific stage of disease) 
successfully survive this.  
These results stemmed from a genome-wide association study (GWAS) 
conducted in S. aureus which aimed to identify novel toxicity-affecting loci that 
contribute to the wide-ranging toxic phenotypes observed in this bacterium. From 
this GWAS and following functional verification of the results to identify true-
positive associations with the phenotype, numerous loci were identified as 
affecting toxicity. One of these, cyoE, is the subject of the first chapter of this 
thesis, which is characterised in-depth to identify the mechanism by which it 
exerts it’s effect on toxicity in S. aureus.   
Research such as this is important in making advances towards a better 
understanding of virulence in S. aureus, which in turn will contribute to the 
development of better treatments and more efficient use of the antibiotic 
treatments which are still effective. While there is specific focus on a single gene 
here, this kind of research is important if the function of individual genes in 
relation to virulence is to be understood in the context of the wider genetic 
network of toxicity effectors. Focussing on individual genes which are associated 
with the toxic phenotype also has the potential to identify novel drug targets, 
which in the short term may help to reduce the burden on current antibiotics as a 
first resort for treatment by expanding the current pool of available antibiotics.  
A long-term aim of research such as this is to eventually develop a system of 
sequenced-based diagnosis, in which an infecting isolate can be sequenced 
quickly and accurately to determine its genetic profile, the specific treatment 
required by an individual patient, and any potential complications which may 
arise. In terms of moving towards this long-term goal, whole genome sequencing 
of bacterial isolates in real time during disease outbreaks has proven to be an 
extremely useful tool (eg. Quick et al., 2016), despite being somewhat limited to 
studying the evolution of bacterial pathogens and the epidemiology of disease 
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transmission in many cases (Young et al., 2012; Harris et al., 2010). However, 
simply knowing the genome sequence of an isolate is of little use unless we can 
fully understand the function of genes which contribute to the pathogenic 
phenotype. This point is highlighted by Viney (2014), which stresses the 
importance of understanding individual gene function in an era when it is 
becoming increasingly common to compare similarities between genomes 
instead of focussing on the function of specific genes. If whole genome 
sequencing is to be used in the future to improve disease treatment, it is 
necessary to study individual gene function in relation to pathogenesis so that 
pathogenic genomes can be sequenced and interpreted in a way which will be 
clinically useful. 
1.4.0 Introduction to Streptococcus pneumoniae 
1.4.1 Pneumococcal disease severity and prevalence 
Streptococcus pneumoniae is an opportunistic pathogen which normally inhabits 
the nasopharynx in a small proportion of the population as a commensal, but can 
cause life-threatening invasive disease in the form of pneumonia if it is able to 
enter the respiratory tract, meningitis if it is able to breach the blood-brain barrier, 
and septicaemia if it is able to enter the bloodstream (Ioachimescu et al., 2004; 
O’Brien et al., 2009; Deng et al., 2016). Carriage rates vary, with children below 
the age of five having the highest carriage rates of up to around 50-60% (Regev-
Yochay et al., 2003; Hussain et al., 2005; Henriques-Normark & Normark, 2010), 
while carriage rates in adults tend to be much lower at around 2-20% (Hussain et 
al., 2005; Hendley et al., 1975; Costello et al., 2016). 
Young children are at a particularly high risk of serious invasive disease, with an 
estimated 800,000 deaths worldwide in children under five attributable to invasive 
pneumococcal disease each year (Deng et al., 2016). The burden of 
pneumococcal disease has been such that the World Health Organization 
recently announced a global action plan to help end preventable child deaths 
from pneumonia by 2025; this is hoped to be achieved through improving 
hygiene, and increasing availability and uptake of the pneumococcal vaccine in 
poor and remote communities where prevalence of the disease is high (WHO & 
UNICEF, 2013).  
While access to vaccines and antibiotic treatment for pneumococcal disease is 
much better in developed countries, pneumococcal infections are becoming 
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increasingly problematic in patients with other underlying health conditions such 
as COPD or previous respiratory tract infection and in hospitalised patients with 
compromised immunity (Niederman & Zumla, 2016; Sibila et al., 2016). 
Complications also arise when infection is caused by multi-drug resistant strains 
of S. pneumoniae, which although not yet at epidemic levels, are also becoming 
an increasing problem. 
A further issue with controlling the spread of disease caused by S. pneumoniae is 
that there are over 90 known serotypes of this bacterium (Henrichsen, 1995; 
Mehr & Wood, 2012), which differ based on the antigenic properties of their 
polysaccharide capsule. Vaccines currently in use cover between 7 and 23 of the 
most virulent serotypes, but the 23-valent vaccine is not immunogenic in children 
below 2 years old, and therefore cannot be administered to the most at-risk age 
group. To induce an immune response in children under 2, a 13-valent conjugate 
vaccine was developed in which capsular antigens are conjugated to inactivated 
diphtheria toxin. 
While these pneumococcal vaccines confer protection against the serotypes they 
target, clinicians are beginning to see increasing evidence of serotype 
replacement, whereby non-vaccine serotypes of S. pneumoniae which have not 
previously caused high levels of disease become more prevalent in clinical 
samples obtained from pneumococcal infection (Spratt & Greenwood, 2000; 
Brueggemann et al., 2003), while serotypes included in the vaccine become less 
prevalent. This is illustrated in figures 1.12 and 1.13 below. 
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Figure 1.12. Incidence of invasive pneumococcal disease in children <2yrs caused 
by vaccine serotypes from 2006-2018/19. Disease caused by strains included in the 
Prevenar13 vaccine is shown to be reduced in incidence over the period from 2006-2019. 
Figure from Public Health England (2018b), reused under the Open Government Licence 
v3.0. 
 
Figure 1.13. Incidence of invasive pneumococcal disease in children <2yrs caused 
by non-vaccine serotypes from 2006-2018/19. Disease caused by strains not included 
in Prevenar13 is shown to have increased in incidence since 2006, showing the inverse 
pattern to figure 1.12. Figure from Public Health England (2018c), reused under the Open 
Government Licence v3.0. 
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Clearly, there is a need to reduce the burden of disease caused by S. 
pneumoniae, and with increasing levels of antibiotic resistance being observed 
there will soon be an urgent need to find alternative treatments for this pathogen. 
To achieve this, we need to fully understand how this pathogen causes disease 
and in turn use this knowledge to find new targets for treatment of disease. 
1.4.2 Streptococcus pneumoniae virulence and pathogenicity 
Streptococcus pneumoniae has an array of virulence factors, including the 
antiphagocytic polysaccharide capsule, a wide range of adhesins and cell surface 
proteins, and the toxin pneumolysin. Interestingly, and unlike other opportunistic 
pathogens which inhabit the nasopharynx, pneumolysin is the only toxin 
produced by this bacterium. The range of virulence factors found in this pathogen 
and their locations within the cell are illustrated in figure 1.14 below, from van der 




Figure 1.14: Virulence factors of pneumococcus. PsaA= pneumococcal surface 
antigen A. PiaA/PiuA= pneumococcal iron acquisition & uptake. PsrP=pneumococcal 
serine-rich repeat protein. NanA=neuraminidase. Eno=enolase. PavA=pneumococcal 
adhesion & virulence. LytA=autolysin. StrA=sortase A. Hyl=hyaluronate lyase. 
LTA=lipoteichoic acid. PspC=pneumococcal surface protein C. PspA=pneumococcal 
surface protein A. Cps=polysaccharide capsule. PAF=platelet-activating factor. Figure 
from van der Poll & Opal (2009), reproduced with permission from Elsevier. 
 
1.4.2.1 The pneumococcal capsule 
The polysaccharide capsule is a key virulence factor for this pathogen, and 
antigenic differences between encapsulated strains are responsible for the large 
number of different serotypes within the species which is such a problem for 
vaccine development. The capsule has several virulence-related functions 
including antiphagocytic activity, prevention of removal of the pneumococcus by 
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mucus in the respiratory tract and reducing sensitivity to antibiotics (Mitchell & 
Mitchell, 2010).  
Several groups have investigated the role of the pneumococcal capsule in 
colonisation of the upper respiratory tract during the initial stages of infection. Kim 
& Weiser (1998) explored the differences in capsule production between the 
opaque and transparent colony phenotypes of S. pneumoniae and the resulting 
effect on virulence. It was shown that the more virulent opaque phenotype was 
generally associated with greater amounts of capsular polysaccharide and 
systemic infection, while the transparent phenotype with comparatively reduced 
capsular polysaccharide in general was selected for during colonisation. 
However, Magee & Yother (2001) observed that the ability of capsule specific 
antibodies to be protective against pneumococcal carriage, in combination with 
variations in the ability of different serotypes to colonise the nasopharynx based 
on capsular differences, suggests an important role for the capsule during the 
colonisation process. The authors go on to demonstrate that capsular 
polysaccharide is essential for colonisation by strains of serotypes 2 and 3, with 
unencapsulated strains shown to be unable to colonise the nasopharynx in a 
mouse model of infection.  
It is well established that the capsule is essential for virulence during the later 
stages of pneumococcal disease, since a body of work has shown that 
unencapsulated strains suffer a significant loss in virulence compared to wild type 
encapsulated strains (Avery & Dubos, 1931; Watson & Musher, 1990; Bender et 
al., 2003). The specific mechanism by which the capsule contributes to virulence 
was confirmed in work by Hyams et al. (2010), in which the authors showed that 
the capsule prevents opsonisation of the bacterium with factors C3b and iC3b of 
the alternative and classical complement pathways, and inhibits conversion of 
surface-bound C3b to iC3b. Binding of IgG and C-reactive protein to 
unencapsulated pneumococci suggested that the capsule also serves to mask 
antibody recognition of subcapsular antigens to inhibit opsonophagocytosis and it 
was further shown that the capsule inhibits a multitude of receptors to interfere 
with neutrophil phagocytosis.  
Work by Wartha et al. (2007) additionally confirms the role of the capsule in 
interference with host neutrophils; here the authors show that presence of a 
capsule around the pneumococcal cell can protect against the action of 
neutrophil extracellular traps. Specifically, it was shown that capsule expression 
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reduces the extent to which pneumococcal cells remain trapped, and that in 
combination with the incorporation of D-alanine to lipoteichoic acid on the 
bacterial membrane, the capsule facilitates resistance to the action of 
antimicrobial peptides (AMPs) produced by neutrophils by creating a positive 
charge that repels the likewise positively charged AMPs.  
Interestingly, pneumococci were shown in work by Hammerschmidt et al. (2005) 
to modulate capsule expression at different stages of infection, such that 
pneumococcal cells in contact with host cells express a reduced amount of 
capsule while those not in contact with the host exhibit a thick capsule layer. It 
was demonstrated that this resulted from active down-regulation of capsule as 
opposed to the enrichment of acapsular mutants within the population. This 
reduction of the capsular polysaccharide layer facilitates adhesion and invasion 
of the pneumococcus, exposing surface proteins and adhesins within the cell wall 
which promote attachment to host epithelial cells. However, capsule production 
must be strictly regulated to prevent exposure of the pneumococcus to clearance 
by the host immune system.  
1.4.2.2 Surface proteins and adhesins 
Several virulence related surface proteins have been described in the literature 
which contribute to pathogenesis throughout the stages of colonisation and 
invasion. These include LPXTG-anchored surface proteins, lipoproteins, and 
choline-binding proteins. Figure 1.15 depicts some of the key families of 
pneumococcal surface proteins. 
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Figure 1.15. The pneumococcal cell wall and surface-exposed proteins. The 
pneumococcal cell wall consists of a phospholipid membrane (LM), peptidoglycan (PG), 
and teichoic and lipoteichoic acids. The cell wall also contains phosphorylcholine (PCho), 
which anchors choline-binding proteins (CBPs) non-covalently on the cell wall. Virulence 
proteins of the different classes of pneumococcal surface proteins are depicted. From 




Table 1.1. Names and functions of pneumococcal LPXTG-anchored surface 
proteins. 
 
LPXTG-anchored surface proteins are so named because of the LPXTG amino 
acid motif found at the C-terminus of these proteins that acts as a substrate for 
sortase enzymes during the anchoring of proteins to the cell wall (Navarre & 
Schneewind, 1994). This group encompasses several proteases, including the 
enzymes IgA1-protease, neuraminidase (NanA) and the serine proteases HtrA 
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and PrtA. These enzymes act to break down connective tissue, extracellular 
matrix and cell wall components within the host, facilitating invasion of host 
tissues and establishment of infection (Mitchell & Mitchell, 2010).  
IgA1-protease acts to cleave the hinge region of human IgA1 bound to the 
bacterial cell surface, thereby subverting the immune response and aiding 
persistence within the host (Chi et al., 2016). NanA cleaves terminal sialic acid 
residues on cell surfaces, affecting the function of immune defence proteins such 
as lactoferrin and IgA2 (King et al., 2004), modifying the surface of competing 
bacteria to gain an advantage within the niche, and exposing potential receptors 
on the epithelial cell surface to which the pneumococcal cell can then adhere 
(King et al., 2006; Parker et al., 2009). NanA has been shown to play a major role 
in adherence, colonisation and to a lesser extent in biofilm formation during 
disease to promote survival and persistence of the pneumococcus within the host 
(Brittan et al., 2012).  
The serine proteases HtrA (high temperature requirement A) and PrtA (cell wall-
associated serine protease A) have both been shown to contribute to virulence in 
models of pneumococcal disease. HtrA is a posttranslational regulator which 
functions in the stress response, competence and cell division in the 
pneumococci, and HtrA-deficient mutants exhibit attenuated virulence (Ibrahim et 
al., 2004; de Stoppelaar et al., 2013). Likewise PrtA has been shown to play an 
important role in intraperitoneal infection and lung inflammation, with PrtA-
deficient mutants exhibiting reduced virulence (Bethe et al., 2001; Hsu et al., 
2018). However, the exact role of this protease is unknown (Mitchell & Mitchell, 
2010).  
Lipoproteins 





Lipoproteins such as pneumococcal surface adhesin A (PsaA) play an important 
role in adhesion to host epithelial cells during colonisation. PsaA is an ABC-type 
permease complex involved in the transport of manganese ions across the cell 
membrane and adhesion to host epithelium (Rajam et al., 2008). Anderton et al. 
(2007) demonstrated that E-cadherin, the eukaryotic cell-cell junction adhesin, is 
the receptor for PsaA in host epithelial tissue. When the function of PsaA is 
disrupted, a loss in virulence and adhesive ability is observed, along with 
increased sensitivity to oxidative stress (Berry & Paton, 1996; Dintilhac et al., 
1997). Interestingly, Ogunniyi et al. (2002) found PsaA to be one of the most 
abundant virulence proteins at various time points after intraperitoneal infection, 
suggesting an extensive role in pneumococcal virulence for this protein. 
Other pneumococcal ABC transporters, including PiaA (pneumococcal iron 
acquisition protein A) and PiuA (pneumococcal iron uptake protein A), have been 
shown to be important for pneumococcal virulence in systemic and pulmonary 
murine models of infection (Brown et al., 2001), and elicit a strong, serotype-
independent immunological response in infants as young as 7 months old 
(Whalan et al., 2005). Peptide permeases such as PlpA and Ami have also been 
found to play an important role in colonization of the respiratory tract by binding to 
glycoconjugate receptors on the surface of pneumocytes - the cells that line the 
walls of the alveoli (Cundell et al., 1995; Salyers & Whitt, 2002). 
Choline-binding proteins 
Table 1.3 Names and functions of pneumococcal choline-binding proteins. 
 
 
The choline-binding protein family are another group of important contributors to 
pneumococcal virulence, and similarly to PlpA and Ami, proteins such as choline-
binding protein A (CbpA) have been shown to adhere to type II pneumocytes and 
glycoconjugate receptors on host epithelial cells. When disrupted in animal 
models, pneumococci deficient in CbpA exhibit a loss in ability to colonise the 
nasopharynx (Rosenow et al., 1997; Paton, 1998). This family of proteins also 
includes one of the major contributors to virulence in pneumococci; the autolytic 
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enzyme LytA which causes lysis of a proportion of the population in the stationary 
phase of growth. This phenomenon is distinguishable from apoptosis in that it can 
be induced in one cell through the action of a related, predatory cell within the 
population. Apoptosis on the other hand is defined as a form of ‘programmed’ cell 
death, which is rarely discussed in the literature in the context of the 
pneumococcus as the focus is usually on virulence-related phenotypes. Autolysis 
is discussed in further detail in section 1.4.2.3 below. 
Non-classical proteins 
Table 1.4 Names and functions of non-classical pneumococcal surface proteins. 
 
 
Other surface proteins and adhesive virulence factors which do not fit into one of 
the above-mentioned categories include the pneumococcal pilus, which is found 
in a small number of clinical strains (Barocchi et al., 2005), and 
phosphorylcholine, which anchors the choline-binding proteins to the cell wall 
(Bergmann & Hammerschmidt, 2006). Analysis of the S. pneumoniae genome by 
Bagnoli et al. (2008) highlighted the presence of genes which encode two types 
of pilus islets, thought to play an important role in initial attachment and 
colonisation of the respiratory tract and in eliciting an inflammatory response 
within the host. Cell wall phosphorylcholine has been shown to bind host cell 
platelet activating factor (PAF) to promote inflammation (Cundell, Masure & 
Tuomanen, 1995; Jenkinson, 1997). 
The surface proteins and adhesins discussed here are just some examples of the 
extensive range of proteins S. pneumoniae employs to colonise and invade the 
host respiratory tract. One of the most interesting and perplexing of these is the 
autolytic enzyme LytA, which has been extensively studied for its contribution to 




An interesting characteristic of the pneumococcus is its propensity to undergo 
autolysis in the stationary phase of growth. Autolysis is the destruction of cells 
within a population as a direct result of the action of their own lytic enzyme(s). 
When the pneumococcal population reaches a particular density, typically during 
the stationary phase of the life cycle, a proportion of cells within the population 
will lyse in response to the action of autolysin, a single lytic enzyme encoded by 
the gene lytA. This results in the release of cytoplasmic components into the 
extracellular environment, including pneumolysin, inflammatory cell wall 
fragments, a host of virulence factors, and non-virulent components including 
nutrients and DNA. 
Many suggestions have been put forward in the literature as to why this process 
occurs in pneumococci, and it is still largely unclear what advantage there is to be 
gained from a bacterial population inducing lysis of a proportion of its own 
cells. Possible explanations include:  
• To release pneumolysin and other virulence factors for the purpose of 
acquiring nutrients from host cells during disease (Berry et al., 
1989; Canvin et al., 1995; Hirst et al., 2008)  
• Fratricidal lysis whereby cells within the population which are not 
competent for genetic transformation are purposefully lysed 
by neighbouring competent cells (Claverys & Håvarstein, 2007; Guiral et 
al., 2005) – discussed further in section 1.4.2.5 below 
• To release intracellular components for evasion of the host immune 
system during disease (Martner et al., 2009; Mellroth et al., 2012)  
• To separate daughter cells at the end of cell division (Ronda et al., 1987)  
Autolysin is an N-acetylmuramyl L-alanine amidase (Howard & Gooder, 1974), 
and a member of the choline-binding family of proteins. It acts specifically to 
cleave the bond between muramic acid and alanine in the peptidoglycan cell wall 
(Howard & Gooder, 1974; Mosser & Tomasz, 1970), causing the cell wall to 
break apart and release intracellular components into the extracellular 
environment. Much research into autolysin has focused on its potential 
fundamental role in pneumococcal virulence, based primarily on observations 
that autolysin-deficient mutants show reduced virulence in comparison to wild 
type strains (Berry et al., 1989; Canvin et al., 1995; Hirst et al., 2008).   
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Berry et al. in 1989 presented an early example of an autolysin-deficient mutant 
in strain D39 which showed a significant reduction in virulence in vivo compared 
to the wild type. Furthermore, Canvin et al. (1995) noted that unencapsulated 
pneumococcus was causing disease in agranulocytic animals (lacking 
neutrophils), while capsular polysaccharide was found to be non-inflammatory in 
these animals. Traditionally the polysaccharide capsule has been considered the 
most important virulence factor employed by the pneumococcus, with 
unencapsulated strains showing reduced virulence in comparison to 
encapsulated strains (Avery & Dubos, 1931; Watson & Musher, 1990); this work, 
however, demonstrated that the capsule was not the only key virulence factor in 
facilitating the onset of disease, and further to the work of Berry et al., it 
was demonstrated by Canvin et al. that mice infected with an autolysin-
deficient strain of D39 showed no signs of disease, and notably the mutant was 
found to die in vivo.   
The most obvious reason for the loss of virulence in these mutants would be that 
they no longer release virulence factors into the extracellular environment as a 
direct result of the deficiency in autolysin. Pneumolysin, for instance, lacks an N-
terminal secretory signal domain (Price & Camilli, 2009), and therefore is not 
secreted by infecting cells, but instead is reliant on the action of autolysin for 
deployment into the extracellular environment. Likewise release of degraded 
peptidoglycan fragments and teichoic acid from lysed pneumococcal cells elicits 
a strong inflammatory response in an infected host as a direct result of the action 
of autolysin (Mitchell, 2000).  
Interestingly, recent work looking at the relationship between the genes encoding 
autolysin and pneumolysin suggests that the lytA and ply genes are tightly linked 
on a pathogenicity island (Morales et al., 2015), and suggests a close 
evolutionary relationship between the two proteins which may add weight to the 
original theory that the primary role of autolysin is to do with the release of 
pneumolysin during infection. 
1.4.2.4 Pneumolysin 
The role of the toxin pneumolysin however is much clearer; pneumolysin is a 
major virulence factor for S. pneumoniae that is present in all serotypes (Hirst et 
al., 2004), and contributes greatly to the symptoms of disease observed in 
patients suffering from pneumococcal infection. Pneumolysin is a cholesterol-
dependent cytolytic pore-forming toxin that is localised to the bacterial cell wall 
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(Price & Camilli, 2009). When released from cells, generally thought to be as a 
result of autolysis, it binds to cholesterol in the membranes of host epithelial cells, 
inserts into the lipid bilayer, and forms a transmembrane pore which ultimately 
causes lysis of the host cell (Paton, 1996). Depending on the location of infection, 
pneumolysin can cause extensive damage to the lungs and central nervous 
system. Several studies have illustrated significantly decreased virulence in 
animal models of infection when S. pneumoniae is deficient in this toxin, and it 
has long been accepted as a key virulence factor alongside the capsule (Canvin 
et al., 1995; Wellmer et al., 2002; Hirst et al., 2004; Hirst et al., 2008). 
Nonetheless, the contribution of pneumolysin to virulence extends much further 
than pore-formation and lysis of host cells (summarised in figure 1.16 below).  
 
Figure 1.16. Inflammatory vs. tolerogenic properties of pneumolysin. The 
contribution of pneumolysin to virulence in S. pneumoniae is extensive, encompassing a 
variety of both inflammatory and tolerogenic properties which are used for different 
purposes depending on the stage of disease. From Neill et al. (2015), reproduced with 
permission from Elsevier. 
Pneumolysin has been shown to activate complement; the classical complement 
pathway is activated by binding to C1q and the Fc region of human IgG (Mitchell 
et al., 1991), which increases inflammation and tissue damage in the host 
through over-production of the anaphylatoxins C3a and C5a (Paton et al., 1984). 
In doing so, pneumolysin also causes a depletion of complement components to 
limit the amount of complement available to opsonise pneumococcal cells; this 
59 
 
reduces complement-mediated clearance, which is an important aspect of host 
immunity to pneumococcal infection (Andre et al., 2017). In conjunction with 
pneumolysin’s haemolytic activity on neutrophil cells, opsonophagocytosis is 
inhibited by the over-stimulation of complement, promoting evasion of the host 
immune system and persistence of pneumococci within the host (Rubins et al., 
1995; 1996).   
Further key interactions with host immunity have been demonstrated for 
pneumolysin, including proinflammatory interactions with Toll-like receptors 
(Malley et al., 2003), stimulation of a range of cytokines (Houldsworth et al., 
1994; Cockeran et al., 2002; Shoma et al., 2008) and the NLRP3 inflammasome 
(McNeela et al., 2010; Witzenrath et al., 2011), and direct interference with the 
function of immune cells such as dendritic cells, macrophages and neutrophils 
(Littman et al., 2009; Bewley et al., 2014; Nel et al., 2016b).  
Malley et al. (2003) demonstrated a specific relationship between pneumolysin 
and Toll-like receptor 4 (TLR4) produced by macrophages, which is responsible 
for the robust proinflammatory response of the host immune system to 
pneumolysin. The authors demonstrated that TLR4-deficient mice were 
significantly more susceptible to invasive pneumococcal disease than an isogenic 
wild type, and that the TLR4 response was independent of the cytolytic pore-
forming function of pneumolysin, as demonstrated using a non-cytolytic mutant of 
the toxin which was found to stimulate TLR4 production similarly to the wild type. 
The result of TLR4 stimulation in the host is the activation of caspase-1 and 
subsequent stimulation of inflammatory cytokines, which has been shown to be 
partly dependent on the NLRP3 inflammasome (Fang et al., 2011).  
The NLRP3 inflammasome plays an important role in immune clearance of 
pneumococci. NLRP3 stands for nucleotide-binding oligomerisation domain-like 
receptor family, pyrin domain containing 3 inflammasome (Witzenrath et al., 
2011); it is a large multimeric protein complex responsible for activation of the 
proinflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) via 
caspase-1, and initiates the process of pyroptosis, a form of programmed cell 
death which is crucial for controlling microbial infections (Bergsbaken et al., 2009; 
Yang et al., 2019). IL-1β and IL-18 regulate the response of the T-helper cells 
Th17 and Th1, respectively. In turn this determines the recruitment of neutrophils 
and macrophages to the site of infection and ultimately leads to bacterial 
clearance (van der Veerdonk et al., 2011). McNeela et al. (2010) identified 
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pneumolysin as an activator of the NLRP3 inflammasome and demonstrated that 
NLRP3 was required by the host for protective immunity against pneumococcal 
infection.  
Witzenrath et al. (2011) expanded on this to demonstrate that NLRP3 was 
specifically activated by pneumococcal serotypes expressing a haemolytic form 
of the toxin, while those expressing variants of pneumolysin with reduced 
haemolytic activity, such as serotypes 1 and 8, did not activate NLRP3. 
Serotypes 1 and 8 are associated with lower case fatality rates and are less 
damaging to the host, however, their ability to better evade recognition by the 
host immune system, including the NLRP3 inflammasome, contributes to their 
increased prevalence in causing invasive disease such as parapneumonic 
effusion and empyema.  
Of note, the genetic changes in the pneumolysin gene of the serotypes used by 
Witzenrath et al. provides an example of how population stratification and data 
filtration can affect statistical associations in GWAS; variations in this gene and 
their subsequent effect on bacterial virulence may be identified from GWAS 
approaches that account for a subset of different serotypes within a clonal 
complex, while approaches that do not account for population structure may 
overlook these associations because the genetic variants will be relatively rare 
within the population as a whole. Furthermore, the pneumolysin gene is generally 
highly conserved among pneumococcal strains, and so SNPs in this gene may 
be excluded from the initial data filtration step due to their relative rarity within a 
clonal complex. 
On the other hand, over-stimulation of NLRP3 by pneumolysin leads to increased 
tissue damage and disease severity in the host. For example, work by Hoegen et 
al. (2011) demonstrated that activation of NLRP3 by pneumolysin contributed to 
increased brain injury during pneumococcal meningitis in a murine model, and 
mutants lacking inflammasome components responsible for caspase-1 activation 
had lower disease severity. Clearly therefore, activation of NLRP3 is a crucial 
aspect of host immunity required for effective clearance of a pneumococcal 
infection, however activity of the inflammasome can be manipulated by 
pneumolysin for the benefit of the bacterium and there is a fine line between an 




The role of pneumolysin in disease extends yet further, with studies in recent 
years elucidating a role for the toxin in: inhibition of host defence cells such as 
microglia during meningitis (Hupp et al., 2019); induction of DNA damage and 
arrest of the cell cycle of host cells (Rai et al., 2016); promotion of host-to-host 
transmission of pneumococcal cells (Zafar et al., 2017); activation of platelets 
(Nel et al., 2016a) and stimulation of a wide range of host proinflammatory factors 
including TNF-α, interleukin-1 and neutrophil extracellular traps (Houldsworth et 
al., 1994; Nel et al., 2016b).  
Recent work has also implicated pneumolysin in initial colonization of the 
nasopharynx, where the bacterium is able to reside asymptomatically in healthy 
individuals; Hotomi et al. (2016) discuss pneumolysin-dependent invasion of 
nasal mucosa in the initial establishment of colonization, suggesting that the toxin 
may also have an important role in behaviour which is not directly related to 
virulence.  
A key problem in the treatment of invasive pneumococcal diseases is that the 
antibiotics which are most effective against S. pneumoniae infection are 
bacteriolytic and induce lysis of the bacterial cells (Hirst et al., 2004). As with the 
natural process of autolysis, this initiates the release of pneumolysin, 
inflammatory cell wall fragments and many other virulence factors which continue 
to damage host tissues in the short term, causing the symptoms of disease to 
worsen (McCullers & English, 2008; Nau & Eiffert, 2002; 2005). A better 
understanding of the genetic basis for pneumolysin production and its 
relationship to autolysis may prove useful in improving treatments for those 
suffering from serious invasive pneumococcal disease.  
1.4.2.5 Competence 
Autolytic activity and toxicity have been shown to be tightly linked in 
pneumococcal virulence. A third key component which contributes to virulence is 
competence for genetic transformation. S. pneumoniae was used in the initial 
experiments by Avery et al. (1944) to demonstrate the principle of genetic 
transformation and has since been used as a model organism for this process 
based on its characteristic of being naturally competent for uptake of DNA. 
Recent work has delved further into the role of competence in this species and 
has demonstrated an important link to both autolysis and virulence. 
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Competence - the state of being able to take up DNA from the extracellular 
environment - has been shown to directly influence lysis of cells within the 
pneumococcal population, whereby competent cells stimulate autolysis in non-
competent, but otherwise identical cells. This has been termed ‘fratricidal lysis’ 
(Claverys & Håvarstein, 2007), in which the only determinant of which cells lyse 
and which do not is the expression of competence-related genes. The 
mechanism of fratricidal lysis is discussed by Guiral et al. (2005) in their 
investigation of a two-peptide bacteriocin system which they named the 
competence induced bacteriocin system CibABC, expression of which is induced 
upon entering the competent state. The authors propose that competent cells 
induce the lysis of non-competent cells through cell-to-cell contacts, in 
which the CibA and CibB molecules of competent cells interact with the 
surface of non-competent cells to trigger the action of LytA (along with two other 
hydrolases LytC and CbpD). Competent cells remain protected from the action 
of CibAB by producing an immunity factor, named CibC. While the exact 
mechanism of action of the CibAB complex is not known, it was speculated 
that in interacting with the surface of non-competent cells, CibAB may insert into 
these cells to disrupt the membrane structure and in turn deplete energy levels 
within the cell, leading ultimately to lysis by hydrolytic enzymes. Figure 1.16 
illustrates the proposed CibAB mechanism of fratricidal lysis, termed ‘allolysis’ by 
Guiral et al.. 
 
 
Figure 1.17. Proposed model of allolysis in S. pneumoniae. (A) Pre-competent (pC) 
cells differ from competent (C) cells by the presence of the amidase CbpD, the two-
peptide bacteriocin CibAB and its immunity factor CibC. (B) Cell-to-cell contacts between 
competent and non-competent (NC) cells allows interaction of CibAB with NC cells, while 
competent cells are protected by CibC. (C) CibAB then triggers the action of CbpD, LytA 
and LytC on the cell wall of NC cells. (D) Cell wall disruption results in the release of 
intracellular components, including Ply, teichoic acid (TA), lipoteichoic acid (LTA) and 
chromosomal DNA. Figure from Guiral et al. (2005), copyright National Academy of 
Sciences.  
 
Cell-to-cell contacts were established as necessary for this interaction, and this is 
supported in previous work by Steinmoen et al. (2003). Here, it was established 
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that the lytic enzymes produced by competent pneumococcal cells are not 
released into the growth medium but are likely to be anchored to the cell surface 
through choline binding domains. To induce lysis in non-competent cells 
therefore, cell-to-cell contact would be required.  
‘Allolysis’, as defined by Guiral et al. (2005), differs from autolysis in that it is 
specifically triggered by the action of competent cells against non-competent cells 
within the population. This is not a suicidal response to nutrient depletion or 
environmental stress but is a predatory behaviour by a proportion of the 
population. Several possible reasons for the evolution of allolysis include the 
facilitation of genetic exchange, predation and competition among strains within a 
stationary phase population, or to facilitate the release of virulence factors from 
seemingly non-competent cells during infection. 
The relationship between competence and virulence has been observed in earlier 
work by Lau et al. (2001) and Bartilson et al. (2001), where mutants with 
disruptions in competence-related genes have been found to have attenuated 
virulence in mouse models of infection. For example, Lau et al. (2001) observed 
that mutants in genes of the com regulon, specifically comB and comD, were 
found to be attenuated in a bacteraemia model and in both bacteraemia and 
pulmonary models of infection respectively. ComB is a component of the ComAB 
ABC transporter system which is involved in processing and secretion of the 
autoinducing competence stimulating peptide (CSP), while ComD is part of 
the ComDE two-component regulatory system involved in regulating the 
competent state of the pneumococcus in response to CSP.  A mutation in 
the comD gene was also found to attenuate virulence in both systemic and lung 
colonisation infection models by Bartilson et al. (2001). Competence is a density-
dependent phenotype; as cell density increases, CSP accumulates in the 
external environment, inducing competence in increasing numbers of cells 
proportional to the accumulation of CSP. 
1.4.2.6 Competence, autolysis and virulence 
Lau et al. and Bartilson et al. speculate that the induction of competence may be 
a response to environmental stresses that the population may encounter 
during stationary growth. Claverys et al. (2006) and Lin et al. (2016) expand 
further on this hypothesis by discussing the role of the regulator comX in 
induction of the competent state. ComX is an alternative σ factor which up-
regulates a number of genes in response to the detection of CSP. However, 
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not all the genes up-regulated by ComX are required for DNA uptake, suggesting 
that induction of competence not only facilitates uptake of DNA but also facilitates 
other phenotypic changes in the pneumococcus in response to environmental 
changes.. Therefore, it was proposed that the competent state be renamed to the 
‘X-state-for-fitness’ and suggested that induction of this state functions as a 
general response to environmental stress. Lin et al. argue that this concept is 
supported by the fact that S. pneumoniae lacks an SOS response, and that DNA 
damaging antibiotics trigger induction of the competent state directly. Most 
importantly however, Lin et al. illustrate that transcription of numerous genes 
involved in virulence are entirely dependent on induction of competence, or the 
proposed ‘X-state-for-fitness’.   
Therefore, while the specifics of the mechanism relating competence, autolysis 
and virulence are yet to be identified, there is a clear link between the three traits; 
induction of competence leads to lysis of a proportion of the population, and this 
leads to release of virulence factors into the extracellular environment which 
instigate disease in the infected host.  While this cycle of events is supported by 
observation of the behaviour of the pneumococcus both in vivo and in vitro, it 
would seem completely counter-intuitive for evolution to favour a behaviour that is 
fatal to a proportion of cells within a population. What is the benefit to the 
pneumococcus of deliberately inducing the lysis of its own cells? 
1.4.3 Overview 
These are just some examples of the extensive range of virulence factors 
employed by S. pneumoniae in colonization, persistence and invasion of the 
human host.  
The action of the autolytic enzyme in conjunction with the toxin pneumolysin 
presents an unusual clinical problem, in that upon treatment with antibiotics lysis 
of pneumococcal cells is induced, causing the symptoms of disease to 
temporarily worsen in response to inflammatory intracellular components that are 
released as a result (Hirst et al., 2004; McCullers & English, 2008; Nau & Eiffert, 
2002; 2005). Working towards a better understanding of how this organism 
causes disease may therefore prove useful in improving treatments for those 
suffering from serious invasive pneumococcal disease.  
This project focuses on the genetic basis for a specific aspect of pneumococcal 
virulence; toxicity. This phenotype was chosen because it is easily quantifiable for 
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GWAS, and directly contributes to virulence in this organism. Furthermore, its 
close relationship with autolysis and competence implies a complex network of 
genetic regulatory factors, which thus far is not fully understood. The work 
presented in this thesis contributes original knowledge to the field by using a top-
down statistical approach to identify and characterise novel genetic effectors of 
toxicity in the two organisms S. aureus and S. pneumoniae.  
1.5.0 Project aims 
As part of my doctoral training programme I was required to complete two distinct 
rotation projects in the first year. Aim 1 below covers the work undertaken in my 
first rotation project, while my second rotation project focused on starting the 
work described in aims 2-3, which was then continued throughout the remainder 
of my PhD. 
1) To characterise the phenotype of the toxicity-deficient S. aureus ΔcyoE 
mutant which was initially associated with toxicity through a genome-wide 
association study (GWAS). 
a. To identify the mechanism by which toxicity is lost in this mutant. 
2) To apply the functional genomics approach used in previous S. aureus 
research (Laabei et al., 2014; 2015) to S. pneumoniae, to elucidate which 
genetic loci are associated with toxicity in this pathogen. 
a. To combine data from three different GWAS methods conducted 
by myself (with assistance from my co-supervisor) and two 
collaborators, such that the number of false positive and false 
negative results can be reduced as much as possible, and genes 
with the strongest associations with toxicity across more than one 
method can be prioritised for further investigation. 
b. To verify true-positive associations and eliminate false-positive 
associations by creating whole-gene deletion mutants and 
measuring their subsequent levels of toxicity. 
3) To characterise any toxicity-deficient mutants which are identified from the 
previous aim with a view to identifying the mechanism by which toxicity is 





2. Materials and methods 
2.1 List of materials used 
Table 2.1. List of all materials used. All materials are detailed by name, description and 
supplier. 
Material Description Supplier 
0.2cm electroporation 
cuvette 
For electroporation of 
competent bacterial cells 
Invitrogen 
1-Butanol Solvent for butanol extraction 
of toxins 
Fisher Scientific 
6X DNA loading dye Loading dye for gel 
electrophoresis 
Fisher Scientific 
Acetone Solvent Sigma 
Agarose DNA gels for electrophoresis Acros Organics 
Ammonium persulfate Polymerising agent for SDS-
PAGE 
Sigma 
Ampicillin Beta-lactam antibiotic, cell 
wall inhibitor 
Sigma 
Anhydrous tetracycline Used for pRMC2 promoter 
induction 
Sigma 
Anti-pneumolysin antibody Polyclonal antibody to 
pneumolysin 
Abcam (ab71810) 
BHI  Brain-heart infusion broth and 
agar 
Oxoid 
Bis-polyacrylamide 40% polyacrylamide solution Bio-Rad 
Bovine serum albumin Used as buffer in haemolytic 
activity assays 
Sigma 
Bromophenol blue Sample buffer dye for SDS-
PAGE 
Sigma 
β-mercaptoethanol Used in sample buffer for 
SDS-PAGE gels 
Sigma 
CaCl2 Calcium chloride Sigma 
Cell freezing media Used for storage of THP-1 
cells 
Sigma 
Chloramphenicol Broad spectrum antibiotic, 





Defibrinated horse blood Used in haemolytic activity 
assay 
Oxoid 
DTT Dithiothreitol Fisher Scientific 




Erythromycin Macrolide antibiotic, protein 
synthesis inhibitor 
Sigma 
Ethanol Solvent Fisher Scientific 
FastRead counting 
chamber 
Cell counting slides Kova 
International 
Fetal bovine serum Fetal bovine serum Gibco 
Gamma-32P-ATP Radioactive phosphorous 
isotope for labelling of DNA 
Hartmann 
Analytic  
Gene ruler 1kb or 50bp DNA ladder Fisher Scientific 
GeneJet Gel extraction kit Extraction of DNA from 
agarose gel 
Fisher Scientific 
GeneJet PCR purification 
kit 
PCR purification kit Fisher Scientific 
GeneJet Plasmid 
purification kit 
Plasmid purification kit Fisher Scientific 
Glycerol Used in bacterial freezer 
stocks and biochemical 
assays 
Fisher Scientific 
Glycine Used in SDS-PAGE buffer Sigma 
Goat Anti-Mouse IgG H&L 
(HRP) 
Horse-radish peroxidase 
coupled IgG, secondary 
antibody to anti-pneumolysin 
Abcam 
(ab205719) 
GoTaq 2X green master 
mix 
PCR master mix Promega 
Guava ViaCount Cell viability stain Millipore 
High pure PCR template 
extraction kit 
DNA extraction kit Roche 
HisTrap Nickel binding 
column 
Used for protein purification GE Healthcare 
HiTrap Heparin affinity 
column 
Used for protein purification GE Healthcare 
HyBond nitrocellulose 
membrane 
Western blot membrane Sigma 




Isopropanol Solvent Fisher Scientific 
KCl Potassium chloride Sigma 
KpnI Restriction enzyme New England 
Biolabs 
LB Luria-Bertani broth and agar Fisher Scientific 
L-glutamine, penicillin, 
streptomycin solution 
Glutamine supplement and 
antibiotic solution for cell 
culture 
Sigma 
Lysostaphin Glycyl-glycine endopeptidase Cell Sciences 
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Lysozyme Muramidase, used for DNA 
extraction 
Sigma 
MgSO4 Magnesium chloride Sigma 
Microspin S-400  Columns used for purification 
of radiolabelled DNA 
GE Healthcare 
MonoQ anion exchange 
chromatography column 
Used for protein purification GE Healthcare 
NaCl Sodium chloride Sigma 
NcoI Restriction enzyme New England 
Biolabs 
Nunc 96-well plate Used in haemolytic activity 
assay 
Fisher Scientific 
Nunc 96-well plate Used for haemolytic activity 
assays 
Nunc 
Opti4CN substrate kit Colorimetric (HRP) substrate Bio-Rad 
Oxacillin Beta-lactam antibiotic, cell 
wall inhibitor 
Sigma 
Page ruler plus Pre-stained protein ladder Fisher Scientific 
PBS Tissue-grade phosphate 
buffered saline 
Gibco 
PBS Phosphate buffered saline Fisher Scientific 
Phusion master mix High fidelity DNA polymerase 
in master mix 
Fisher Scientific 
PMSF Phenylmethylsulfonyl fluoride Fisher Scientific 
Protein G-HRP Protein G-Horseradish 
peroxidase conjugate 
Invitrogen 
Proteinase K Broad spectrum serine 
protease 
Sigma 
qScript cDNA synthesis kit Used for reverse transcription 
of RNA to cDNA 
Quantabio 




RNA extraction kit Zymo 
Rabbit anti-hla Polyclonal wole antiserum 
against α-haemolysin 
Sigma 
RPMI 1640 Roswell Park Memorial 
Institute cell culture medium 
SLS/Lonza 
SDS Sodium dodecyl sulfate Fisher Scientific 
Sheep blood in Alsever’s 
solution 
Used in haemolytic activity 
assay 
Oxoid 
SimplyBlue SafeStain SDS-PAGE gel stain Fisher Scientific 
Sodium citrate Used to make LK agar plates Sigma 
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Spectinomycin Aminocyclitol antibiotic, 
protein synthesis inhibitor 
Generon 
Sucrose Used in electroporation & 
protein purification 
Sigma 
SYBR-Safe DNA gel stain Invitrogen 
T4 PNK T4 polynucleotide kinase New England 
Biolabs 
T-25 Tissue culture flask Corning 
T-75 Tissue culture flask Corning 
TAE Tris-acetate EDTA buffer Fisher Scientific 
TBE Tris-borate EDTA buffer Fisher Scientific 
TCA Trichloroacetic acid Fisher Scientific 
TCEP Tris(2-carboxyethyl)phosphine Sigma 
TEMED N, N, N, N'-
tetramethylethylenediamine 
Sigma 
Triton X-100 Detergent  Sigma 
Tris Trisaminomethane Sigma 
Trypan blue Viable cell stain Sigma 
Tryptone Used to make LK agar Sigma 
TSA Tryptic soy agar Sigma 
TSB Tryptic soy broth Sigma 
Turbo DNA-free kit DNAse digestion kit Fisher Scientific 
Tween-20 Detergent Sigma 
Urea Used for resuspension of 
protein extractions 
Sigma 
Virkon Disinfectant Fisher Scientific 
XhoI Restriction enzyme New England 
Biolabs 
Yeast extract Used to make LK agar Fisher Scientific 
Zeta-probe blotting 
membrane 
Blotting membrane Bio-Rad 
 
2.2 Experiments using Staphylococcus aureus 
Experiments were conducted by myself unless otherwise stated. Where 
experiments were not conducted by me, this is due to both resources and 
expertise being more readily available in collaborating labs regarding those 
individual experiments.  
70 
 
2.2.1 Strains and cultivation conditions used throughout 
The ΔcyoE mutant was obtained from the Nebraska Transposon Mutant Library 
(mutant NE1434), which is a collection of 1,952 S. aureus mutants in the 
background strain USA300 JE2 (Bae et al., 2008; Fey et al., 2013). The USA300 
JE2 wild type was used as a control in all assays. Bacterial strains were grown at 
37°C in brain heart infusion broth (BHI) or on tryptic soy agar (TSA). When 
needed, erythromycin (5µg/ml), chloramphenicol (10µg/ml) and tetracycline 
(50ng/ml) were added to both plates and liquid cultures to select for and maintain 
the growth of mutant and complemented strains. 
2.2.2 Phenotypic assays 
2.2.2.1 Growth, pH and acetic acid assays 
** These assays were done by Stewart Gardner, with input from Greg Somerville, 
at the University of Nebraska.  
These assays were done to characterise the metabolic differences between the 
ΔcyoE mutant and JE2 wild type. 
Bacterial strains were grown in filter-sterilized tryptic soy broth (TSB) and 
cultivated at 37°C, with 225 rpm aeration, and using a flask-to-medium ratio of 
10:1. Bacterial pre-cultures were prepared from overnight cultures diluted 1:100 
in TSB and incubated for 1.5 to 2 h. These pre-cultures were centrifuged for 5 
min at 5,000 rpm, and the exponentially growing cells were inoculated into pre-
warmed TSB to an optical density at 600 nm (OD600) of 0.02. No antibiotics were 
used in this assay. Cultures were diluted prior to reading the density at the later 
stages of growth to avoid any saturation effects in the spectrophotometer. The pH 
of the culture medium was determined hourly using an Accumet AR60 pH meter 
(Fisher Scientific). The acetic acid assays were performed on culture 
supernatants (1ml) that were harvested hourly by centrifugation and acetate 
concentrations were determined with Acetic Acid Test Kits purchased from R-
Biopharm and used according to the manufacturer’s protocol.  
2.2.2.2 Toxicity assay 
This assay was done to characterise the toxicity phenotype of the ΔcyoE mutant. 
THP-1 cells are an immortal monocytic cell line (Tsuchiya et al., 1980) that is 
sensitive to 13 of the 15 toxins produced by S. aureus and present in the 
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bacterial supernatant (Laabei et al., 2014). They are continuously sub-cultured at 
2-3 day intervals in a solution of RPMI 1640 containing foetal bovine serum and 
an antibiotic solution of 200mM L-glutamine, 10,000 units of penicillin and 
10mg/ml streptomycin. Following overnight growth in BHI broth, the bacterial 
cultures were centrifuged for 10 minutes at 10,000-12,000 x g and the 
supernatant was harvested. Supernatant was not tested to determine whether it 
was completely cell free in part due to the number of cultures used in each assay 
and the feasibility of doing so for each sample, and also as it was thought that 
any residual cells in the culture would not affect the outcome, as toxins are 
secreted by S. aureus into the external medium. The supernatant was diluted to a 
30% vol/vol in BHI broth and 20µl of this was added to 20µl of washed THP-1 
cells at a concentration of 120-150 cells per 1µl, and incubated for 12 minutes at 
37°C. Following incubation of bacterial supernatant with THP-1 cells, samples 
were stained with 260µl Guava ViaCount reagent, incubated at room temperature 
for 5 minutes, and loaded onto a Guava flow cytometer to determine the 
percentage of THP-1 cell death in each sample. 
2.2.2.4 RNAIII activity assay 
This assay was done to determine the levels of activity of the the global toxicity 
regulator Agr in the ΔcyoE mutant compared to the JE2 wild type. 
A plasmid containing a GFP-tagged copy of the RNAIII gene was transformed 
into strains USA300 JE2, ΔcyoE, RN6390B (an agr-positive strain) and RN6911 
(an agr-negative strain). Single colonies were inoculated into BHI as described 
above for liquid overnight cultures, and the following morning a 1:10,000 dilution 
was made into BHI at a flask to medium ratio of 10:1. Strains were cultured at 
37°C and aerated at 180rpm; OD(600) and GFP fluorescence (485/520) readings 
were then taken at hourly intervals over 12 hours.  
2.2.2.5 Aconitase activity assay 
** This assay was done by Stewart Gardner, with input from Greg Somerville, at 
the University of Nebraska.  
This assay was done to determine the levels of activity of the TCA cyle in the 
ΔcyoE mutant compared to the JE2 wild type 
Bacteria were harvested during the post-exponential growth phase (6 h) by 
centrifugation, suspended in ACN buffer (100M fluorocitrate, 90 mM Tris/HCl, pH 
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8.0), and lysed with lysing matrix B tubes and a FastPrep instrument (MP 
Biomedicals). The lysate was centrifuged for 5 min at 13,200 rpm at 4°C, and the 
aconitase activity in the cell-free lysate was measured by the method of Kennedy 
et al (1983). One unit of aconitase activity is defined as the amount of enzyme 
necessary to give a A240 min-1 of 0.0033. 
2.2.2.6 Anti-α-toxin Western blot 
This assay was done to determine whether a reduction in alpha toxin production 
could be observed in the ΔcyoE mutant, corresponding to its observed loss of 
toxicity in the THP-1 assay. 
Proteins were precipitated from bacterial supernatant using trichloroacetic acid 
(TCA) at a final concentration of 20% for 1 hour on ice. Samples were then 
washed three times using ice cold acetone and solubilised in 100µl 8M urea. 20µl 
of each sample was mixed with 20µl loading dye and heated at 100°C for 2 
minutes. 10µl of each sample was then subjected to 10% SDS-PAGE and 
separated proteins were electroblotted onto a nitrocellulose membrane using a 
semi-dry blotter at 15V for 30 minutes (BioRad). Membranes were blocked 
overnight using 3% BSA in PBS-T (containing 0.1% Tween) and were then 
incubated for 1 hour with rabbit polyclonal antibodies specific for α-toxin. After 
washing 3 times for 5 minutes with PBS, membranes were incubated for another 
hour with horseradish peroxidase-coupled Protein G. All incubation steps were 
done at room temperature. Membranes were washed twice for 20 minutes in 
PBS, and blots were visualised using an Opti-4CN detection kit. Band intensities 
were quantified using ImageJ (v 1.46r).  
2.2.2.7 PSM (phenol soluble modulins) quantification 
This assay was done to determine whether a reduction in PSM production could 
be observed in the ΔcyoE mutant, corresponding to its observed loss of toxicity in 
the THP-1 assay. 
Overnight cultures were diluted 1:1000 in 50ml BHI and grown for 18 hours at 
37°C with shaking (180rpm). 30ml supernatant was added to 10ml 1-butanol and 
these samples were incubated for 3 hours at 37°C with shaking. Samples were 
then centrifuged for 3 minutes and 1ml of the upper organic phase was collected. 
Protein samples were concentrated overnight using a SpeedVac and dried 
samples were then solubilised in 150µl 8M urea. Samples were loaded and run 
on 10% SDS-PAGE as described above and then stained using SimplyBlue 
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SafeStain as per the protocol. Band intensities were quantified using ImageJ (v 
1.46r).  
2.2.2.8 Micro-aerobic environment 
This assay was done to assess whether the wild type JE2 strain grown in micro-
aerobic conditions exhibited a comparable phenotype to the ΔcyoE mutant. 
To assess the effect of microaerobic growth conditions on toxicity in the wild-type 
strain JE2, bacteria were cultivated using a flask-to-medium ratio of 10:8 and 
toxicity assays were conducted using culture supernatant as described above. All 
other growth conditions remained unchanged. 
2.2.3 Phage transduction of transposon mutation into SH1000 
This was done to illustrate the the cyoE gene is required for toxicity in more than 
one S. aureus strain, and its importance in toxicity is therefore not unique to JE2. 
Donor cells were inoculated into liquid culture from single colonies and grown 
overnight, and the following day 200µl of this culture was added to 25ml BHI 
containing 250µl 1M MgSO4 and 250µl 1M CaCl2. This was grown for one hour 
after which 100µl phage 11 was added to the culture and grown for a further four 
hours minimum. Supernatant was obtained from this culture through 
centrifugation (12,000 x g for 3 minutes) and was then filter sterilised. Optimal 
plaque titre was in the range of 107-10. Next, recipient cells were grown overnight 
in 20ml LK broth (1% tryptone, 0.5% yeast extract, 0.7% potassium chloride), 
then this culture was centrifuged (2,500 x g for 10 minutes) and the pellet 
suspended in 1ml LK broth. To 250µl of recipient cells was added 500µl LK broth 
plus 10mM CaCl2 and 250µl of the phage lysate from the previous step. This 
culture was incubated statically for 25 minutes and then with shaking at 180rpm 
for 15 minutes. 500µl ice cold 0.02M sodium citrate was then added, and the 
culture centrifuged at 10,000 x g for 10 minutes. The pellet was suspended in 
500µl 0.02M sodium citrate and left on ice for 2 hours. 100µl of this was then 
plated neat on LKA plates containing 0.02M sodium citrate and selective 
antibiotic, and this was incubated for at least 20 hours at 37°C. 
2.2.4 Construction of complemented mutant 
This was done to demonstrate that restoration of the wild type cyoE gene in the 
ΔcyoE mutant rescued its toxicity, showing that it is specifically this gene that is 
responsible for the observed phenotype. 
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To confirm that loss of the cyoE gene was responsible for the observed loss in 
toxicity, the wild type cyoE gene was cloned into the transposon mutant. The 
plasmid vector pRMC2 was used because it contains a tetracycline-inducible 
promoter region that allows transcription of the gene of interest to be controlled. 
The wild type cyoE gene was amplified by PCR using the following primer 
sequences:  
cyoE FW: GCTGGTACCATGAACAAATTTAAGGAG 
cyoE RV: GCGAATTCAATTTCATCCTAACTTAATT 
Restriction enzyme sites for KpnI and EcoR1 were added to the forward and 
reverse primers, respectively. The cyoE gene and plasmid pRMC2 were then 
digested with KpnI and EcoR1 and the resultant products were ligated using T4 
DNA Ligase. Successfully ligated plasmids containing the wild-type cyoE gene 
were transformed into E. coli DH5α competent cells through electroporation, 
plasmid DNA was isolated and passaged through S. aureus RN4220, before 
finally being transformed into the strain JE2 ΔcyoE transposon mutant NE1434. 
For transformation through electroporation, bacteria were cultivated in BHI liquid 
culture to an OD(550) of 0.2-0.3 and washed four times in ice cold 0.5M sucrose. 
After the final wash bacteria were suspended in 100µl of 0.5M sucrose before 
being added to 20-30µl of DNA. Bacteria were incubated on ice with the DNA for 
20 minutes and electroporated in 0.2cm cuvettes for 4.2-4.6 milliseconds. 
Following electroporation, 800µl BHI was added to the cuvettes and incubated for 
1 hour at 37°C without shaking. The transformants were then plated on TSA 
containing 10µg/ml chloramphenicol, and for the transposon mutant strain 5µg/ml 
erythromycin was also added to the agar.  
2.2.5 Statistical comparisons 
Statistical comparisons were performed using a Student’s T-test in Microsoft 
Excel, comparisons were two-tailed and assumed unequal variance. 
2.3 Experiments using Streptococcus pneumoniae 
2.3.1 Strains and growth conditions used throughout 
Clinical strains used were all samples of the PMEN1 clone obtained from 
Stephen Bentley (Wellcome Trust Sanger Institute, Cambridge); most were of 
serotype 23F, but the collection also included samples of serotypes 6A, 15B, 
19A, 19F and 23B. This clonal complex was chosen because it is a globally 
prevalent group of multidrug-resistant clinical isolates taken from patients 
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suffering from pneumococcal disease (Croucher et al., 2011). Whilst the group 
mainly consists of one serotype, some serotypes have undergone capsular 
switching, likely in response to inclusion of the 23F capsular antigen in 
pneumococcal vaccines. Whilst there is a high degree of genetic diversity 
between strains in this collection due to the high rates of recombination that take 
place in the pneumococcus, all are descended from the same ancestral strain 
(thought to have emerged around 1930). The underlying genome of each strain 
therefore corresponds to and can be compared to the reference strain ATCC 
700669. 
Strains were grown for up to 24 hours in 5% CO2 at 37°C, on brain-heart infusion 
(BHI) blood agar plates containing 5% defibrinated horse blood. To obtain 
overnight liquid cultures several colonies were inoculated in 5ml BHI broth 
without blood and grown for 16-24 hours in the same incubation conditions. 
Some strains did not grow from single colonies; hence several colonies were 
used to inoculate all liquid cultures. 
Control strains used for the haemolytic activity assays of the clinical strains were 
wild type TIGR4 (serotype 4) and a TIGR4 pneumolysin-deficient mutant. Growth 
conditions for both were as above, with the addition of 2-5µg/ml chloramphenicol 
to the media for the TIGR4 pneumolysin-deficient mutant, as this mutant was 
constructed with a chloramphenicol resistance cassette and as such is selected 
for with this antibiotic.  
2.3.2 Haemolytic activity assay for clinical isolates 
This was done to assess the toxicity levels of each clinical isolate for use in a 
subsequent GWAS. 
Strains were grown overnight in liquid culture as described above. The following 
day strains were sub-cultured at a 1:1 ratio of overnight culture to fresh medium 
and grown for one hour until OD(600) 0.4-0.7 was reached. This represents the 
exponential phase of growth at which the pneumolysin toxin will be secreted into 
the culture medium, and optimisation assays using the wild type TIGR4 strain 
showed that there was no significant difference in toxicity levels within this range.  
Cultures for each strain were then serially diluted 4-fold in a 96 well plate 
containing BSA assay buffer. This buffer consisted of 0.05g bovine serum 
albumin and 0.077 dithiothreitol dissolved in 50ml sterile phosphate buffered 
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saline. Six serial 4-fold dilutions were done for each strain, to which was added 
50µl of triple washed sheep red blood cells.  
The 96-well plate was incubated for one hour in 5% CO2 at 37°C, following which 
it was centrifuged at 2000rpm for 10 minutes at room temperature. Supernatants 
from each well were transferred to a fresh 96-well plate and absorbance values 
read at 596nm were obtained using a FLUOstar Omega microplate reader. 
2.3.3 Genome-wide association study - SNP-based method 
This was done to identify statistical associations between genetic loci and the 
toxic phenotype. 
166 isolates from the PMEN1 collection were used in a genome wide association 
study to identify single nucleotide polymorphisms (SNPs) which were significantly 
associated with toxicity. SNP data was obtained from Nick Croucher (Imperial 
College London), and has been published previously in work by Croucher et al. 
(2011). All statistical analysis was completed in the program ‘R’ (version 3.2.1). 
SNP data was first converted to a data frame of 1s and 0s, where 1s represent 
the presence of a SNP at any given position, relative to the reference genome 
ATCC 700669 (SPN23F). Missing data was converted to NA values and 
therefore excluded from statistical analysis. The genotype frequency threshold 
was set at 5% and the minor allele frequency threshold was set at 3%. Pearson’s 
product-moment correlation was then used to identify any associations between 
SNP positions and high levels of haemolytic activity. P-values were then 
empirically derived using permutation of the dataset and converted to –log10 
before being plotted onto a Manhattan plot to visualise the results. 
2.3.4 Construction of S. pneumoniae knockout mutants 
2.3.4.1 Overlap extension PCR 
** This protocol was adapted from the methods published by Ge & Xu (2012) and 
Chen et al. (2015).  
This was done to create whole gene deletions of genes in which specific loci had 
been statistically significantly associated with toxicity in a GWAS, for the 
purposes of verifying genes which when disrupted cause a loss in toxicity. 
DNA from the reference strain ATCC 700669 (SPN23F) was extracted using a 
High Pure PCR Template Preparation Kit. The plasmid pVA838, containing the 
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erythromycin resistance cassette ermAM, was extracted from E. coli DH5α using 
a GeneJet Plasmid Extraction kit, and the ermAM cassette amplified through 
PCR using the following primers: 
ermAM FW: GTAATTAAGAAGGAGTGATTACATG 
ermAM RV: GAATTATTTCCTCCCGTTAAATAATAG 
For each knockout mutant, six primers were designed to amplify three fragments 
in separate PCR reactions, which were then combined in a further PCR reaction 
to construct a single linear insert. This insert was then used to transform the 
reference strain through homologous recombination. 
F1 and R1 primers amplified the 1kb region upstream of the gene to be knocked 
out, F2 and R2 primers amplified the ermAM cassette, and F3 and R3 primers 
amplified the 1kb region downstream of the gene. The F2 and R2 primers were 
designed to overlap with R1 and F3, respectively, such that the three fragments 
would stitch together to create a linear construct (see figure 2.1). All primers were 
designed to have an annealing temperature as close to 60°C as possible to aid 
the second PCR step in which the three fragments were stitched together. To 
reduce any potential downstream effects on other genes, for example to protect 
potential promotor regions and ribosome binding sites used by the neighbouring 
gene, the first 6 bases after the start codon and the last 30 bases before the stop 
codon were retained. Phusion high fidelity polymerase was used to amplify each 





Figure 2.1: Overlap extension PCR. Method used to create linear insert, which is then 
transformed into reference strain through homologous recombination. A. Amplification of 
three individual fragments with overlapping R1/F2 and R2/F3 primers. B. PCR to stitch 
together three fragments to construct a linear insert, which is then used to create a 
whole-gene deletion of the target gene (C).  
 
2.3.4.2 Transformation of linear insert into ATCC 700669 SPN23F 
** This protocol has been adapted from a method used by Jane Brittan and 
Angela Nobbs at the Oral and Dental hospital, Bristol.  
Bacteria were inoculated into 5ml BHI broth, from which 10-fold serial dilutions 
were made into three further tubes. These were incubated overnight. The tube 
containing the highest dilution of cells that had successfully grown (therefore the 
lowest concentration of cells) was used to inoculate 2ml of growing culture into a 
fresh pre-warmed tube of 20ml BHI broth. This was incubated for 2 hours. 0.5ml 
of this culture was added to 9.5ml pre-warmed BHI broth and incubated for 30 
minutes. 1ml of this culture was transferred to at least two sterile Eppendorf 
tubes, to which 10µl of 10µg/ml competence-stimulating peptide-2 (CSP-2) was 
added each. These were incubated for 10-15 minutes, following which 200µl 
portions were dispensed into fresh Eppendorf tubes containing either 2µl of DNA 
or sterile water for the negative controls. These were incubated for a further 2 
hours. 100µl of these cultures were dispensed into petri dishes and mixed with 
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10ml molten BHI agar containing 5% defibrinated horse blood. Two plates were 
used for the negative control; one to which antibiotics were added in a later step, 
and one to which antibiotics were not added. This is to test firstly that the 
antibiotic does not permit growth of non-transformed cells, while also 
demonstrating that cells are viable. Once set the plates were incubated for 2 
hours. Plates were then overlaid with a further 10ml molten agar containing 5% 
defibrinated horse blood, to which erythromycin (2µg/ml) was added, except for 
the second negative control. Plates were incubated for up to five days at 37°C, or 
until colonies appeared within the agar.  
For the ΔSPN23F12470(aad9) mutant constructed with the spectinomycin 




Spectinomycin was added to transformation plates for this mutant at a final 
concentration of 200µg/ml to select for successfully transformed mutants.  
2.3.4.3 Primer design for insert construction using the ply gene as an 
example 
The following sequence contains the 1kb sequence upstream of the ply gene, the 
first nine bases of the ply gene (highlighted in yellow), the sequence encoding the 
erythromycin resistance cassette ermAM (highlighted in grey), the last 33 bases 
of the ply gene (highlighted in yellow), and the 1kb sequence downstream of the 






















































Overlapping primers were designed to amplify three individual fragments which 
could then be stitched together to form a single linear insert containing the 
ermAM cassette in place of the wild type gene of interest, as described in section 
2.3.4.1 above. Example primers for the ply gene are as follows:  
Fragment 1 primers: 
F1: 5’ CGCCCTTGCTCTGGTTAAAAAAAGAAGC 3’ 
R1: 5’ GGAGGTAGAAGATGGCAAATATGAACAAAAATAT 3’ 
Reverse complement for R1 primer: 
5’ ATATTTTTGTTCATATTTGCCATCTTCTACCTCC 3’ 
 
Fragment 2 primers: 
F2: 5’ GAAGATGGCAAATATGAACAAAAATATAAAATATTC 3’ 
R2: 5’ AACGGGAGGAAATAACCTCAGGTAGAAG 3’ 
Reverse complement for R2 primer: 




Fragment 3 primers: 
F3: 5’ GGAGGAAATAACCTCAGGTAGAAGATAAG 3’ 
R3: 5’ CTATGTAGCAGCTAAAAAAGGTGATCCAG 3’ 
Reverse complement for R3 primer: 
5’ CTGGATCACCTTTTTTAGCTGCTACATAG 3’ 
 
Following amplification of each individual fragment, all three were stitched 
together in one PCR reaction using the F1 and R3 primers. Each insert was then 
transformed into S. pneumoniae strain ATCC 700669 (SPN23F) using the 
method described in section 2.3.4.2. Successful mutants were verified using PCR 
checks as described in section 2.3.4.5 below. 
2.3.4.5 Primer design for verification of successfully transformed 
inserts using the ply gene as an example 
For verification of successfully transformed mutants, primers were designed for 
three different PCR checks: 
1) Confirmation that the mutant is not a contaminating organism using 
primers to the wild type SPN23F ply gene (except for the Δply mutant, in 
which primers to the wild type SPN23F13160 gene were used instead) 
2) To verify the absence of the wild type gene that has been replaced with 
the antibiotic resistance cassette 
3) To verify uptake of the 3kb insert in the correct position, using primers for 
the region 1kb upstream of the 3kb insert to within the antibiotic 
resistance cassette 
1) Primers to the wild type ply gene used for the first PCR check for all mutants 
except Δply were: 
FW: GCAGTAAATGACTTTATACTAGCTATGATAAAC 
RV: GAGAGTTGTTCCCCAAATAGAAATCG 
Primers used to verify the Δply mutant only for this step were to the wild type 





2) Primers for the second PCR check were designed as follows, with the forward 
primer starting at least 6bp after the start codon and the reverse primer starting at 
least 30bp before the stop codon, since these bases were not deleted in the 
mutants. 





























Primers to the wild type ply gene (highlighted in red in sequence above): 
FW: GCAGTAAATGACTTTATACTAGCTATGATAAAC 
RV: GAGAGTTGTTCCCCAAATAGAAATCG 
3) Primers for the third PCR check were designed as follows. 























































Primers to verify presence of insert at correct location within genome (highlighted 
in red in sequence above): 
FW: ATCTCTTCAAAAGTGGTACGCTGAACACTAAC 
RV: GTGTTCGGTGAATATCCAAGGTACGCTTG 
2.3.4.4 Primers used to construct mutants 
A full list of the primers used to construct whole-gene deletion mutants, and the 




2.3.5 Characterisation of toxicity-deficient mutants 
2.3.5.1 Haemolytic activity assay for ATCC 700669 (SPN23F) whole 
gene deletion mutants 
Haemolytic activity assays were conducted as described above with a few minor 
changes and additions to characterise the toxicity phenotype of successfully 
constructed mutants in the ATCC 700669 SPN23F background. 
Overnight cultures were added to the 96-well plate containing BSA assay buffer 
without sub-culturing for 1 hour. This was done because it was established while 
assaying the clinical strains that sub-culturing made little difference to the 
outcome of the assay, as toxins which were present in the supernatant of the 
overnight culture will be carried over to the sub-culture the following morning. The 
clinical strains were only sub-cultured because it was initially thought that cells 
would need to be grown to early exponential phase on the day of the assay for 
the toxicity to be observed. It was also established through several experiments 
with the wild type strain that the same level of toxicity was observed within the 
range of 0.2-0.9 OD(600). Since this strain grows only to a maximum OD(600) of 
around 1, it was established that past the point of OD(600) 0.2, there was no 
significant difference in toxicity, making the 1 hour sub-culture unnecessary. 
Haemolytic activity was measured by reading absorbance at 490nm. 
Haemolytic activity of the supernatant was also assayed using the mutant strains, 
primarily for comparison to the whole cell culture method and also to specifically 
investigate whether pneumolysin is being released from cells into the external 
medium. It was not assayed for the clinical strains as the whole cell culture 
method was deemed to be sufficient for observing variations in toxicity and it 
would have been too time consuming to measure both supernatant and whole 
cell culture for each strain. Supernatant was taken from overnight cultures by 
centrifugation at 3000 x g for 10 minutes. Six serial 2-fold dilutions were then 
made in BSA assay buffer in a 96-well plate, with the first well remaining 
undiluted, and the haemolytic activity assay was conducted as described above 
with no further changes. 
2.3.5.2 Contact-dependent haemolytic activity assay 
This assay was done to characterise (by proxy) the activity of pneumolysin toxin 
that is specifically localised to the bacterial cell wall.  
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All bacterial strains which were tested for contact-dependent haemolysis, 
including whole gene deletion mutants and the ATCC 700669 (SPN23F) wild 
type, were grown overnight in 10ml and harvested by centrifugation. All 
centrifugations were done at 3000 x g for 7 minutes at 4°C unless stated 
otherwise. Supernatant was discarded, cells were washed in 2ml ice-cold PBS 
and harvested by centrifugation. Strains were resuspended in ice-cold PBS to 
OD(600) 1. The maximum volume which could be taken equivalently from all 
strains was harvested by centrifugation, and cell pellets were resuspended in 
400µl ice-cold PBS. Red blood cells were harvested by centrifugation from 1ml 
fresh sheep blood. Supernatant was discarded and erythrocytes were 
resuspended in 3ml PBS to give a final concentration of 25% cells/volume. 50µl 
bacterial suspension was mixed with 50µl 25% erythrocytes and centrifuged at 
9600 x g for 5 minutes at 4°C to achieve close contact between bacterial cells 
and erythrocytes. Controls used were: bacterial and erythrocyte suspensions not 
centrifuged; bacteria centrifuged while blood cells not centrifuged and vice versa; 
bacteria replaced by PBS only and blood replaced by PBS only. Samples were 
then incubated statically for 3 hours at 37°C. After incubation, 70µl of supernatant 
was discarded and pellets resuspended in 150µl ice cold PBS. Samples were 
centrifuged at 9600 x g for 1 minute at 4°C, and 100µl aliquots of supernatant 
were transferred from each sample to a 96-well plate. Haemolytic activity was 
measured by reading absorbance at 490nm.  
2.3.5.3 Anti-pneumolysin Western blot  
** Protein extraction protocols for supernatant and cell pellets were taken from 
Balachandran et al. (2001) as follows: 
This was done to determine whether there were differences in the amount of 
pneumolysin produced in wild type and mutant strains.  
Proteins were precipitated from the bacterial supernatant of 15ml overnight 
cultures using trichloroacetic acid (TCA) at a final concentration of 10%, 
incubated overnight at 4°C. Samples were centrifuged at 3000 x g for 15 minutes 
and washed twice using ice cold acetone. Samples were then resuspended in 
400µl sterile water and stored at -20°C. Proteins were extracted from the cell 
pellets of 15ml overnight cultures using a solution of 0.01% SDS, 0.1% sodium 
deoxycholate and 0.015M sodium citrate, which was added at a volume 
corresponding to 10% of the original culture volume (1.5ml). Samples were 
incubated in this solution for 30 minutes at 37°C and then stored at -20°C. SDS-
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PAGE gels and Western blotting were conducted as described in section 2.2.2.6 
above, with the exception that anti-pneumolysin was used as the primary 
antibody, and goat anti-mouse IgG H&L (HRP) was used as the secondary 
antibody (see list of materials). 
2.3.5.4 Autolysis assay 
This was done to determine whether differences in autolysis were responsible for 
observed differences in toxicity between wild type and mutant strains. 
5ml liquid cultures were inoculated and grown for 18-20 hours. Cultures were 
then washed once in ice cold PBS and resuspended in 5ml ice cold PBS. Optical 
density readings were taken for each culture at this point at OD(600). Triton X-100 
was added to a final concentration of 0.1% for each culture following this OD600 
reading and cultures were returned to the incubator. Every 15 minutes OD600 
readings were taken for each culture up to the 1 hour 15 minute time point, at 
which point OD600 readings for the wild type strain began to plateau. Autolysis-
deficient mutants retain high optical density throughout the assay in comparison. 
2.3.5.5 Comparison of amount of ICESp23FST81 element present in 
circularised form between ΔSPN23F12470 mutant and isogenic wild 
type 
This was done to determine whether mobilisation of the ICESp23FST81 was 
affected in the ΔSPN23F12470 mutant. 
Plasmids were extracted from 5ml overnight cultures for ΔSPN23F12470 and the 
ATCC 700669 (SPN23F) isogenic wild type strain using a GeneJET Plasmid 
Purification kit. Primers were designed firstly to amplify the genes at the start and 
end of the ICESp23FST81 element, as defined by Croucher et al. (2009), using 
the following primers: 
SPN23F12410 FW: CAAAGACAAAGAAATATAAAGGTGTATAC 
SPN23F12410 RV: TCAACTCTGGCAGGAATTTGGTAG 
 
SPN23F13160 FW: ATGAAACGAATTACCGCAAATCAATATC 
SPN23F13160 RV: AACCACCTCCTTTTCTAACACGATTATTC 
Following successful amplification of these genes to demonstrate that the primers 
worked, the SPN23F12410 FW and SPN23F13160 RV primers were used to 
amplify the junction of the circularised ICE element where the two linear ends join 
in both the wild type strain and the ΔSPN23F12470 mutant, to confirm it was 
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present in its circularised form in both strains. The amount of circularised ICE 
element present in the ΔSPN23F12470 mutant was then compared to its isogenic 
wild type by PCR using three separate plasmid extractions from three 
independent cultures for each strain. Plasmid extractions for each strain were 
standardised to a quantity of 20ng/µl, of which 1µl was used as template for each 
PCR. 
2.3.5.6 qRT-PCR 
This was done to investigate differences in transcript expression of key virulence-
related genes in the ΔSPN23F12470 mutant compared to its isogenic wild type. 
Two separate cultures were grown per strain for 18 hours to stationary phase in 
5ml BHI with antibiotics where required. RNA was extracted using a Zymo Quick-
RNA Fungal/Bacterial Miniprep kit following the manufacturer’s protocol. Excess 
DNA was digested using a Turbo DNase digest kit, as per the manufacturer’s 
protocol. RNA was then quantified and its quality determined using a Nanodrop. 
RNA quality was determined from the A260/280 ratio. RNA was reverse 
transcribed to cDNA using a qScript cDNA synthesis kit, as per the 
manufacturer’s protocol. RNA samples were standardised such that 100ng/µl 
was added to each cDNA synthesis reaction. cDNA was subsequently quantified 
using a Nanodrop and where necessary was standardised again to ensure the 
same quantity in each sample. qPCR was performed using a Mic qPCR cycler 
(Bio Molecular Systems) and reactions were set up using a SensiFAST SYBR 
No-ROX master mix. Three technical repeats were conducted for each cDNA 
sample. The following primer pairs were used for each strain, with recA used as 
the housekeeping gene: 
ply FW: GGCTGATTTCGCTGAACAAG 
ply RV: CCTTGAGTTGTTCCATGCTG 
 
lytA FW: TTATCACTGGCGGAAAGACC 
lytA RV: TCAGTTCAACCGCTGCATAG 
 
comA FW: TCACCGCTTGACTATTGCTG 
comA RV: GCATGCTTTCCTTCTTCGAC 
 
comE (SPN23F22680) FW: CAAGACAACGGGAAAAGTCC 
comE (SPN23F22680) RV: AGCTGAGCCACTTCAAATCC 
 
recA FW: ATCGGAGATAGCCATGTTGG 
recA RV: ATAGAGGCGCCAAGTTTACG 
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qRT-PCR data were analysed using the 2-ΔΔCT method. Negative controls of 
water-only and each original RNA sample were used to ensure there was no 
contamination of either cDNA or the reaction mix. 
2.3.5.7 Complementation of ΔSPN23F12470 mutant 
This was attempted to demonstrate that restoration of the wild type 
SPN23F12470 gene in the ΔSPN23F12470 mutant rescued its toxic phenotype. 
Unfortunately, attempts to complement this mutant have thus far been 
unsuccessful. 
Complementation of the ΔSPN23F12470 deletion was attempted using the vector 
pMSP7517 (provided by Angela Nobbs, University of Bristol), as it contains a 
nisin-inducible promoter to allow transcription of the complemented gene to be 
controlled. pMSP7517 contains a gene (prgB) flanked by restriction sites for NcoI 
and XhoI only, however, XhoI digests SPN23F12470 at a site 1,857 bases into 
the gene. In the absence of an alternative plasmid, site directed mutagenesis was 
conducted to change the digest site sequence from CTCGAG to CTGGAG, which 
is a synonymous change that does not cause a change in the resulting amino 
acid. Site directed mutagenesis was done by PCR amplification of the wild type 






Primers F1 and R2 were then used to stitch together the two fragments, resulting 
in a wild type SPN23F12470 gene with a single, synonymous base change to 
eliminate the XhoI digest site in the middle of the gene (designated 
SPN23F12470a). Restriction enzyme sites for NcoI and XhoI were added to the 
F1 and R2 primers, respectively. The SPN23F12470a gene and pMSP7517 
vector were subsequently digested with NcoI and XhoI and the resulting products 
were gel extracted and ligated using T4 DNA ligase. Ligations were transformed 
into E. coli DH5α using heat shock: 5µl ligation mix was added to 50µl competent 
cells and incubated for 30 minutes on ice, cells were then incubated at 42°C for 
two minutes followed by a further 5 minutes on ice, after which 750µl BHI broth 
was added and cells were incubated for 45 minutes at 37°C with shaking. Cells 
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were then centrifuged for 1 minute at 10,000 x g, and pellets resuspended in 
100µl supernatant for plating onto BHI containing 200µg/ml erythromycin. 
No successful transformants have been obtained following transformation into E. 
coli DH5α. Transformation of the ligation mix was also attempted directly into S. 
pneumoniae ATCC 700669 ΔSPN23F12470(aad9) as per the protocol described 
in section 2.3.4.2 above, with no success.  
2.3.5.8 Purification of SPN23F12470 wild type protein 
** This was done on my behalf by Oliver Wilkinson, Roz Williamson and Elliott 
Mainstone in the Dillingham lab. 
This was done to isolate wild type SPN23F12470 protein for use in a subsequent 
electrophoretic mobility shift assay. 
SPN23F12470 protein was purified from BL21(DE3) E. coli cells transformed with 
the plasmid pET15b containing the SPN23F12470 gene modified with a 6x 
Histidine tag at its N-terminus. Cells were grown at 37°C in LB broth containing 
100µg/ml ampicillin to an OD(600) of around 0.5, whereupon cells were 
temperature acclimatised to 18°C and gene expression was induced for 12 hours 
via the addition of 1mM IPTG. Cells were harvested by centrifugation for 20 
minutes at 6000rpm and resuspended in buffer containing 50mM Tris pH 7.5, 
150mM NaCl, 10% sucrose and 0.1mM PMSF. Cells were lysed by sonication in 
buffer containing 1mM TCEP, 500mM NaCl, 20mM imidazole and a protease 
inhibitor cocktail, and cell debris was removed by centrifugation for 30 minutes at 
21,500rpm. Cell lysate was loaded onto a 5ml HisTrap Nickel binding column 
which had been equilibrated in HisB buffer (20mM Tris pH7.5, 500mM NaCl, 
1mM TCEP, 5% glycerol) plus 20mM imidazole. Proteins possessing His-tags 
were eluted with a gradient from 20mM to 500mM imidazole over 32 minutes with 
a flow rate of 3ml/min. Protein elution was monitored by measuring absorbance 
at 280nm. Fractions containing the most protein were pooled and applied to a 
HiTrap Heparin affinity column equilibrated with HepQ/B buffer (20mM Tris 
pH7.5, 1mM TCEP) plus 100mM NaCl. Heparin-binding proteins were eluted with 
a gradient from 100mM to 1M NaCl over 30 minutes, monitored by absorbance at 
280nm. 2ml fractions containing the highest protein concentrations were pooled 
and applied to a MonoQ anion exchange chromatography column equilibrated 
with HepQ/B buffer plus 100mM NaCl. Proteins were eluted with a gradient from 
100mM to 1M NaCl over 30 minutes, with protein absorbance monitored at 
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280nm, and 0.3ml fractions were collected. Fractions containing the highest 
concentrations of eluted protein were pooled and stored in HepQ/B buffer plus 
330nM NaCl, corresponding to the salt concentration at which the protein was 
eluted from the column. Nanodrop A280 and the SPN23F12470 protein’s predicted 
extinction coefficient (118390mol/L/cm) were used to determine that 
SPN23F12470 had been purified to a concentration of 7.0µM.  
2.3.5.9 Electrophoretic mobility shift assay 
This was done to investigate whether the wild type SPN23F12470 protein was 
interacting with BOX repeat regions either side of the ply gene. 
The intergenic region between ply and the neighbouring gene SPN23F19460, 
containing BOX repeat regions, was amplified using the following primers: 
FW: GAGAGGAGAATGCTTGCGAC  
RV: TAGGAATCTCCTTTTTTCACATTTTAATCTTTC 
This yields a product size of 882bp. A region of the ply gene was simultaneously 




A 10X reaction buffer was prepared containing 200mM Tris (pH 8), 500mM 
sodium chloride, 10mM dithiothreitol and 30% glycerol. A 1X protein dilution 
buffer was prepared containing 20mM Tris (pH 8), 200mM sodium chloride, 1mM 
Tris(2-carboxyethyl)phosphine (TCEP) and 10% glycerol. SPN23F12470 protein 
was serially diluted in 1X protein dilution buffer to give 5X stock concentrations of 
5µM, 2.5µM, 1.25µM, 0.625µM, 0.3125µM and 0.15625µM. Six corresponding 
reaction mixes were then prepared for each DNA sample containing 1µl 10X 
reaction buffer, 2µl 5X protein stock, DNA added to a final concentration of 10nM 
and water to make the reaction volume up to 10µl. A seventh control reaction 
was also included containing 2µl protein dilution buffer in place of 5X protein 
stock. The resulting protein concentrations in the final reaction mixes were: 1µM, 
500nM, 250nM, 125nM, 62.5nM, 31.25nM and no protein. Samples were then 
run on a 1.5% agarose gel in 1X TAE buffer for 110 minutes at 90V. Following 
this the gel was stained in TAE containing 1X SYBR Safe DNA gel stain for 30 
minutes, and bands were visualised using a Typhoon FLA 9500.  
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A second EMSA was run exactly as described above but using a more focused 
range of protein concentrations from 2.5-80nM. The DNA concentration was also 
halved to 5nM for this run to aid clearer visualisation of bands. 
Radiolabelling of DNA for follow-up EMSAs was done using gamma-32P-ATP by 
Mark Dillingham. A third 882bp PCR product was amplified for this experiment 




50nM of each PCR product was added to a reaction containing 2µl phosphorous-
32 (gamma-32P-ATP), 2µl T4 polynucleotide kinase (PNK) and 5µl PNK buffer, 
made up to 50µl with water. This reaction mix was incubated at 37°C for 1 hour, 
then at 65°C for 20 minutes to heat inactivate the PNK enzyme. Radiolabelled 
DNA was purified using Microspin S-400 columns as per the manufacturers 
protocol. 2nM DNA was used in an EMSA exactly as described above, using the 
protein concentrations from 2.5-80nM, with the exception that the gel was not 
stained with SYBR safe, but squashed for three hours before being dried using a 
vacuum-heated gel dryer (BioRad). Bands were visualised as before using a 
Typhoon FLA 9500. 
2.3.6 Statistical comparisons  
Statistical comparisons for phenotypic assays were performed using a Student’s 
T-test in Microsoft Excel, unless otherwise stated comparisons were two-tailed 
and assumed unequal variance. 
2.4 Experiments used for both bacterial species 
2.4.1 DNA extractions 
All DNA extractions were done using High Pure PCR Template Preparation Kit 
(Roche) as per the manufacturer’s instructions. Resulting DNA samples were 
stored at -20°C 
2.4.2 PCR purifications and gel extractions 
All PCR purifications were done using the GeneJET PCR purification kit, and gel 
extractions were done using the GeneJET Gel Extraction kit. 
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2.4.3 Plasmid extractions 
All plasmid extractions were done using the GeneJET Plasmid Miniprep kit. 
2.4.4 DNA agarose gel electrophoresis 
All PCR products were run on a 0.5-1.5% agarose gel made up using either 1X 
TAE or 1X TBE. SYBR Safe stain was added to each gel (final concentration 1X) 
and samples were run for 50-75 minutes at 90V. Either a 1kb or 50bp GeneRuler 




















3. Cytolytic toxin production by 
Staphylococcus aureus is dependent 
upon the activity of the protoheme IX 
farnesyltransferase 
Publication reference 
Stevens, E., Laabei, M., Gardner, S., Somerville, G.A. & Massey, R.C. Cytolytic 
toxin production by Staphylococcus aureus is dependent upon the activity of the 
protoheme IX farnesyltransferase. Scientific Reports, 7(13744). 
Author contributions 
ES carried out the experiments, with the exception of those presented in figures 
3.1 and 3.5. Figure 3.1 shows data obtained by ML for a previous publication that 
led to identification of the cyoE gene, and figure 3.5 shows data obtained by SG 
and GAS due to resources and expertise being more readily available in the 
Somerville lab at that point. All figures were produced by ES even where data 
was obtained by collaborators.  
3.1 Introduction 
The work presented in this chapter constituted my first six-month rotation project 
as part of my doctoral training programme and was subsequently published in 
Scientific Reports. The successful identification and characterisation of a novel 
toxicity-associated locus in S. aureus led to expansion of the functional genomics 
approach to a clinical collection of Streptococcus pneumoniae isolates, which 
was the core focus for the remainder of my PhD. 
Following a genome-wide association study (GWAS) using a large collection of 
clinical isolates of the Staphylococcus aureus sequence type ST239 (Laabei et 
al., 2014), several genes of interest were identified as being statistically 
significantly associated with the toxic phenotype in this bacterium. True positive 
associations amongst these genes were subsequently identified using 
corresponding mutants from the Nebraska Transposon Mutant Library in the 
genetic background USA300 JE2, which were tested for toxicity using the human 
monocytic cell line THP-1 (see Materials & Methods, section 2.2.2.2 for details). 
From these assays, disruption of the cyoE gene was shown to cause a significant 
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reduction in toxicity in comparison to the isogenic wild type. To complete this 
functional verification of the statistical association between cyoE and toxicity, 
work was undertaken to characterise the specific role of this gene in production 
and secretion of staphylococcal toxins.  
This work represents the final stages of the GWAS method and demonstrates 
that it can be successfully applied to identification of novel contributors to a 
bacterial phenotype. It builds on the work of Laabei et al. (2014) by taking one 
locus of interest and focussing on its specific role in relation to toxicity and adds 
to the work of Yokoyama et al. (2018) which characterised a different locus of 
interest that arose from this GWAS. By characterising an individual genetic locus 
to establish its contribution to a phenotype, this work is a small step towards 
improving our overall understanding of the complex network of genetic factors 
which contribute to toxicity, and in turn virulence, in S. aureus.  
Central to S. aureus’ ability to cause disease is the synthesis of numerous 
virulence determinants that help facilitate nutrient acquisition and immune 
evasion. Specifically, S. aureus produces adhesins that allow it to adhere to and 
colonise host tissues; proteins and a capsule that facilitate evasion of the host 
immune system; and secreted toxins that damage host cells and release 
nutrients. The expression of these virulence determinants is in part regulated by 
the Agr quorum sensing system, with a poorly defined post-exponential growth 
phase signal independent of Agr (Vandenesch et al., 1991; Geiger et al., 2008). 
The tricarboxylic acid (TCA) cycle activity (Somerville et al., 2002) is also critical 
for cytolytic activity where TCA cycle mutants have decreased synthesis of 
secreted toxins. In staphylococci, TCA cycle activity is induced during the post-
exponential growth phase, providing the bacterium with carbon, energy, and 
reduced dinucleotides (Somerville et al., 2003a). TCA cycle-derived four- and 
five-carbon intermediates are used in biosynthetic reactions to synthesize 
precursors (e.g. amino acids); while energy (e.g. ATP) drives many critical 
cellular processes and reduced dinucleotides can donate electrons to the 
electron transport chain to generate ATP by oxidative phosphorylation.  
Recently genetic polymorphisms were analysed within S. aureus clinical isolates 
from the major hospital-associated MRSA lineage ST239 (Holden et al., 2010), 
and it was found that there was little variability in their adhesive capabilities, but 
significant variation in cytolytic toxin production (Laabei et al., 2014). The 
application of GWAS (genome wide association studies) to this data identified a 
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number of polymorphic loci that were statistically associated with altering cytolytic 
toxin synthesis. One of those loci, cyoE, encodes the enzyme protoheme IX 
farnesyltransferase, an enzyme involved in catalysing the conversion of haem B 
to haem O (Saiki et al., 1992; 1993). Haem O is incorporated into the electron 
transport chain as an electron acceptor, facilitating aerobic respiration and energy 
production (Hill et al., 1992; Nakamura et al., 1997). As mentioned, TCA cycle 
mutants have decreased accumulation of cytolytic toxins; hence, the connection 
between the electron transport chain and the TCA cycle suggests these variants 
may have decreased TCA cycle activity and toxin accumulation. To address 
these possibilities, the metabolism and phenotype of a cyoE-deficient mutant and 
complemented strains were analysed. 
 
3.2 Results 
3.2.1 Association between toxicity and the polymorphic cyoE 
gene 
A recent GWAS study identified an association between a polymorphic version of 
the cyoE gene with changes in the cytolytic activity (toxicity) of S. aureus, 
suggesting this locus may contribute to toxicity (Laabei et al., 2014). A 
comparison of these data has demonstrated that there was a 2.9-fold reduction 
(figure 3.1; p=0.0008) in the mean toxicity of S. aureus containing the SNP in the 
cyoE gene relative to those with the cyoE gene with no SNPs (i.e. that found in 




Figure 3.1. Polymorphisms in the cyoE gene are associated with a reduction in 
toxicity. Result of a GWAS study on a collection of 90 ST239 MRSA isolates that 
associated polymorphisms in the cyoE gene with the toxicity of the bacteria. The data 
presented is the mean toxicity, as measured by lysis of fluorescent dye containing 
vesicles (Thet et al., 2013) of the isolates with and without polymorphisms in the gene. 
Eight isolates contained the TW20 reference cyoE gene, and 82 isolates contained the 
SNP. Data presented here are from vesicle lysis assays originally performed by 
Maisem Laabei (Laabei et al., 2014). 
 
The SNP change observed in the collection of clinical strains confers a change 
from proline to leucine at position 87 in the translated product of the cyoE gene. 
To determine the likelihood of this change affecting the activity of this protein a 
model of it was built using SWISS-MODEL (Biasini et al., 2014). This model was 
then viewed in Chimera to visualise where the SNP change occurred and how it 
might therefore affect toxicity in the clinical strains (figure 3.2a & 3.2b). As this is 
a membrane protein, a model was also generated using Protter (Omasits et al., 
2014) shown in figure 3.2c. Based on these it was hypothesised that the change 
to leucine could give the loop in which it is located more flexibility and make it 
more hydrophobic, which could result in the loop flipping inwards on itself. The 
change also appears to be within a region that could be the haem binding site of 
this enzyme; figure 3.2b shows the suggested structure of this protein with 
coulorimbic surface colouring to show positively and negatively charged regions 
of the protein. The blue region in the lower middle of the structure is thought to be 
the active site of this enzyme, thus any change to the structure of the loop 
beneath, particularly the loop flipping inwards, could affect the function of the 
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active site. Further analysis of the structure of this protein would be required to 
confirm this hypothesis. 
 
 Figure 3.2. Amino acid change from proline to leucine in the polymorphic CyoE 
protein. A) The position of the amino acid change P87L in the protein, protoheme IX 
farnesyltransferase, encoded by the cyoE gene has been mapped to a ribbon model of 
the structure of this enzyme, and in B) coulorimbic surface colouring has been used to 
illustrate the white hydrophobic domains of the protein, the blue positively charged amino 
acid residues, and the red negatively charged amino acid residues. C) A model of the 
protoheme IX farnesyltransferase situated in the cell membrane, and position of the 






3.2.2 Functional verification of the contribution protoheme IX 
farnesyltransferase makes to S. aureus toxicity 
To verify the association between the cyoE gene and toxicity, the cytolytic activity 
of a ΔcyoE transposon mutant from the Nebraska Transposon Mutant library and 
the isogenic strain JE2 were compared. To quantify cytolytic activity, the THP-1 
monocytic cell line, which is sensitive to both the Phenol Soluble Modulins 
(PSMs) and the other cytolytic toxins secreted by S. aureus, was exposed to 
culture supernatants and toxicity was assessed; concentration of the toxin was 
not directly quantified. As suggested by the GWAS results, the ΔcyoE mutant had 
significantly decreased toxicity relative to the isogenic wild-type strain (figure 3.3; 
p<0.0001). Complementation of the ΔcyoE mutant resulted in restoration of 
toxicity to wild type levels. To ascertain if the effect of inactivating cyoE was 
strain-dependent, the mutation was transduced into S. aureus strain SH1000 and 
toxicity was assessed. Like in the JE2 background, inactivation of the cyoE gene 
in strain SH1000 caused a significant loss of toxicity (figure 3.3; p=0.004). Taken 
together, these data confirm that the cyoE gene contributes to the ability of S. 
aureus to produce toxins.  
 
Figure 3.3. Functional verification of the contribution the cyoE gene makes to 
toxicity. The cyoE gene was inactivated by transposon insertion in both the JE2 and 
SH1000 backgrounds. In the JE2 background the loss of toxicity was restored by 
expressing the gene from an inducible promoter on the pRMC2 vector plasmid. 
Complementation controls of the empty vector (JE2 ΔcyoE (pRMC2)), and the vector with 
the cyoE gene cloned, but uninduced (JE2 ΔcyoE (pCyoE)) have been included. 
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3.2.3 Protoheme IX farnesyltransferase activity affects the 
ability to activate the Agr quorum sensing system 
As the Agr quorum sensing system is a major regulator of toxin synthesis (Recsei 
et al., 1986; Janzon et al., 1990; Arvidson & Tegmark, 2001) and inactivation of 
cyoE dramatically affects toxicity, it was hypothesised that this effect of the loss 
of cyoE may be mediated through the Agr system. To test this hypothesis, an 
RNAIII::gfp fusion plasmid, which acts as a reporter of Agr activity, was 
introduced into the JE2 wild-type and ΔcyoE mutant strains and fluorescence was 
monitored over time (figures 3.4a & 3.4b). Optical density data is shown here to 
demonstrate that inactivation of the cyoE gene has a minimal effect on growth of 
S. aureus during this time frame in vitro. Growth of the Agr+ strain RN6390B is 
slower than JE2 and the ΔcyoE mutant, which may account for the lower level of 
RNAIII activity in this strain compared to JE2 as observed in figure 3.4b, 
however, it is included as a control along with the Agr- strain RN6911 for 
comparison.  
There was a significant reduction in fluorescence in the ΔcyoE mutant (p=0.025), 
demonstrating that RNAIII transcription and consequently Agr activation is altered 
in the ΔcyoE mutant relative to the wild-type strain. To further examine the effect 
of the loss of the cyoE gene on Agr activity the expression of toxins known to be 
under its regulation was quantified, where the secretion of alpha toxin was 
quantified by western blotting and PSMs by butanol extraction. These assays 
were performed in triplicate (figure 3.4c) where it was found that on average there 
was 2.2-fold more alpha toxin, and 1.5-fold more PSMs expressed by the wild 
type JE2 strains when compared to the ΔcyoE mutant. These results confirm that 
in the absence of the cyoE gene the expression and activity of the Agr quorum 











Figure 3.4. Activation of the Agr quorum sensing system is dependent upon 
protoheme IX farnesyltransferase activity. A) The growth of strains carrying the RNAIII 
reporter plasmid was monitored over 12 hours demonstrating that inactivation of the cyoE 
gene has minimal effect on the growth of S. aureus during this time frame in vitro. B) 
Expression of Agr was monitored over 12hours of growth where the inactivation of cyoE 
was found to have a negative effect on Agr activity. Control strains RN6390B (Agr+) and 
RN6911 (Agr−) have been included for comparison. C) The downstream effect of the loss 
of Agr activity was verified by comparing the production of alpha toxin and the PSMs by 
both the wild-type and ΔcyoE mutant, where the mutant produced 2.2-fold less alpha 






3.2.4 Protoheme IX farnesyltransferase affects the TCA cycle 
The protoheme IX farnesyltransferase (CyoE) is essential for electron transport in 
many organisms, and electron transport facilitates the oxidation of reduced 
dinucleotides that are generated from TCA cycle activity. As such the inactivation 
of cyoE in S. aureus should dramatically decrease TCA cycle activity. The 
decreased Agr activity (figure 3.4) coupled with decreased TCA cycle activity 
could provide a potential explanation for the decreased cytotoxicity observed for 
the ΔcyoE mutant, as it has been previously shown secretion of cytotoxins 
requires TCA cycle activity (Somerville et al., 2002). Furthermore, this would 
explain why growth of the ΔcyoE mutant is not affected, as shown in figure 3.4a; 
as toxin production is an energetically costly process, sacrifice of this phenotype 
in response to TCA cycle downregulation would allow the cell to continue to 
produce sufficient energy for growth using micro-aerobic or anaerobic 
metabolism pathways, for which TCA cycle activity is not required.  
To test this hypothesis, the catabolism of acetate, which requires TCA cycle 
activity, was assessed. Acetate accumulates in the culture medium during the 
exponential growth phase due to the incomplete oxidation of carbohydrates when 
the TCA cycle is repressed. The catabolism of acetate begins when 
carbohydrates are depleted and the TCA cycle is de-repressed in the post-
exponential growth phase. Loss of a functional TCA cycle will result in a 
deficiency in acetate catabolism, leading to a build-up of acetate in the culture 
medium and lowering its pH. As expected, the acidification of the media was 
equivalent, as was the accumulation of acetate between the wild-type, ΔcyoE 
mutant and complemented strains over the first five hours of growth (figures 3.5a 
& 3.5b). However, once the bacteria ceased growing exponentially (from 5hr 
onwards) the ΔcyoE mutant failed to alkalinise the culture medium and did not 
catabolise acetate (figures 3.5a & 3.5b).  
To specifically verify the effect of cyoE on the TCA cycle activity aconitase activity 
was also quantified, which is a major TCA cycle enzyme catalysing the 
interconversion of citrate and isocitrate.  During the post-exponential growth 
phase (6hr) it was found that the wild-type and complemented mutant strains 
both had significantly more aconitase activity when compared to the ΔcyoE 
mutant (figure 3.5c; p=0.001). Taken together, the ΔcyoE mutant’s inability to 
catabolise acetate and alkalinise the culture medium, demonstrates that 
inactivation of cyoE blocks TCA cycle activity.  
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Figure 3.5. Activity of the TCA cycle is affected by the loss of expression of 
protoheme IX farnesyltransferase. The pH A) and acetate B) levels of the supernatant 
of the wild type (JE2), ΔcyoE mutant and the complemented mutant were quantified over 
12hours of growth. Inactivation of the cyoE gene affected both the pH and acetate levels, 
the effects of which were complemented by expression of the gene from the plasmid 
pCyoE. C) Aconitase activity, a key feature of the TCA cycle, was quantified in the wild 
type (JE2), ΔcyoE mutant and complemented mutant. Inactivation of the cyoE gene 
significantly reduced aconitase activity, the effect of which was complemented by 
expression of the gene from the pCyoE plasmid. Data shown here are the results of 






3.2.5 Growth of S. aureus under micro-aerobic conditions 
mimics the effect of a loss of cyoE 
As an alternative means of demonstrating the effect of reducing TCA cycle 
activity on toxicity, it was examined whether an effect equivalent to the 
inactivation of cyoE could be achieved by culturing the bacteria in a microaerobic 
environment. As a facultative anaerobic bacterium, S. aureus can grow under 
anaerobic conditions, however its growth rate is significantly affected with one 
study finding a nine-fold difference in final cell density when aerobic and 
anaerobic growth conditions were compared (Coleman, 1985). This study also 
found that under anaerobic conditions S. aureus secretes less alpha toxin, 
however these effects on cell growth make assessing the relative levels of 
expression of quorum-sensing dependent proteins complicated. As such, to 
repress the TCA cycle while minimising the growth defects associated with 
anaerobic conditions a micro-aerobic environment was created by growing the 
bacteria in air, but manipulating the flask-to-medium ratio (Somerville & Proctor, 
2013). JE2 was grown for 18hrs and the effect of comparing a flask-to-medium 
ratio of 10:1 and 10:8 on the secretion of toxins was quantified (figure 3.6). The 
bacteria grown in micro-aerobic conditions had a relatively small (1.9-fold) 
decrease in biomass when compared to those grown aerobically. There was 
however a significant effect on toxicity with the bacteria growing in a micro-
aerobic environment expressing levels of toxicity equivalent to an aerobically 





Figure 3.6. Repression of the TCA cycle by growing S. aureus under microaerobic 
conditions repressed the expression of cytolytic toxins. The wild type (JE2) strain 
was grown under microaerobic (10:8 flask to broth volume ratio) and under aerobic (10:1 
flask to broth volume ratio) conditions to determine the effect this has on cytolytic toxin 
production. An Agr mutant and the ΔcyoE mutant both grown aerobically were included. 
Growth of the wild type strain under microaerobic conditions had an equivalent effect on 
toxicity as inactivation of either the Agr system or the cyoE gene, demonstrating the 
contribution the TCA cycle makes to the toxicity of S. aureus. 
 
3.3 Discussion 
S. aureus is one of the most sequenced bacterial pathogens, with many 
thousands of genomes being publicly available. We are at a point in which this 
sequence data can be used to understand the biology of this important pathogen 
in greater detail. This study began as a GWAS analysis of a collection of ST239 
isolates and is completed here as the molecular detail of the role of a GWAS 
identified locus on virulence is characterised. Here it is demonstrated that the 
cyoE gene, which encodes a protoheme IX farnesyltransferase enzyme, plays a 
critical role in the ability of S. aureus to secrete cytolytic toxins. In the ΔcyoE 
mutant, activation of the Agr quorum sensing system is significantly delayed, 
despite the bacteria reaching sufficient cell density. This effect on the Agr system 
is coupled to repression of the TCA cycle caused by the loss of haem O 
production and its role as an electron acceptor in the electron transport chain. 
This work reiterates the important link between metabolism and virulence in S. 
aureus, but also demonstrates the variability that exists in these attributes 
amongst clinical isolates causing disease in humans. As genome sequencing 
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becomes more embedded in clinical diagnostic procedures, information relating 
to such polymorphic loci could be used to assist in the diagnosis of highly virulent 
infections. 
This study contributes a novel finding to a wider project which aimed to better 
characterise the genetic basis for toxicity in Staphylococcus aureus. Focussing 
on one locus which was statistically associated through a genome-wide 
association study with the toxic phenotype in S. aureus, it is demonstrated here 
that the cyoE gene plays an important role in cellular metabolism, in turn 
influencing the production and secretion of cytolytic toxins. The cyoE gene 
encodes the enzyme protoheme IX farnesyltransferase, which processes haem B 
into haem O for use as an electron acceptor in the electron transport chain. In a 
mutant deficient in the cyoE gene, toxicity is significantly reduced, Agr activity is 
downregulated and metabolism of the cell, specifically TCA cycle activity, is 
affected such that the bacterium grows as if it were in micro-aerobic conditions.   
Agr activity is critical to the production and secretion of staphylococcal toxins, so 
it is not surprising that its activity is observed to be downregulated in this toxicity-
deficient mutant. Toxin production is an energetically costly process, and the 
cyoE gene is an important component in electron transport for generation of ATP. 
Without this gene, aerobic respiration cannot continue and the mutant is forced to 
respire micro-aerobically. Under these conditions, toxin production becomes too 
energetically costly for the cell, so Agr activity, and in turn toxin production is 
downregulated accordingly.  
Tightly linked to this is activity of the TCA cycle, which is demonstrated to be 
repressed in the cyoE mutant. This repression is caused by the loss of function of 
the electron transport chain. This deficiency in electron transport means reduced 
dinucleotides (i.e. NADH/FADH2) produced by the TCA cycle cannot be oxidised, 
and the TCA cycle becomes inhibited through negative feedback. As a result, 
metabolic by-products of exponential phase growth, which would normally be 
catabolised by the TCA cycle during stationary phase, build up in the culture 
medium and the mutant behaves as if it were growing in micro-aerobic 
conditions.  
Altogether the effect of the cyoE mutation is to cause a deficiency in electron 
transport which prevents the mutant from respiring aerobically. This has a critical 
effect on other metabolic pathways and reduces the amount of ATP that the cell 
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can produce. In response to these metabolic changes, activity of the regulatory 
Agr system is repressed and toxin production is significantly reduced. 
While this work focusses on a very specific contributor to toxin production in S. 
aureus, it builds on a wider body of knowledge regarding the complicated genetic 
regulatory network that influences staphylococcal toxicity. In this era of antibiotic 
resistance, and with the increasing availability of genetic information, it will 
become increasingly important to understand the intricacies of how bacteria such 
as S. aureus are able to cause disease if we are to find alternative treatment and 
prevention methods, and this can be achieved through better understanding 
individual gene function in relation to disease.  
It is shown here that GWAS can be a useful tool in working towards this goal. 
Using a statistical approach along with whole genome sequence data, individual 
genetic contributors to a phenotype can be identified and characterised to 
establish their specific function in the context of bacterial virulence. This work 
represents the later stages of this process, and demonstrates how understanding 
individual gene function can help to further our understanding of how bacteria 













4. Investigating the genetic basis 
for toxicity in Streptococcus 




Streptococcus pneumoniae is a major cause of disease worldwide, ranging from 
minor infections such as sinusitis and otitis media, to serious invasive disease 
such as pneumonia, meningitis and septicaemia. A key virulence factor of the 
pneumococcus is the cytolytic pore-forming toxin pneumolysin, which can cause 
extensive damage to host tissues at the site of infection. Following successful 
identification of novel toxicity-associated loci in Staphylococcus aureus using 
genome-wide association (Laabei et al., 2014; 2015), and the means by which 
these loci affect toxin production (Stevens et al., 2017; Yokoyama et al., 2018), 
this functional genomics approach was applied to the investigation of toxicity-
affecting loci in S. pneumoniae.  
The aims of this project were: 
1) To identify novel genetic contributors to toxicity in S. pneumoniae to 
further our understanding of how this bacterium causes disease 
2) To compare results from three different GWAS methods to aid 
prioritisation of genes for functional verification 
A crucial difference between S. aureus and S. pneumoniae is that S. pneumoniae 
produces only one toxin, while S. aureus produces up to fifteen. However, the 
genetic regulation of toxicity is complex and incompletely understood. By further 
elucidating genetic effectors of toxicity in this organism, this work contributes to 
the increasing body of knowledge regarding how S. pneumoniae causes disease, 
ultimately working towards better treatment and prevention of pneumococcal 
disease. From the functional genomics approach used here, a novel effector of 
toxicity is identified in S. pneumoniae. 
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A further aspect of this project is to extend the functional genomics approach 
used in previous work on S. aureus by applying three different GWAS methods to 
the dataset. The purpose of this is to aid prioritisation of statistically significant 
loci for further investigation, to determine whether true positive results are 
identified consistently between the different methods.  
4.2 Results 
4.2.1 Generation of the dataset for GWAS 
GWAS requires a quantitative set of phenotypic data and a corresponding set of 
genotypic data from a large number of bacterial isolates. In this case, the 
phenotypic dataset consists of toxicity data from a collection of 166 clinical 
isolates of the clonal complex PMEN-1, taken from patients with pneumococcal 
disease, each of which varies based on single nucleotide polymorphisms present 
throughout the genome. These single nucleotide polymorphisms make up the 
genotypic dataset. Clinical isolates and their corresponding SNP data were 
obtained from Stephen Bentley and Nicholas Croucher at the Sanger Institute, 
Cambridge, with technical assistance from Rebecca Gladstone. 
4.2.1.1 Toxicity assays for clinical strains 
A haemolytic activity assay was developed using S. pneumoniae TIGR4 wild type 
and an isogenic TIGR4 pneumolysin-deficient strain, obtained from Angela 
Nobbs at the University of Bristol, to quantify variations in toxicity across the 
collection of clinical isolates. Use of a pneumolysin-deficient mutant as a control 
demonstrated that lack of the toxin gene ply resulted in no lysis of red blood cells, 
therefore showing that pneumolysin alone was responsible for cell lysis, and any 
variations in toxicity of the clinical isolates could be attributed to variations in 
pneumolysin production (see figure 4.1). 
For this assay, whole cell culture at mid-exponential phase was serially diluted 4-
fold, 6 times in a 96-well plate and mixed with 2% sheep red blood cells. Cells 
were incubated in this manner for 1 hour at 37°C with 5% CO2, and lysis of red 
blood cells was measured by transferring the supernatant to a fresh plate and 
reading absorbance at 596nm (see Materials & Methods, section 2.3.2 for further 
details).  
The wild type TIGR4 and pneumolysin-deficient mutant were included as controls 
in every assay. Average haemolytic activity for each control along with a buffer-
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only blank is shown in figure 4.1 below, with toxicity shown as absorbance of the 
supernatant at 596nm; high absorbance values indicate high toxicity, and vice 
versa. All toxicity data presented is for the first 4-fold dilution, which was 
determined to be the most useful for showing variations in toxicity. 
 
Figure 4.1: Haemolytic activity of wild type TIGR4 and isogenic TIGR4 Δply strains. 
These were used as controls on each 96 well plate in the subsequent haemolytic activity 
assays. For TIGR4 WT and TIGR4 Δply strains n=17, for the buffer only n=3. Boxes 
represent the interquartile range of the dataset, with the thick black line representing the 
median. Whiskers show the highest and lowest data points. The difference between the 
Δply strain and the buffer is statistically significant in a T-test (p=0.04), however there are 
only 3 data points for the buffer, compared to 17 for Δply, and there is also a greater 
amount of variation in the Δply dataset as this represents data from several assays 
combined. 
 
Each of the 166 clinical isolates was then run through the haemolytic activity 
assay to gather the quantitative phenotypic dataset, the results of which are 
shown in figure 4.2. Data are presented as a scatterplot in descending order of 















































































































4.2.2 Genome-wide association studies 
The phenotypic data generated from the toxicity assays and genome sequence 
data for each clinical isolate were then used in three different GWAS methods: 
1) SNP-based GWAS – run with assistance from Mario Recker at the 
University of Exeter 
2) SEER – run by John Lees, formerly at the Sanger Institute, Cambridge 
3) Bugwas – run by Daniel Wilson and Sarah Earle at the University of 
Oxford 
4.2.2.1 SNP-based GWAS 
With guidance and R scripts from Dr. Mario Recker, my co-supervisor based at 
the University of Exeter, the SNP data file was converted into numerical values, 
with 1 representing presence of a SNP at a given position, and 0 representing no 
SNP change at a given position, relative to the reference genome of 
ATCC700669 (SPN23F). Missing data was converted to NA values and therefore 
excluded from statistical analysis. Positions with a high number of missing values 
were also excluded; this is the genotype frequency, the threshold for which was 
set at 5%; this means that any SNP positions which had 95% or more NA values 
were excluded from the study. A further threshold was set for positions with less 
than 3% SNP changes; this is the minor allele frequency and excludes SNP 
positions at which fewer than 3% of isolates had a SNP change. Pearson’s 
product-moment correlation was then performed using the filtered SNP data and 
toxicity data from each strain, to identify associations between SNP positions and 
the toxic phenotype.  
Following this, a permutation test was conducted to determine whether the 
observed results are exchangeable under the null hypothesis: this being that 
there is no significant association between a SNP position and the toxic 
phenotype. A permutation test illustrates that significant results are not obtained 
through chance but are actually correlated with the phenotypic data. A 
permutation test is done by scrambling the dataset to remove the association 
between genotype and phenotype, and then re-doing the correlation analysis to 
see if the same significant results are observed. This is done, for example, a 
thousand times, therefore scrambling results which are biologically significant and 
showing the likelihood of specific SNP positions remaining significant once the 
dataset has been scrambled numerous times. The results of this permutation are 
112 
 
used to produce empirically derived p-values which gives more support to the 
statistically significant results produced from the GWAS. Following permutation, 
p-values were converted to -log10 and plotted on a Manhattan plot, as shown in 
figure 4.3 below. The threshold for statistical significance was set to p=0.05, 
results which cross this threshold are highlighted in red in figure 4.3. 
Figure 4.3: Manhattan plot showing GWAS results. Thresholds were set to eliminate 
data with a genotype frequency of less than 5% and a minor allele frequency of less than 
3%. P-values shown were empirically derived following permutation of the dataset, and 
statistically significant values have been colour coded in red based on a threshold for 
significance which is set as –log10(0.05).  
 
Loci identified using this method as statistically significantly associated with 
toxicity totalled 548 within 56 genes and 11 intergenic regions. These genes are 
listed in table 4.1 below. 
 
Table 4.1: SNP-based GWAS results. Genes in reference strain ATCC 700669 
(SPN23F) in which SNPs were identified that were statistically significantly associated 
with toxicity using SNP-based GWAS. 
Gene Name Gene Function 
agaS putative tagatose-6-phosphate aldose/ketose isomerase 
SPN23F00810 putative aldose 1-epimerase 
SPN23F00820 
glyoxalase/bleomycin resistance protein/dioxygenase 
superfamily protein 
SPN23F02870 putative glycosylhydrolase 




Intergenic intergenic between mraY and clpL - contains BOX repeats 
clpL putative ATP-dependent protease ATP-binding subunit ClpL 
SPN23F03140 conserved hypothetical 
Intergenic 
intergenic between SPN23F03370 and aliA - contains RUP 
repeat 
aliA putative extracellular oligopeptide-binding protein 
SPN23F03400 cell wall surface anchored protein 
valS valyl-tRNA synthetase 
Intergenic  
intergenic between SPN23F05220 and pheS - contains RUP 
repeat 
pheS phenylalanyl-tRNA synthetase alpha chain 
Intergenic intergenic between SPN23F05240 and pheT 
pheT phenylalanyl-tRNA synthetase beta chain 
SPN23F05380 putative uncharacterised protein 
SPN23F05470 putative amino acid ABC transporter, permease protein 
ntpE V-type sodium ATP synthase subunit E 
ntpK V-type sodium ATP synthase subunit K 
SPN23F12160 putative ROK family protein 
Intergenic intergenic between SPN23F12160 and SPN23F12170 
SPN23F12170 putative oxidoreductase 
Intergenic intergenic between SPN23F12170 and SPN23F12180 
SPN23F12180 putative sialidase (neuraminidase) 
SPN23F12190 conserved hypothetical protein 
SPN23F12200 putative sodium:solute symporter 
nanA probable N-acetylneuraminate lyase 
Intergenic intergenic between SPN23F12270 and SPN23F12280 
SPN23F12640 putative uncharacterised protein 
SPN23F12650 putative uncharacterised protein 
SPN23F12660 putative uncharacterised protein 
SPN23F12670 putative uncharacterised protein 
Intergenic intergenic between SPN23F12670 and SPN23F12680 
SPN23F12680 putative uncharacterised protein 
SPN23F12760 putative membrane protein 
SPN23F12770 putative uncharacterized protein 
Intergenic intergenic between SPN23F12770 and SPN23F12780 
SPN23F12780 putative conjugative transposon DNA recombination protein 
SPN23F12820 putative uncharacterized protein (pseudogene) 
SPN23F12840 
putative conjugal transfer protein (possible involvement with cell 
wall metabolism) 
SPN23F12850 putative conjugal transfer protein 
SPN23F12860 putative uncharacterized protein 
SPN23F12870 putative uncharacterized protein 
SPN23F12880 putative uncharacterized protein 
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traG putative conjugal transfer protein TraG 
SPN23F12900 putative uncharacterized protein 
SPN23F12910 putative uncharacterized protein 
SPN23F12930 conserved hypothetical protein 
orf21 conjugative transposon FtsK/SpoIIIE-family protein 
tetM conjugative transposon tetracycline resistance protein 
SPN23F13110 putative CAAX amino terminal protease 
SPN23F13120 putative uncharacterized protein 
SPN23F13130 putative uncharacterized protein 
SPN23F13140 putative uncharacterized protein 
SPN23F13150 putative DNA methylase 
Intergenic intergenic between SPN23F13150 and SPN23F13160 
SPN23F13160 putative replication initiator protein 
SPN23F15080 putative membrane protein 
priA putative primosomal protein N' 
SPN23F19110 putative polysaccharide repeat unit polymerase 
SPN23F19120 sucrose phosphorylase 
Intergenic 
intergenic betwteen SPN23F12190 and msmG - contains BOX 
repeats 
msmG multiple sugar-binding transport system permease protein 
msmF multiple sugar-binding transport system permease protein 




Sequence element enrichment analysis (SEER) is a GWAS method developed 
by John Lees (Lees et al., 2016) which uses short sections of DNA instead of 
SNPs as the unit of genetic variation. These ‘sequence elements’, referred to as 
k-mers, vary in length and are produced from the original genome sequence data 
instead of SNP data. The benefit of using k-mers in place of SNPs alone is that 
they capture other types of genetic variation along with individual polymorphisms, 
including indels, recombinations and variations in promotor sequences and gene 
content. Further differences between this and the SNP-based GWAS method are 
that SEER uses logistic and linear regression to identify associations between 
genotype and phenotype, it controls for population structure using metric multi-
dimensional scaling, and corrects for multiple testing using a conservative 
Bonferroni cut off for significance. It is open to debate as to whether this is better 
than the SNP-based approach, hence why the different methods are combined in 
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this project, to see if one method produces more true positive associations than 
another. 
SEER was conducted on this dataset by John Lees and I did not contribute 
to running this analysis, only to analysing the results. This approach 
identified 34 genes and 9 intergenic regions containing k-mers which were 
statistically significantly associated with the toxic phenotype, details of which are 
presented in table 4.2 below. Four of these genes were also identified as 
containing statistically significant loci by the SNP-based GWAS method and 
these are highlighted in red.  
Table 4.2: SEER results. Genes in reference strain ATCC 700669 (SPN23F) in which k-
mers were identified as being statistically significantly associated with toxicity using 
SEER. 
Gene name Gene function 
trcF putative transcription repair coupling factor 
SPN23F00770 sugar phosphotransferase system - sorbose-specific family IIC 
SPN23F01610 putative ABC transporter system permease protein 
Intergenic intergenic between SPN23F01610 and SPN23F01620 
SPN23F01620 putative membrane protein 
SPN23F01630 putative membrane protein 
SPN23F01640 putative histidine sensor kinase 
SPN23F05060 putative uncharacterised protein 
Intergenic 
intergenic between SPN23F05060 and SPN23F05070 - 
contains BOX repeats 
SPN23F05070 conserved hypothetical protein 
SPN23F06470 putative coenzyme 
SPN23F07400 putative IS640-Spn1 transposase (pseudogene) 
Intergenic intergenic between SPN23F07430 and SPN23F07440 
SPN23F07440 putative amino acid ABC transporter system permease protein 
SPN23F08070 putative type I RM modification system 
SPN23F09200 putative IS630-Spn1 transposase (pseudogene) 
gidB methyltransferase GidB 
SPN23F12470  putative DNA helicase II UvrD 
SPN23F12510 putative NTPase protein 
SPN23F12530 putative phosphoserine phosphatase 
SPN23F12690 putative lantibiotic transport/processing ATP-binding protein 
SPN23F12701 putative lantibiotic precursor 
Intergenic intergenic between SPN23F12701 and SPN23F12710 
SPN23F12710 putative lantibiotic ABC transporter 
Intergenic intergenic between SPN23F12820 and SPN23F12830 
SPN23F12830 putative uncharacterised protein 
SPN23F12840 putative conjugal transfer protein 
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traG putative conjugal transfer protein TraG 
SPN23F12930 conserved hypothetical protein 
SPN23F13710 putative membrane protein 
SPN23F15290 autolysin 
Intergenic intergenic between SPN23F15290 and hol 
hol antiholin 
SPN23F15590 hypothetical phage protein 
scrA 
putative sucrose-specific phosphotransferase system (PTS), 
IIABC component 
fmt methionyl-tRNA formyltransferase 
Intergenic intergenic between fmt and priA 
priA putative primosomal protein N' 
SPN23F18300 conserved hypothetical protein 
Intergenic  
intergenic between trpE and SPN23F18390 - contains BOX 
repeats 
SPN23F19510 putative IS1381 transposase (pseudogene) 
Intergenic intergenic between SPN23F21680 and pcpA 
pcpA cell surface choline binding protein PcpA 
 
4.2.2.3 Bugwas 
Bugwas is an alternative GWAS method developed by Daniel Wilson and Sarah 
Earle at the University of Oxford (Earle et al., 2016). This approach uses linear 
mixed models (LMMs) to identify associations between genotype and phenotype 
and, like SEER, controls for population structure. However, Bugwas uses 
principal components to test for lineage effects and control for population 
structure as opposed to metric multi-dimensional scaling. This approach employs 
the Bonferroni correction to correct for multiple testing. Here, both SNP data and 
k-mer data are used as the unit of genetic variation to test for association with the 
phenotype; results are presented from four different analyses; one using bi-allelic 
SNPs as the genotypic data (the SNP change is always the same compared to 
the reference genome), one using tri/tetra-allelic SNPs (the SNP change could be 
to one of two or three different bases respectively, compared to the reference 
genome), one using fixed-length k-mers and one using variable-length k-mers. 
Bugwas was conducted on this dataset by Sarah Earle and I did not 
contribute to running this analysis, only to analysing the results. Results 
from the SNP-based analysis identified 57 genes and 9 intergenic regions 
containing SNPs which were statistically significantly associated with the toxic 
phenotype; three of these genes were also identified as statistically significant by 
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the SNP-based GWAS method (text coloured red), and one gene was identified 
as statistically significant by SEER (text highlighted in yellow), as shown in table 
4.3 below. 
 
Table 4.3. Bugwas SNP results. Genes in reference strain ATCC 700669 (SPN23F) in 
which SNPs were identified that were statistically significantly associated with toxicity 
using Bugwas. 
Bi-allelic loci 
Gene name Gene function 
trcF putative transcription repair coupling factor 
SPN23F00830 conserved hypothetical protein 
SPN23F00840 putative uncharacterized protein 
SPN23F00850 conserved hypothetical protein 
SPN23F01020 
binding-protein-dependent transport system membrane 
protein 
agaD 
putative N-acetylgalactosamine-specific phosphotransferase 
system (PTS), IID component 
SPN23F03010 heparinase II/III-like protein 
SPN23F03020 LacI family regulatory protein 
SPN23F03030 membrane protein 
Intergenic intergenic between SPN23F03030 and SPN23F03040 
pbpX penicillin-binding protein 2X 
mraY phospho-N-acetylmuramoyl-pentapeptide- transferase 
glnQ3 putative glutamine transporter, ATP-binding protein 3 
SPN23F07870 conserved hypothetical protein 
Intergenic intergenic between lacT2 and lacD2 
udk uridine kinase 
SPN23F11330 conserved hypothetical protein 
ffh signal recognition particle protein 
SPN23F14040 putative transposase remnant (pseudogene) 
SPN23F17530 conserved hypothetical protein 
SPN23F17550 conserved hypothetical protein 
Intergenic intergenic between SPN23F17550 and SPN23F17560 
SPN23F17560 GTP-binding protein 
SPN23F17580 CorA-like Mg2+ transporter protein 
SPN23F17800 putative glycosyltransferase 
psrP cell wall surface anchored protein 
Intergenic intergenic between SPN23F18050 and SPN23F18060 
SPN23F18400 hypothetical protein 
SPN23F18970 sugar phosphotransferase system (PTS), IIABC component 
SPN23F20870 putative exported protein 
dnaN DNA polymerase III, beta chain 
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SPN23F00470 putative uncharacterized protein (pseudogene) 
purK 
putative phosphoribosylaminoimidazole carboxylase ATPase 
subunit 
ribE riboflavin synthase alpha chain 
SPN23F02770 
putative CAAX amino terminal protease family membrane 
protein 
folP dihydropteroate synthase 
folC putative putative folylpolyglutamate synthase 
SPN23F03400 cell wall surface anchored protein 
alsS acetolactate synthase large subunit 
SPN23F05080 putative uncharacterized protein 
SPN23F05210 
beta-glucoside-specific phosphotransferase system (PTS), 
IIABC component 
SPN23F05680 putative carboxypeptidase 
rplA 50S ribosomal protein L1 
Intergenic 
intergenic between SPN23F06400 and thiM - contains BOX 
repeats 
rpiA ribose 5-phosphate isomerase A 
pfk 6-phosphofructokinase 
SPN23F08620 putative replication initiation protein (pseudogene) 
Intergenic intergenic between comEC and SPN23F08820 
Intergenic intergenic between prsA and SPN23F09070 
Intergenic intergenic between SPN23F09270 and lmb 
SPN23F10470 putative glycerate kinase-family protein 
zmpA IgA-protease 
potD spermidine/putrescine extracellular binding protein 
aldB alpha-acetolactate decarboxylase 
pstS 
putative phosphate ABC transporter, extracellular phosphate-
binding lipoprotein 
pclA putative NADPH-dependent FMN reductase 
nanA sialidase A (neuraminidase A) 
Intergenic 
intergenic between SPN23F18610 and xpt - contains BOX 
repeats and SPRITE repeat 
SPN23F20830 putative pyrrolidone-carboxylate peptidase 
hasC UTP-glucose-1-phosphate uridylyltransferase 
SPN23F21510 putative Major Facilitator Superfamily protein 
glpK glycerol kinase 
SPN23F17520 putative isochorismatase 
SPN23F17570 putative hydrolase 
Tri- or tetra-allelic loci 
SPN23F14660 putative amino acid ABC transporter ATP-binding protein 
mraY phospho-N-acetylmuramoyl-pentapeptide- transferase 
pbpX penicillin-binding protein 2X 
SPN23F00840 putative uncharacterized protein 
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Results from the two k-mer-based analyses identified 6 genes and 1 intergenic 
region containing k-mers that were statistically significantly associated with 
toxicity. None of the genes identified using the fixed-length k-mer analysis were 
identified in any of the other GWAS methods, while 2 genes identified using the 
variable-length k-mer analysis were also identified by both the SNP-based GWAS 
method and the SNP-based Bugwas method. These genes are shown in red in 
table 4.4 below. 
Table 4.4. Bugwas k-mer results. Genes in reference strain ATCC 700669 (SPN23F) in 
which k-mers were identified that were statistically significantly associated with toxicity 
using bugwas. 
Fixed-length k-mers 
Gene name Gene function 
SPN23F21490 putative uncharacterized protein 
SPN23F20850 MarR family regulatory protein 
Intergenic intergenic region containing BOX-repeat elements 
SPN23F20870 putative exported protein 
Variable-length k-mers 
pbpX penicillin-binding protein 2X 
mraY phospho-N-acetylmuramoyl-pentapeptide- transferase 
SPN23F05430 two-component system, response regulator 
 
4.2.2.4 Summary of key features and differences between the three 
methods 
SNP-based GWAS: 
• Uses SNPs as the unit of genetic variation 
• Does not control for population structure 
• Corrects for multiple testing using permutation 
SEER: 
• Uses k-mers as the unit of genetic variation 
• Controls for population structure using metric multi-dimensional scaling 
• Corrects for multiple testing using the Bonferroni correction 
Bugwas 
• Uses both SNPs and k-mers as the unit of genetic variation 
• Controls for population structure using principal component analysis 
• Corrects for multiple testing using the Bonferroni correction 
 
4.2.3 Functional verification of GWAS results 
GWAS approaches are notorious for producing false positive results. Direct 
associations are causative genetic loci that are directly responsible for changes in 
the phenotype. Indirect associations, or false positives, are genetic loci that are 
120 
 
falsely associated with the phenotype because polymorphisms at these positions 
have been inherited by chance alongside the causative locus, with which they are 
in linkage disequilibrium. For this reason, polymorphisms that have been 
statistically associated with the toxic phenotype tend to cluster around a particular 
genetic locus as seen in figure 4.3, where only one polymorphism may in fact be 
causative of the observed phenotype.  
To identify which genetic loci are directly associated with this phenotype, it is 
necessary to verify the function of each gene of interest in the lab. Here, this was 
done by attempting to disrupt each gene significantly associated with toxicity and 
testing the toxic phenotype of the resulting mutant using the haemolytic activity 
assay. Through discussion with collaborator Tim van Opijnen at Boston College, 
we obtained transposon mutants in 15 associated genes in the S. pneumoniae 
TIGR4 2394 background, which we could use to begin the process of functional 
verification (results section 4.2.3.1). Alongside this, it was intended that I would 
make whole-gene deletions of each associated gene in the reference S. 
pneumoniae strain ATCC 700669 (SPN23F), results for which are shown in 
section 4.2.3.2. 
4.2.3.1 Transposon mutants in the TIGR4 2394 background strain 
35 transposon mutants were obtained in the TIGR4 2394 background from 
collaborators Tim van Opijnen and Derek Thibault at Boston College. These 
mutants have transposon insertions in 15 associated genes, with different 
mutants having transposon insertions at different positions within the same gene. 
The Opijnen lab has previously constructed a large number of transposon 
mutants in the TIGR4 2394 background, and the ones provided here were all of 
the mutants in the Opijnen lab collection that crossed over with the GWAS results 
from the SNP-based method. Table 4.5 below gives details of each of these 








Table 4.5: Transposon mutant details. Genes in which knockout mutants were provided 
for us by Professor Tim van Opijnen in the background strain TIGR4 2394. 
Gene name in 
ATCC 700669 




























subunit ClpL SP0338 1 312171 








aliA 1 339543 
SPN23F03400 
cell wall surface anchored 








protein SP0595 1 564606 
SPN23F12160 
putative ROK family 















protein SP1327 1 1251839 
SPN23F12200 
putative sodium:solute 















aspC 1 1451657 








These mutants were each tested for haemolytic activity to begin functional 
verification of genes identified from GWAS to verify any true positive 
associations. The figure below shows toxicity data for each of the TIGR4 2394 
mutants and the 2394 wild type strain, based on the averages of ten biological 
repeats per mutant. Six mutants have been identified as having statistically 
significantly lower toxicity than the wild type strain (p<0.05, one-tailed Student’s 
T-test), as shown in figure 4.4. Results are ordered numerically, first based on the 
locus tag of the gene and secondly based on the position within the gene at 
which transposons have inserted. Groups of transposon mutants that are within 











































































































































































































































































































































































Results highlighted in red in figure 4.4 are mutants with a significant reduction in 
toxicity compared to the TIGR4 2394 wild type strain. Details of these mutants 
are listed in table 4.6 below. 
Table 4.6: Transposon mutants with reduced toxicity. Mutants identified as having 
statistically significantly lower toxicity than the TIGR4 2394 wild type strain. 
Gene locus tag in TIGR4 
(location of Tn insertion) 
Gene name in 
SPN23F Gene function 
SP0366 339543 aliA 
putative extracellular 
oligopeptide-binding domain 
SP0368 342722 SPN23F03400 cell wall surface anchored protein 
SP0368 343006 SPN23F03400 cell wall surface anchored protein 
SP1324 1247707 SPN23F12160 putative ROK family protein 
SP1324 1247993 SPN23F12160 putative ROK family protein 
SP1326 1250124 SPN23F12180 putative sialidase (neuraminidase) 
 
Interestingly, where more than one mutant was provided with transposon 
insertions at different locations within the same gene, not all these mutants 
exhibited the same loss in toxicity. For example, the mutants with transposon 
insertions at positions 1247707 and 1247993 within the gene SP_1324 are two of 
four mutants with transposon insertions within this gene, and yet the other two 
mutants do not exhibit significantly reduced toxicity compared to the wild type. 
Both these insertions are within the first half of the gene after the start codon (see 
figure 4.5), and so the remaining two mutants could be producing a truncated 
form of the protein which may still retain some degree of normal function. 
Figure 4.5. TIGR4 2394 gene SP1324, labelled with the positions of each 
transposon insertion. Transposon insertions at positions 1247707 and 1247993 are 
marked green and blue, respectively.The purple and red markers represent the two 
insertions which do not cause a loss in toxicity.  
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However, the insertions at positions 1247707 (low-toxic, green marker in figure 
4.5) and 1247683 (toxic, red marker in figure 4.5) are in very close proximity, so it 
is unexpected that one would cause a significant reduction in toxicity while the 
other wouldn’t; the transposon used to disrupt the gene would likely be disrupting 
the same structural feature of the resulting protein given the close proximity of 
these two loci, so it is unexpected that such a substantial difference in toxicity is 
observed between these two particular mutants. Furthermore, of five transposon 
insertions in the gene SP0368, only the second and third insertions (from the 
start codon) exhibit a reduction in toxicity (see figure 4.4).  
It is noted that even after 10 repeats of the toxicity assay the variance of this 
dataset is high, as demonstrated by the lengths of the whiskers on the box and 
whisker plots in figure 4.4, therefore it is difficult to draw any firm conclusions 
from these results. Furthermore, the wild type TIGR4 2394 background strain in 
which these mutants were constructed, and which is used here as a control, is an 
unencapsulated pneumococcal strain which has lower toxicity than the 
encapsulated clinical strains used in the GWAS (absorbance at 596nm of 0.15-
0.25 compared to 0.25-0.45 for the TIGR4 wild type), so variation between 
mutants and wild type is likely to be less pronounced. To determine if any 
differences in toxin production could be observed in the six mutants exhibiting a 
significant reduction in toxicity, a Western blot was conducted on cell pellet 
extractions using anti-pneumolysin antibody. The results of this are shown in 








Figure 4.6.  Anti-pneumolysin western blots. Cell pellet extractions from each of the 
TIGR4 2394 transposon mutants which showed a reduction in toxicity were used in a 
Western blot using anti-pneumolysin antibody, along with the TIGR4 2394 wild type, the 




Here, mutant SP1324 1247993 appears to produce more pneumolysin than the 
two wild type controls; when quantified with ImageJ there is on average a 1.4-fold 
increase in pneumolysin production in this mutant in comparison to the TIGR4 
2394 wild type control. Likewise there is on average a 2.5-fold decrease in 
pneumolysin production in the mutant SP1324 1247707 in comparison to the 
TIGR4 2394 wild type. This is an interesting result in that these two mutants 
contain transposon insertions at different positions within the same gene 
(SP1324 in strain TIGR4, SPN23F12160 in strain SPN23F). The western blot 
results for mutant SP1324 1247993 also contradict the results of the toxicity 
assay, in which this mutant was determined to be significantly less toxic than the 
wild type.  
The fact that the unencapsulated TIGR4 2394 background strain is less toxic 
than the encapsulated TIGR4 strain could explain why it is difficult to distinguish 
differences in toxicity in this collection of mutants using the haemolytic activity 
assay. Western blotting may be more indicative of changes in toxicity in these 
mutants, however, as these results contradict those of the haemolytic activity 
assay, investigation of these mutants was not taken any further. It was decided a 
different approach was needed to screen the large number of GWAS hits.  
4.2.3.2 Construction of whole gene knockout mutants in ATCC 
700669 (SPN23F) 
Given the variability and inconsistencies in the results from the transposon 
mutant collection in the background TIGR4 2394, it was thought a better 
approach would be to construct whole-gene deletion mutants in the high-toxic 
GWAS reference strain ATCC 700669 (SPN23F) in as many toxicity-associated 
genes as possible. A review of the literature (Ge & Xu. 2012; Chen et al., 2015) 
suggested that high-throughput mutant construction in S. pneumoniae was a 
relatively straightforward process in this naturally competent bacterium. Initially, it 
was planned to construct mutants in as many associated genes as possible from 
each of the three different GWAS methods, and to compare which method or 
combination of methods produced the most accurate results.  
It was also thought that whole gene deletion was a better strategy than making 
SNP changes at the specific loci which were associated with toxicity. This was in 
part due to the sheer number of statistically significant loci identified, but 
predominantly because slight differences in toxicity which may be present in 
strains with a SNP compared to those without may not be visible using the 
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haemolytic activity assay, while whole gene deletion is more likely to have a 
pronounced effect on the phenotype. 
To begin the mutant construction process, a Δply mutant deficient in the 
pneumolysin gene was constructed for use as a negative control in subsequent 
phenotypic assays. For in-depth description of the method used for mutant 
construction, see chapter 2, section 2.3.4. Briefly, overlap extension PCR was 
used, in which three DNA fragments are amplified; one homologous to the 1kb 
region upstream of the associated gene, one containing the antibiotic resistance 
cassette (in this case ermAM, amplified from pVA838) and one homologous to 
the 1kb region downstream of the associated gene. These fragments are 
designed to overlap each other, such that they can be stitched together in a 
separate PCR reaction to construct a linear insert around 2.75kb in length, with 
the antibiotic resistance cassette in place of the associated gene (see chapter 2, 
section 2.3.4.3 for details of the primer design process). This can then be 
transformed into S. pneumoniae ATCC 700669 (SPN23F) where it will recombine 
into the chromosome, deleting the associated gene. Figures 4.7 & 4.8 
demonstrate the results of each PCR step to generate the ply 2.75kb insert. 
 
 
Figure 4.7. Initial PCR steps for mutant construction. A) Amplification of ermAM 
antibiotic resistance cassette from pVA838 for use as a template for amplification of 














Figure 4.8. Stitch PCR for construction of ply 2.75kb insert. Fragments 1-3 were 
combined into one PCR reaction, in which the overlapping ends of each fragment were 
stitched together using the forward primer for fragment 1 and the reverse primer for 
fragment 3, creating a single linear insert around 2.75kb in length.  
 
This 2.75kb insert was then transformed into S. pneumoniae strain ATCC 700669 
(SPN23F). Successful transformants were verified using three PCR checks: one 
to a different S. pneumoniae-specific gene to verify the transformant isn’t a 
contaminating organism (for all other mutants primers to the ply gene were used 
for this check, in this case primers were used to gene SPN23F13160 of strain 
ATCC 700669 [SPN23F]); one to the wild type gene that has been deleted; and 
one to the region 1kb upstream of the 2.75kb insert to within the ermAM cassette 
to verify both that the insert is there, and that it has inserted into the correct 
position on the chromosome. Figures 4.9, 4.10 & 4.11 below demonstrate these 





Figure 4.9. Verification that successful transformants are not contaminating 
organisms. PCR was conducted using primers to the SPN23F13160 gene of strain 
ATCC 700669 (SPN23F), to verify that successful transformants were S. pneumoniae.  
 
 
Figure 4.10. Verification that the Δply mutants do not contain the wild type gene. 
PCR was conducted using primers to the wild type ply gene. Results show amplification 




Figure 4.11. Mutant verification for Δply mutants. PCR was conducted using a forward 
primer placed 1kb upstream of the 2.75kb transformed insert, and a reverse primer 
placed within the middle of the ermAM cassette. Results show amplification for the 
successfully transformed mutants, but not for the SPN23F WT, or the ply insert DNA 
controls, as expected. 
 
After verification of the successful construction of a Δply whole gene knockout, 
mutant construction was attempted for as many toxicity-associated genes from 
each of the GWAS methods as possible. Genes were prioritised for mutant 
construction on the following basis: 
• Genes identified by more than one GWAS method (eg. trcF, traG, priA 
etc.) 
• Genes from the group of TIGR4 2394 transposon mutants which were 
shown to have reduced toxicity (eg. aliA, SPN23F03400, SPN23F12160, 
& SPN23F12180) 
• Genes which were thought to be likely to affect toxicity based on current 
knowledge of their function and correspondence with collaborators (eg. 
nanA) 
• All other genes – inserts were constructed and transformed for all 
remaining genes in the order of first to last genes in the results tables 
A number of signature-tagged mutagenesis screens could also have been used 
at this stage to aid the process of defining genes most likely to be involved in 
virulence. Examples of these include Polissi et al. (1998), Lau et al. (2001), Hava 
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& Camilli (2002) and Obert et al. (2006). Hava & Camilli, for example, identified a 
number of tissue-specific virulence factors in a serotype 4 pneumococcal strain, 
some of which were also identified as significant associations in the GWAS 
analyses presented here (eg. gidB, ntpK and msmF). 
To date, 2.75kb inserts have been constructed for 59 associated genes. Figures 
4.12 & 4.13 give examples of successful insert construction for the first four of 
these.   
Figure 4.12. Fragment amplification for the first four inserts. Successful amplification 
of fragments 1-3 for the genes SPN23F12840, traG, SPN23F12930 and priA, all of which 






















Figure 4.13. Stitch PCR for the first four inserts. 2.75kb inserts were stitched together 
using the forward primer for fragment 1 and the reverse primer for fragment 3.  
 
Transformations were attempted for each of the 59 inserts at least once, with 
success for 9 associated genes as listed below. 
• nanA – probable N-acetylneuraminate lyase 
• priA – putative primosomal protein N 
• SPN23F12470 – putative DNA helicase II, UvrD-like protein 
• SPN23F01610 – putative ABC transporter system permease protein 
• SPN23F01620 – putative membrane protein 
• SPN23F02870 – putative glycosylhydrolase 
• SPN23F15290 – autolysin 
• trcF – transcription repair coupling factor 
• gidB – methyltransferase GidB 
Difficulties in the mutant construction process were thought to be primarily due to 
inefficiency of the background strain in transformations, this is discussed further 
below and variations that were made to the protocol to try and increase efficiency 
are presented in table 4.7. 
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Figures 4.14 & 4.15 below illustrate the mutant verification process using priA as 
an example, which was the only one of the four inserts shown in figure 4.13 to 
transform successfully.  
Figure 4.14. Verification that ΔpriA mutants are not contaminating organisms. Two 
ΔpriA transformants were obtained, which are verified here to be S. pneumoniae and not 
a contaminating organism using primers to the wild type ply gene.  
 
Whilst it was initially thought that use of the wild type ply primers would 
demonstrate that transformants were colonies of Streptococcus pneumoniae, it 
was later established that a highly similar gene is present in the genome of S. 
















Figure 4.15. Verification of successful gene deletion in ΔpriA mutants. Primer set A 
- primers to detect the wild type priA allele (expected product size 2397bp), with expected 
amplification for the SPN23F WT DNA, but not for the ΔpriA mutants or the priA insert 
DNA. Primer set B - primers to amplify the region from 1kb upstream of the transformed 
2.75kb insert to within the centre of the ermAM resistance cassette (expected product 
size 2430bp), with expected amplification for the ΔpriA mutants, but not for the SPN23F 
WT DNA or the priA insert DNA. 
 
Each of the 9 whole gene deletion mutants were subsequently tested for toxicity 
using the haemolytic activity assay, using wild type ATCC 700669 (SPN23F) and 
the SPN23F Δply mutant as positive and negative controls, respectively. Results 
for each mutant are shown below in figure 4.16. 
135 
 
Figure 4.16. Average toxicity of SPN23F whole gene deletion mutants. Toxicity of 
each SPN23F whole gene deletion mutant was tested using the haemolytic activity 
assay, results shown are the averages of at least three biological repeats. Controls used 
were the SPN23F wild type strain (first box), the pneumolysin-deficient mutant and buffer 
only (last two boxes).  
 
Of the 9 mutants constructed here, one mutant deficient in the gene 
SPN23F12470 (identified by SEER) shows a significant reduction in toxicity in 
comparison to the isogenic wild type similar to the reduction in toxicity observed 
for the Δply mutant. Detailed characterisation of the role this gene plays in 
relation to toxicity is presented in chapter 5.  
Of the genes which were identified by more than one GWAS method 
(SPN23F12840, traG, SPN23F12930, priA, trcF, pbpX, mraY, SPN23F03400), 
mutants were successfully created in the priA and trcF genes, despite several 
attempts to transform inserts for the other genes. After inconsistencies in 
transformation efficiency were observed, several variations to the protocol were 
used in separate experiments to attempt to determine why the process was not 







Table 4.7. Variations to transformation protocol for ATCC 700669 (SPN23F). Several 
variations to the protocol were introduced to try to improve transformation efficiency. 
Results recorded are based on observation of the number of colonies which grew on 
transformation plates over numerous repeated experiments. 
Change to protocol Result (observation only) 
Introduction of a positive control using 
original ply insert 
Inconsistent results - transformations 
were inconsistent for both this control 
insert and genes of interest 
Varied amount of competence 
stimulating peptide 2 (CSP-2) from 2-
20ng/ul 
No change in transformation efficiency 
Varied amount of DNA added to 
competent cells 
No change in transformation efficiency 
Varied starting density of cells using 
up to 6 serial 10-fold dilutions of 
inoculum for overnight culture 
No change in transformation efficiency 
Varied recovery time from 30 minutes 
to 2 hours 
No change in transformation efficiency 
 
After several attempts at transforming each insert, it was established that 
transformation of the ATCC 700669 (SPN23F) wild type strain is inefficient. This 
was corroborated through communication with Tim Mitchell at the University of 
Birmingham and Nick Croucher at the Sanger Institute, who confirmed that this 
background strain is less efficient in the transformation process than other 
pneumococcal strains. For this reason, it is difficult to establish whether many of 
the inserts which were used in attempted transformations did not produce viable 
mutants because they were disrupting essential genes, or whether it was due to 
the inefficiency of the background strain. 
4.3 Discussion 
Genome-wide association studies (GWAS) are increasingly being applied to 
studies of bacterial phenotypes thanks to advances in sequencing technology 
and a subsequent increase in the number of complete bacterial genomes which 
have become available. Since the first study which applied GWAS to bacterial 
genomes (Sheppard et al., 2013), the approach has been gathering momentum, 
with several more studies being published which use GWAS to identify genetic 
associations with a phenotype (Farhat et al., 2013; Alam et al., 2014; Laabei et 
al., 2014; Chen & Shapiro, 2015; Schubert et al., 2019).  
Due to the high number of loci identified as significantly associated with toxicity 
from all three methods used here, and the lack of a library of mutants such as the 
Nebraska Transposon Mutant Library which was used for functional verification of 
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GWAS in Staphylococcus aureus (Laabei et al., 2014; 2015), it was thought that 
comparison of results between GWAS methods would a be useful process to aid 
prioritisation of genes for further investigation. It was hypothesised that true 
positive loci would consistently appear in the results of different GWAS methods 
despite variations in the approach used, and that it would in turn be easier to both 
identify likely false positive results and prioritise true positive genes for functional 
verification.  
Comparing the results of different methods was also done to try to reduce the 
likelihood of wrongly excluding loci which directly affect the phenotype; i.e. the 
likelihood of obtaining false negative results. Furthermore, following the rapid 
increase in the number of studies using GWAS to investigate bacterial 
phenotypes, and the resulting diversity of methods used, it was of interest to 
compare the results of different methods to determine whether one, or a 
combination of methods, gives a more accurate representation of true genetic 
associations with a phenotype. 
4.3.1 SNP-based GWAS 
The SNP-based GWAS approach used to gather the first set of data (table 4.1) is 
based on identifying statistically significant correlations between the presence of 
individual SNPs at loci throughout the genome and high or low levels of toxicity 
using Pearson’s product-moment correlation. A potential limitation of this 
approach when used in isolation is that individual SNPs that cause a minor 
change to the resulting protein may not correlate very highly with changes in 
toxicity, while the whole gene containing that SNP may be functionally important 
in regulating, producing or releasing pneumolysin; this will appear as a false 
negative in the results of our GWAS analysis. This is the traditional method used 
in GWAS to identify genetic associations with the phenotype, but combining this 
method with the other two approaches used here was thought to minimise the 
potential for exclusion of false positive results. Likewise, since SNPs close 
together in the genome may be inherited together during recombination, while 
only one may in fact be associated with the toxic phenotype, this approach may 
incorrectly identify many loci as being statistically associated with the phenotype 
when they are not, and indeed this approach can be prone to producing high 
numbers of false positive results. Again, combining this method with the other two 




Highly conserved loci in which there are very few SNP changes will also be 
excluded from the analysis in the initial data filtration step, and therefore could be 
wrongly considered a negative result; this is an artefact of the initial data filtration 
step aimed at reducing the number of statistical comparisons that need to be 
made to reduce the computational intensity of the analysis. A good example of 
this is the pneumolysin gene ply, which is a highly conserved locus that has a 
direct effect on toxicity in S. pneumoniae. Due to the lack of SNP changes within 
this gene this region was excluded from the analysis in the initial data filtration 
step based on the minor allele frequency threshold of 5%, and therefore all loci 
within this gene are discounted.  
The SNP-based approach does not correct for population structure, and so 
causative variants that are present only within small subsets of the population 
may confound the results, reducing the statistical power of the analysis and 
increasing the number of false positive results. To some degree, the inverse may 
also be true, whereby causative variants are missed precisely because they are 
only present in a small subset of the population. Controlling for population 
structure in GWAS relies on a trade-off between these two situations; a reduction 
in false positive associations can lead to an increase in false negative 
associations and vice versa. However, all strains used in this collection are taken 
from the same clonal complex, PMEN-1, and S. pneumoniae is a highly 
recombinogenic bacterial species; as such it was thought this would reduce the 
confounding effects of population structure on the SNP-based GWAS, so it was 
not corrected for in this method.  
Application of the Bonferroni correction to this dataset resulted in no loci crossing 
the threshold of statistical significance as the cut off was too stringent. This 
reduced the power of the analysis effectively to zero, however, visualisation of 
the results in a Manhattan plot without application of the Bonferroni correction 
clearly showed peaks of significant loci clustered at several points across the 
genome. It was decided that a permutation test would be a better alternative to 
correct for multiple tests in this case, in which the dataset is scrambled up to a 
thousand times to determine the likelihood of a locus being associated with the 
phenotype by chance alone. P-values are then re-calculated to give empirically 
derived results in which significance is determined not to be an artefact of 
chance. Figure 4.3 shown in results section 4.2.2.1 shows the result of the SNP-
based analysis after permutation, with a significance threshold set at p=0.05, in 
which peaks of significant loci can be clearly seen. While permutation is a useful 
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method of reducing the false positive error rate in an analysis with such a high 
number of statistical comparisons, functional verification is still essential to 
eliminate false positive results.  
4.3.2 SEER 
SEER (sequence element enrichment analysis), the method developed by John 
Lees, uses logistic and linear regression to look for associations between k-mers 
and phenotypic variation; k-mers are sections of DNA of length ‘k’ (usually 7-35 
nucleotides) which can encompass numerous types of genetic variation across a 
collection of genomes including insertion and deletion of genetic elements, 
changes in promoter architecture, and recombinations, to name a few examples 
(Lees et al., 2016). This increases the statistical power of the analysis and 
produces more biologically relevant results, because SNPs, although a common 
effector of phenotypic change, are not the only genetic elements responsible for 
a change in bacterial phenotypes. Use of k-mers therefore widens the scope of 
the analysis and reduces the extent to which genetic loci are discarded as non-
significant associations when they are in fact causative of a change in the 
phenotype. 
A second major difference between the SNP-based approach and SEER is that 
SEER corrects for clonal population structure within the collection of 
pneumococcal genomes using metric multi-dimensional scaling (mMDS). Lees et 
al. (2016) describe the metric multi-dimensional scaling method as being 
analogous to use of principal components of the SNP matrix in human genetics to 
control for divergent ancestry. mMDS was preferentially used here because it 
does not rely on core gene alignment or SNP calling, but can be directly applied 
to the k-mer counting result to accurately estimate bacterial population structure. 
The benefit of controlling for population stratification in this way is that it reduces 
the rate of false positive associations by excluding from the results those variants 
that are causative of a change in the phenotype in only a small subset of the 
population, however, the threshold at which these associations are excluded from 
the results could cause an increase in false negative associations if set too high.  
Unlike the SNP-based approach, SEER utilises the Bonferroni adjustment to 
correct for multiple testing but does not correct for every test conducted. A 
conservative adjustment is made to the threshold p<0.05, which is corrected to 1 
x 10-8 to prevent a high number of false positive associations while not over-
correcting based solely on the number of tests conducted. Application of the 
140 
 
Bonferroni correction to the SNP-based results demonstrated that the cut-off for 
significance is too stringent using the traditional Bonferroni calculation, as it made 
every result from the analysis non-significant, while here a conservative 
adjustment is made so that power is not lost from the analysis but the number of 
false positive results is reduced. 
Table 4.2 shows that SEER produced a smaller list of genes which were 
statistically associated with toxicity, four of which were also identified by the SNP-
based approach. Mutant construction was successful for one of these - the priA 
gene - which was then verified to be false positive. Mutant construction for the 
remaining three genes was unsuccessful, so functional verification of these 
results could not be completed. However, SEER is the only method from which a 
true positive association with toxicity has been identified at the time of writing. 
The SPN23F12470 gene identified by SEER showed a significant reduction in 
toxicity in comparison to the isogenic wild type strain when tested for haemolytic 
activity (figure 4.6), and this gene was not identified using either of the other 
methods. In depth characterisation of the relation of this gene to toxicity is 
presented in chapter 5. 
4.3.3 Bugwas 
The third method used to contribute to the dataset was Bugwas, which uses 
linear mixed models (LMMs) to look for associations between genotype and 
phenotype. Bugwas makes use of both SNPs and k-mers as the units of genetic 
variation by conducting separate analyses on both, the results of which are split 
into two groups for comparison (tables 4.3 and 4.4). Bugwas further divides the 
SNP results into bi-allelic and tri-/tetra-allelic loci and the k-mer results into fixed-
length and variable-length k-mers. The original SNP-based approach does not 
distinguish between bi-, tri- or tetra-allelic loci, and SEER uses only variable 
length k-mers. Similarly to SEER, Bugwas controls for clonal population structure 
within the collection of genomes, and applies the Bonferroni adjustment to correct 
for multiple testing. 
The use of SNPs, fixed length k-mers and variable length k-mers allows an 
interesting comparison between three different sets of results from the same 
analysis. The number of SNPs statistically associated with the toxic phenotype is 
substantially larger than the number of k-mers statistically associated with the 
phenotype, even with the results of the fixed and variable length k-mers 
combined. There is crossover between the two datasets at the pbpX and mraY 
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genes, suggesting a strong association with the phenotype which is supported by 
the simultaneous identification of pbpX and mraY in the SNP-based method. 
Unfortunately, mutant construction was unsuccessful for both genes, so 
functional verification of these results has not been possible. 
As with SEER, Bugwas accounts for population structure in the GWAS analysis, 
but specifically allows for identification of groups of lineage-specific variants that 
collectively show a strong association with the phenotype. Bugwas uses a slightly 
different approach to SEER to do this, using principal components to identify 
lineage-level differences in association with the phenotype. However, it does not 
eliminate the need for functional verification, as controlling for population 
structure in this way requires a trade-off between detecting causative groups of 
variants within different lineages of the population that show a collective 
association with the phenotype and causative variants present in only a small 
subset of the population which may only serve to confound the results. 
4.3.4 treeWAS 
A fourth method was attempted called treeWAS, originally developed by Caitlin 
Collins and Xavier Didelot at Imperial College London (Collins & Didelot, 2018). 
The aim of this approach is to account for population stratification, much like 
Bugwas and SEER, but by using the genomic dataset to build a phylogenetic tree 
from which population structure is inferred prior to the GWAS analysis. However, 
this method produced no significant hits because use of the traditional, highly 
stringent Bonferroni correction is built into the program, and it cannot be excluded 
from the analysis. As with the SNP-based GWAS, application of the Bonferroni 
correction meant the threshold for significance was too high for any of the results 
to be significant. For this reason, the treeWAS results have not been included 
here. 
4.3.5 Collective GWAS results 
It is particularly interesting that no one gene has been identified as statistically 
significantly associated with toxicity in all three of the GWAS methods used. 
Additionally, the pneumolysin gene has not been identified as an effector of 
toxicity using this method. This is because the gene is highly conserved within 
the PMEN-1 clonal complex, and as such the number of SNPs present within this 
gene were too low to cross the minor allele frequency threshold of 3%, which 
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requires there to be a minimum of 3% SNP changes present at each locus in the 
clinical collection of strains in order to be included in the subsequent GWAS. 
While there is some crossover of genes that are identified in two of the three 
methods, there are relatively few genes which are identified by more than one 
method. In total, 8 genes were identified by more than one method out of a 
combined total of 181 genes and intergenic regions across the three 
approaches.In some cases, several genes in close proximity to each other have 
been individually identified by one GWAS method, while other genes within the 
same region have been identified in another method. For example, genes within 
the region from agaS to SPN23F00850 were individually identified by both the 
SNP-based GWAS method and Bugwas. Genes from agaD to clpL are likewise 
identified by these two methods. A large cluster of genes on the ICESp23FST81 
mobile genetic element are identified by both the SNP-based method and SEER, 
and a small number of genes close to the priA locus are identified by all three 
methods.  
This implies that all three methods combined may be useful for identification of 
specific clusters of loci on the chromosome where the search for toxicity-affecting 
loci should be focussed, however, no one method or combination of methods 
seems at this point to be preferable for identification of individual true positive loci 
which directly affect the phenotype. Data from signature-tagged mutagenesis 
screens could also be added to these results to better identify true positive 
associations with toxicity (eg. Polissi et al., 1998; Lau et al., 2001; Hava & 
Camilli, 2002; Obert et al., 2006). Furthermore, without successfully constructed 
mutants in and around these clusters of loci, their potential role in toxicity cannot 
be determined.  
4.3.6 Functional verification 
Tentatively, four genes have been identified as causing a significant loss in 
toxicity in the unencapsulated background strain TIGR4 2394 in comparison to 
the isogenic wild type strain. These genes include a putative extracellular 
oligopeptide binding domain (aliA), a cell wall surface anchored protein 
(SPN23F03400), a putative ROK family protein (SPN23F12160) and a putative 
sialidase otherwise known as neuraminidase (SPN23F12180).  
AliA is an oligopeptide-binding lipoprotein (Alloing et al., 1994) with high 
homology to the oligopeptide permease ABC transporter AmiA (Claverys et al., 
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2000). The aliA gene neighbours the capsular polysaccharide biosynthetic 
pathway in S. pneumoniae type 19F, although it is not involved in this pathway 
(Morona et al., 1997). The SPN23F03400 locus is annotated as a cell wall 
surface anchored protein, and immediately neighbours the aliA gene in strain 
ATCC 700669 (SPN23F). However, the specific role of this gene appears to be 
uncharacterised, with only one reference to it in the literature which sequenced 
genes around the cps (capsular biosynthetic pathway) locus in S. pneumoniae to 
study the evolution of multi-drug resistance in serotype 6D (Ko et al., 2012). 
ROK family proteins (Repressor, ORF, Kinase) include transcriptional repressors, 
sugar kinases and uncharacterised open reading frames (Titgemeyer et al., 
1994). Neuraminidase, encoded by the gene SPN23F12180 in strain ATCC 
700669 (SPN23F), is a known virulence factor of S. pneumoniae which cleaves 
terminal sugars from glycoconjugates (Kadioglu et al., 2008), and has been 
shown to be involved in invasion and inflammation of host tissues (Berry et al., 
1989; Xu et al., 2011).  
However, firm conclusions cannot be drawn regarding the role of these four 
genes in toxicity for the following reasons: firstly, the background strain used is 
an unencapsulated, low-toxic isolate, and as such variations in toxicity are more 
difficult to distinguish using the haemolytic activity assay; secondly, the variation 
in the toxicity data for these four genes is very high even after 10 repeats, so 
statistical significance may not reflect a true biological difference in toxicity in this 
case; and finally, in some cases transposon mutagenesis at different positions 
within these four genes does not result in a reduction in toxicity based on the 
results of the haemolytic activity assay. Whole gene deletion of these genes in 
the high-toxic reference strain ATCC 700669 (SPN23F) would provide clearer 
evidence as to whether these genes are causative of a change in the toxic 
phenotype. Where present, genes would also need to be deleted in other 
pneumococcal strains to determine whether their effect on toxicity, if any, is 
universal between strains. 
Through the process of whole gene deletion in strain ATCC 700669 (SPN23F) 
eight genes have been identified as false positive associations, including the priA 
and trcF genes which were each highlighted by two GWAS methods. It is 
interesting that deletion of the SPN23F15290 gene, which is annotated as an 
autolysin, does not result in a significant loss of toxicity. Autolysis is thought to be 
key in releasing the pneumolysin toxin into the extracellular environment, as the 
144 
 
toxin does not contain an N-terminal secretory signal sequence, and therefore 
cannot be actively exported out of the cell. A possible explanation for the 
sustained level of toxicity in this mutant could be that since it is not interfering 
with pneumolysin production, or it’s exportation to the cell wall where it is known 
to be located prior to autolysis of the cell, the toxin is still able to exert its effect on 
red blood cells during the hour-long incubation period through physical contact 
between bacterial cells and erythrocytes.  
One gene – SPN23F12470 – has been identified as a true positive association 
with the toxic phenotype, and this was identified using SEER. This gene encodes 
a UvrD-like protein containing a helicase domain and two tandem repeat 
nuclease domains at the N-terminus. Detailed characterisation of how this gene 
affects toxicity in S. pneumoniae is presented in chapter 5.  
4.3.7 Overview 
Use of the GWAS method is the first step towards understanding the genetic 
basis of phenotypic variation. However, it is only useful for initial identification of 
causative genetic loci and does not reveal information about individual gene 
function in relation to a phenotype. If we are to work towards an improved ability 
to understand and interpret genome sequencing data in the context of disease, 
we must first understand the role of individual genes in pathogenesis.  
GWAS is a top-down approach to achieving this goal, and by no means gives a 
complete picture of the genetic contributors to a phenotype as the method is 
prone to producing high numbers of both false positive and false negative results. 
Nonetheless, it is a useful starting point, and while the number of true positive 
associations identified thus far is extremely low, it has led to the identification of 
an interesting gene which would otherwise have remained unknown in its relation 
to toxicity in S. pneumoniae. Short of making a knockout mutant in every single 
gene within the pneumococcal genome and assaying each of these for their 
effect on toxicity, the role of the SPN23F12470 gene may otherwise have gone 
unnoticed. While it has its limitations, GWAS has therefore proven a useful tool in 
identifying a novel genetic contributor to toxicity in the pneumococcus.  
4.4 Conclusions 
GWAS has been used as a starting point in this project to identify genetic loci 
which have the highest probability of being associated with the toxic phenotype in 
S. pneumoniae. Comparison of the results from three different methods was 
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thought to be useful in better identifying true positive results without having to 
construct knockout mutants in every gene within the genome. However, the 
results presented here show that crossover of findings between methods was 
relatively low and due to the difficulties encountered in constructing mutants in 
the ATCC 700669 (SPN23F) background, functional verification of the results has 
been restricted to a relatively small number of genes.  
Further, in-depth investigation of each of these genes is required to eliminate loci 
that have been falsely associated with this phenotype, and to identify loci which 
are directly associated with toxicity. From this it will be possible to build a more 
complete picture of the complex genetic network which is involved in regulation, 
production and release of the pneumolysin toxin.  
The next steps for this project would be to continue construction of whole gene 
deletion mutants in the reference strain ATCC 700669 (SPN23F). Construction of 
a mutant in every associated gene from the GWAS analyses would allow 
verification of direct and indirect associations to be completed, from which firm 
conclusions could then be drawn regarding which GWAS method, or combination 
of methods, produced the highest number of true positive associations with 
toxicity. More importantly, completion of the mutant construction process would 
allow identification of true positive, novel associations with the toxic phenotype.  
Short term, work such as this could lead to identification of novel drug targets for 
treatment of pneumococcal disease, but ultimately, research in the wider field is 
looking to better interpret the vast amount of genome sequencing information 
which is being gathered from an increasing number of bacterial species and 
strains. This information could prove useful in the long term if genome 
sequencing is to be used as a diagnostic tool for patients suffering from 
pneumococcal disease, to identify the specific strain causing infection and its 
corresponding pathogenicity and antibiotic resistance profile.  
To achieve this, a thorough understanding of the genetic contributors to virulent 
phenotypes and antibiotic resistance profiles will be required, along with an ability 
to correctly interpret this information such that patients receive the correct 
treatment as efficiently as possible. There is a long way to go in improving our 
understanding of the genetic basis for bacterial virulence before such a system 
can be developed, and improvements in technology, the speed of sequencing, 
and the cost of such technology will also be required if this system is to become 
widely used in healthcare in the future.  
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Central to all of this will be the fundamental understanding of the genetic basis for 
bacterial virulence. The work presented here demonstrates how a statistical 
approach can be successfully applied to identify a novel genetic contributor to 
virulence in S. pneumoniae and has led to the identification of the novel effector 























5. Characterisation of a toxicity-
deficient ∆SPN23F12470 mutant 
in Streptococcus pneumoniae 
 
5.1 Introduction 
Streptococcus pneumoniae produces only one toxin, pneumolysin (Ply), which is 
primarily responsible for the lysis of host cells during infection. Whilst the ply 
gene is the major contributor to toxicity in this species, it is demonstrated here 
that other genetic factors make a significant contribution to production of this 
toxin. In an era where whole genome sequences are becoming readily available 
to researchers, work such as this contributes to a better understanding of 
individual gene function in relation to a specific phenotype. Genome sequencing 
information by itself is useful in studying the evolution and epidemiology of a 
bacterial species, but if we are to start interpreting genome sequencing 
information or developing alternative treatments for disease, it is important to fully 
understand as much about the genetic contributors to pathogenesis as possible.  
The work presented here follows on from the GWAS analyses discussed 
previously in chapter 4, which identified 181 genes and intergenic regions that 
are statistically significantly associated with the toxic phenotype in S. 
pneumoniae clonal complex PMEN-1. Through the process of functional 
verification of these GWAS results a whole gene deletion mutant was constructed 
in the gene SPN23F12470 in the background strain ATCC 700669 (SPN23F) 
which is shown here to have a deficiency in toxicity in comparison to the isogenic 
wild type. 
SPN23F12470 is annotated as a putative DNA helicase II, homologous to the 
uvrD gene in other bacterial species such as E. coli. To determine how loss of 
function of this gene results in a loss of toxicity, work is presented here to 
elucidate the contribution of this gene and resulting protein product to 






5.2.1 Identification of the SPN23F12470 gene as a novel 
toxicity-associated locus in S. pneumoniae 
Through the GWAS method SEER, described in the previous chapter, SNPs in 
the SPN23F12470 gene were statistically associated with toxicity in S. 
pneumoniae. A comparison of toxicity data for the original clinical strains with and 
without a SNP in the SPN23F12470 gene shows that strains with the polymorphic 
SPN23F12470 gene have on average a slightly higher toxicity than those with the 
reference SPN23F12470 gene, as shown in figure 5.1. A T-test between the two 
groups shows that this difference is significant (p=0.0018).  
Figure 5.1. Comparison of toxicity of clinical isolates with and without SNPs in the 
SPN23F12470 gene. A significant difference is observed (p=0.0018) between clinical 
isolates with (n=6) and without (n=149) a SNP change within the SPN23F12470 gene, 
with higher toxicity observed on average in strains with a polymorphic SPN23F12470 
gene. 
 
5.2.1.1 SPN23F12470 encodes a UvrD-like helicase with two tandem 
repeat nuclease domains 
The SPN23F12470 gene is annotated as a ‘putative DNA helicase II’ in strain 
ATCC 700669 (SPN23F). Upon discussion with Mark Dillingham (Dept. of 
Biochemistry, University of Bristol), it was ascertained that the gene encodes a 
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protein with three domains; a UvrD-like domain encoding a helicase motor for 
unwinding of DNA, and two tandem repeat domains encoding nucleases similar 
to those found in restriction enzymes and Cas4 proteins (see figure 5.2 below). 
Both tandem repeat domains contain an iron sulfur cluster region and are thought 
to be active nucleases, although this has not been confirmed. It was noted that 
this appears to be a highly unusual protein, when a BLAST is conducted to look 
for homologous genes in other species results show 98%-100% identical 
homologues in only two other strains of Streptococcus pneumoniae, two strains 
of Streptococcus mitis and two other strains of Streptococcus annotated as 
Streptococcus sp. JS71 and Streptococcus sp. A12. No other homology is 
identified. 
 
Figure 5.2. BLAST results for SPN23F12470. Results of protein BLAST for the 
SPN23F12470 gene in ATCC 700669 (SPN23F), showing the UvrD helicase domain and 
the two downstream tandem repeat nuclease domains. 
 
5.2.1.2 Identification of SNP changes in clinical strains with a 
polymorphic SPN23F12470 gene 
Table 5.1 below lists each of the SNP changes identified in the SPN23F12470 
gene in the collection of clinical isolates used for GWAS. The position of each 
SNP in the genome is detailed, along with the SNP change, the resulting amino 
acid change, and the strains in which these mutations are present. 
Table 5.1. SNP changes in the SPN23F12470 gene of clinical isolates. Details of each 
SNP change in the SPN23F12470 gene in the collection of clinical isolates used for 
GWAS, including the position of each SNP in the genome, the specific nucleotide 




5.2.1.3 SPN23F12470 resides on an integrative-conjugative element 
This protein resides on the integrative-conjugative element ICESp23FST81, 
which has clinical significance because it confers resistance to the antibiotics 
chloramphenicol and tetracycline. It is a composite element with homology to the 
transposons Tn5252 and Tn916 and it can be excised from the chromosome to 
form a circularised plasmid of around 81kb in size (Croucher et al., 2009), as 
depicted in figure 5.3 below.  
To characterise the specific function of this UvrD-like protein in relation to toxicity 
in Streptococcus pneumoniae, a whole-gene deletion mutant was constructed as 
described in section 5.2.2 below. The toxicity phenotype of this mutant is 
characterised in detail, and the effect of this mutation on expression of other 
virulence-related genes in investigated. Further work in section 5.2.9 also looks at 
the effect of the SPN23F12470 gene deletion on mobilisation of the 
























































































































































































5.2.2 Mutant construction 
A ΔSPN23F12470 whole gene deletion mutant was constructed using the 
method described in chapter 2, section 2.3.4. Figures 5.4 & 5.5 below show the 
results of each PCR reaction to amplify the three fragments of the knockout 
insert, and the subsequent stitch PCR reaction to create the final ~2.75kb insert 
containing the resistance cassette and homologous regions either side.  
Figure 5.4. SPN23F12470 insert fragment amplification. Amplification of fragments 1-3 




















Figure 5.5. Stitch PCR for SPN23F12470 full insert. Fragments 1-3 were combined into 
one PCR reaction, in which the overlapping ends of each fragment were stitched together 
using the forward primer for fragment 1 and the reverse primer for fragment 3, creating a 
single linear insert around 2.75kb in length. 
 
The ~2.75kb insert was transformed into S. pneumoniae strain ATCC 700669 
(SPN23F) as described in chapter 2, section 2.3.4.2. Construction of the 
ΔSPN23F12470 mutant was verified through PCR, as shown in figures 5.6-5.8, 
using primers directed to: 
1) The wild type ply gene to confirm the successful transformant was S. 
pneumoniae and not a contaminant 
2) The wild type SPN23F12470 gene to verify that it was present in the 
isogenic wild type strain ATCC 700669 (SPN23F) and absent in the 
ΔSPN23F12470 mutant 
3) A region starting 1kb upstream of the transformed linear insert to within 
the ermAM cassette to confirm both that the insert had inserted into the 
genome and that it had inserted into the correct position 
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Figure 5.6. Verification that transformants are not a contaminating organism. PCR 
was conducted using primers to the wild type ply gene, to confirm that transformants 
were not contaminating organisms. Controls were wild type SPN23F DNA, Δply DNA and 
a water only negative control. ΔSPN23F12470 mutant colony 1 shows a very faint band 
here, which may not be clearly visible in print.  
 
Figure 5.7. Verification that mutant colonies do not contain the wild type 
SPN23F12470 gene. PCR was conducted using primers to the wild type SPN23F12470 
gene. Controls used were wild type SPN23F DNA, the SPN23F12470 insert used for the 
transformation, and a water only negative control. A band is only visible for the wild type 




Figure 5.8. Verification that mutant colonies contain the antibiotic resistance 
cassette in place of the wild type SPN23F12470 gene. PCR was conducted using 
primers to amplify the region starting 1kb upstream of the 2.75kb transformed insert to 
within the middle of the ermAM cassette. This verifies both that the ermAM cassette has 
been taken up, and that it has recombined in the correct position within the genome to 
delete the wild type gene. ΔSPN23F12470 mutant colony 2 shows a faint band here at 
the correct size, which may not be clearly visible in print.  
 
All subsequent assays for this mutant were conducted using the third colony 
because this showed clear bands for the first and third PCR checks (figures 5.6 & 
5.8). Successful mutant construction was further verified for this colony through 
sequencing of the PCR product from figure 5.8, which confirmed insertion of the 
linear construct into the genome at the correct location. The primers used for 
sequencing were as follows: 
F1: TGCCCACTATTTTTATCTAGTTGCTTACC 
F2: TATCTGATCTAAGACACTTAGCAGAGG 
WT F3: GGATAGATTAGAAAAATTAATTGGAG 
WT RV: AAATACTTTGATCATCATCCCCTACAAC 
ΔSPN23F12470 F3: GGATTCTACAAGCGTACCTTGGATATTC 




5.2.3 The ΔSPN23F12470 mutant shows a significant reduction 
in toxicity compared to the isogenic wild type 
Pneumolysin is an intracellular toxin which lacks an N-terminal secretory signal 
sequence and is specifically localised to the wall of the pneumococcal cell. For 
release of the toxin into the extracellular environment, it is thought that 
pneumolysin is mostly dependent on the action of the autolytic enzyme LytA, 
which stimulates lysis of a subset of cells in a growing pneumococcal population 
to release intracellular pneumolysin.  
The results of a toxicity assay for this mutant using whole cell culture have been 
presented in chapter 4, figure 4.16, but are included in figure 5.9 below for 
comparison. Due to the unusual nature of release of pneumolysin, a further two 
toxicity assays were conducted to investigate its toxic phenotype in detail. The 
first of these was conducted in same manner as the assay used in chapter 4, 
section 4.2.3, but used only the supernatant from a stationary phase culture. This 
was to determine specifically the level of pneumolysin which had been released 
into the extracellular environment. Results from this and the original toxicity assay 
are presented below in figure 5.9 and demonstrate a significant reduction in 
toxicity of ΔSPN23F12470 in comparison to the isogenic wild type using both 














Figure 5.9. Haemolytic activity of ΔSPN23F12470 mutant whole cell culture and 
supernatant. A significant reduction in toxicity is observed between whole cell culture of 
the ΔSPN23F12470 mutant compared to the isogenic wild type strain (p=0.001) and 
between the supernatant only of the mutant compared to the wild type (p=0.004).  
 
The third toxicity assay looked to investigate the effect of the ΔSPN23F12470 
mutation on localisation of pneumolysin to the cell wall. This assay involved 
harvesting cells from a stationary phase culture for centrifugation with 25% sheep 
red blood cells and is referred to as a contact-dependent haemolytic activity 
assay. Through centrifugation of pneumococcal cells with red blood cells, the two 
are forced into contact with each other before being incubated for a longer period 
of three hours. Samples were then centrifuged again, and absorbance readings 
taken for the resulting supernatant, as with the previous assays. As demonstrated 
by higher absorbance readings for the wild type strain ATCC 700669 (SPN23F) 
in figure 5.10 below, toxicity of the wild type strain appears much greater when 
the bacterial cells are forced into contact with red blood cells and incubated for a 
longer period with a higher concentration of red blood cells. Because of these 
differences in experimental procedure, results from this experiment are presented 
separately to those from the previous two toxicity assays.  
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Figure 5.10. Contact-dependent haemolysis of ΔSPN23F12470 mutant. A significant 
reduction in contact-dependent toxicity is observed in the ΔSPN23F12470 mutant in 
comparison to the isogenic wild type strain (p<0.0001), which is comparable to the loss of 
toxicity observed in the Δply mutant. 
 
This assay can be used as an initial investigation into the localisation of 
pneumolysin to the cell wall, with reduced toxicity here indicating less 
pneumolysin is in contact with red blood cells, and by proxy that there is less 
present in the cell wall of the ΔSPN23F12470 mutant.  
5.2.3.2 Construction of a ΔSPN23F12470 mutant containing a 
spectinomycin resistance cassette for complementation 
To complement the ΔSPN23F12470 mutant, the plasmid pMSP7517 was 
provided to us by Angela Nobbs at the University of Bristol. This plasmid was 
chosen on the basis that it contains a nisin-inducible promoter which provides 
control over expression of the complementation gene. As pMSP7517 is selected 
for using erythromycin, the original mutant was re-constructed using the 
spectinomycin resistance cassette aad9. It was later established that plasmid 
pVA838 could have been used for complementation, however, this plasmid does 
not have an inducible promoter region for control of gene expression. Toxicity 
data is shown in figure 5.11 for this re-constructed mutant to demonstrate a 





Figure 5.11. Toxicity of ΔSPN23F12470(aad9) whole cell culture. The haemolytic 
activity assay was repeated with whole cell culture for the reconstructed ΔSPN23F12470 
mutant containing the spectinomycin resistance cassette aad9 instead of ermAM. Toxicity 
is significantly reduced compared to the isogenic wild type (p=0.00017). 
 
Unfortunately, attempts to ligate the wild type SPN23F12470 gene into 
pMSP7517 and transform it into the ΔSPN23F12470(aad9) mutant have thus far 
been unsuccessful, so it has not yet been possible to see if the toxicity phenotype 
of this mutant can be rescued with the wild type SPN23F12470 gene.  
 
5.2.4 Loss of the SPN23F12470 gene affects pneumolysin 
production  
To characterise the effect of the ΔSPN23F12470 mutation on pneumolysin 
production and release, a Western blot was conducted using protein extracted 
from both cell pellet and supernatant samples. Pneumolysin does not have an N-
terminal secretory signal sequence, and as such is not actively secreted out of 
the cell. Release of this toxin is thought to be partly reliant on the autolytic activity 
of S. pneumoniae from mid-exponential to stationary phase growth, in which a 
proportion of the population will autolyse. This is an interesting and unusual 
phenomenon which, although not fully understood, has been heavily linked to 
virulence in the literature (Berry et al., 1989; Canvin et al., 1995; Martner et al., 
2009, Skovbjerg et al., 2017). For this reason, proteins were extracted from both 
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the cell pellet and supernatant of ΔSPN23F12470 and its isogenic wild type, to 
determine if pneumolysin production inside the cell and/or its release into the 
extracellular environment were affected by this mutation. 
Results showed a 21.56-fold reduction in the amount of pneumolysin present in 
the ΔSPN23F12470 cell pellet compared to the wild type, and a 26.63-fold 
reduction in pneumolysin in the supernatant of ΔSPN23F12470 compared to the 
wild type, as quantified using ImageJ and averaged from three biological repeats. 
Figure 5.12 below illustrates this reduction in pneumolysin quantity; here 
pneumolysin appears to be completely absent from the ΔSPN23F12470 mutant, 








Figure 5.12. Western blots using anti-pneumolysin antibody. A substantial reduction 
is observed in the amount of pneumolysin (53kDa size) present in the cell pellet and 
supernatant protein extractions of the ATCC 700669 (SPN23F) wild type (WT), 
ΔSPN23F12470 and Δply, which was included for comparison. 
 
These results imply a significant loss in production of pneumolysin in 
ΔSPN23F12470 which appears comparable to that of the Δply mutant. It is noted 
however that cell pellets of mutants which are deficient in autolytic activity are 
resistant to the detergent lysis solution used here to obtain cell pellet extractions 
(Balachandran et al., 2001). As such, although a significant difference is 
observed here in the amount of pneumolysin between wild type and mutant, it is 
possible that a deficiency in autolysis could be affecting this result; if pneumolysin 
is present in the ΔSPN23F12470 cell pellet and the mutant is autolysis-deficient, 
cells will not have lysed and pneumolysin will not be evident in the cell pellet 
extraction from ΔSPN23F12470 in this blot. Deoxycholate could have been used 
here to lyse bacterial pellets, however, to specifically show whether or not 




5.2.5 The ΔSPN23F12470 mutant is not deficient in autolytic 
activity 
Autolysis of a proportion of the pneumococcal population is thought to be mostly 
responsible for the release of pneumolysin into the extracellular environment, 
since the pneumolysin protein does not contain an N-terminal secretory signal 
sequence for exportation out of the cell. For detailed description of the 
mechanism of autolysis and its proposed association with toxicity, see chapter 1, 
section 1.4.2.3. Autolytic activity of ΔSPN23F12470 was therefore tested (figure 
5.13) to demonstrate both that deficiency in autolysis is not affecting the results of 
the Western blot above, and that it is not the reason for the observed loss of 
toxicity in the haemolytic activity assays. 
For this assay, a ΔSPN23F15290 mutant was used as a control, as this gene is 
annotated as an autolysin in strain ATCC 700669 (SPN23F) and a mutant in this 
gene had been constructed following its significant association with toxicity from 
the SEER results (chapter 4, section 4.2.2.2). This gene does not encode the 
main autolysin LytA, which is encoded by the lytA gene, however, deletion of 
SPN23F15290 yields an autolysis-deficient phenotype and therefore this mutant 
was a suitable control to use.  
The effects of autolysis can be measured in vitro by growing the bacteria to 
stationary phase, harvesting and washing the cells and resuspending them in 
PBS to equivalent optical densities. Triton X-100 is added to a final concentration 
of 0.1%, after which cells are incubated at 37°C and OD(600) readings taken at 15 
minute intervals to quantify detergent enhanced autolysis. Figure 5.13 below 
shows the results expressed as percentage cells remaining alive, using the 
average of three biological repeats for each strain and using data from time point 






Figure 5.13. The ΔSPN23F12470 mutant is not deficient in autolytic activity. 
Autolytic activity was measured by assaying the lysis of a stationary phase culture 
following addition of 0.1% Triton X-100. Data are expressed as percentage cells 
remaining intact and the difference in % live cells between the wild type and the 
ΔSPN23F12470 mutant is not significant. 
 
Using this assay, a clear difference was observed in cell density between the 
autolysin-deficient ΔSPN23F15290 mutant compared to the wild type and 
ΔSPN23F12470 mutant strains, whilst there was no significant difference 
between the wild type and ΔSPN23F12470. This confirms that autolysis is not 
affected in the ΔSPN23F12470 mutant, as cells in this culture lysed comparably 
to the isogenic wild type strain, and critically it demonstrates that the loss of 
toxicity in ΔSPN23F12470 is not due to a deficiency in autolytic activity. 
 
5.2.6 ΔSPN23F12470 exhibits reduced transcription of the ply 
gene 
As the results of the toxicity assays and Western blotting have demonstrated a 
reduction in pneumolysin production in ΔSPN23F12470, and as this has been 
shown not to be due to a deficiency in autolytic activity, qRT-PCR was used to 
investigate whether this effect on toxicity was at the transcriptional level. qRT-
PCR was conducted to the ply and lytA genes, with the major autolysin gene lytA 
included here for verification that autolysis is not affected in the ΔSPN23F12470 
mutant. The competence genes comA and comE (annotated as gene 
SPN23F22680) were also included to investigate whether there is a change in 
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the competence phenotype of the mutant in comparison to the wild type, as 
competence is thought to be linked to virulence in the pneumococcus. It was 
hypothesised that with such a strong impact on toxicity in the ΔSPN23F12470 
mutant, competence could also be affected. 
The comA gene encodes a subunit of the ComAB transporter complex which 
exports the competence-stimulating peptide (CSP) out of the pneumococcal cell 
and comE is a DNA-binding protein that regulates expression of genes in the 
competence operon. For further description of the competence operon in S. 
pneumoniae and its relation to pneumococcal virulence, see chapter 1, section 
1.4.2.5. 
RNA was extracted from two cultures each for the ΔSPN23F12470 mutant and 
the isogenic wild type strain and converted to cDNA through reverse 
transcription. cDNA quantity was standardised prior to addition to the qPCR 
reaction mix, and three technical repeats were conducted for each cDNA sample. 
For further details of the method, see chapter 2, section 2.3.5.6. Results are 
shown in figure 5.14 below as fold-change in transcript expression of genes in the 
ΔSPN23F12470 mutant compared to the isogenic wild type strain, as calculated 
by comparison to the housekeeping gene recA, using the 2-ΔΔCT method. Error 
bars represent standard error of the mean. 
 
Figure 5.14. qRT-PCR results. Fold-change in transcript expression of key virulence and 
competence-related genes in the ΔSPN23F12470 mutant compared to the isogenic wild 
type, as calculated by comparison to the housekeeping gene recA, using the 2-ΔΔCT 




These results support previous findings from the toxicity assay and Western 
blots, showing that transcript expression for the ply gene is down-regulated 6.8-
fold in the ΔSPN23F12470 mutant. It also supports the finding of the autolysis 
assay, showing that there is no reduction in autolytic activity in the 
ΔSPN23F12470 mutant; in fact a 3-fold increase is observed here in transcript 
expression for lytA, which could explain the slightly lower percentage of cells 
remaining alive in the ΔSPN23F12470 mutant compared to the wild type at the 
1hr 15mins time point in figure 5.13 above. A 4.8-fold increase is also observed 
for the comA gene, suggesting that transcript expression of competence 
machinery is up-regulated in ΔSPN23F12470, however, transcript expression of 
comE is not up-regulated to the same extent, with only a 1.8-fold increase 
observed here which implies very little change to transcription of this gene.  
 
5.2.7 The UvrD-like protein encoded by SPN23F12470 binds to 
regions either side of the ply gene containing BOX repeats 
Having identified that loss of the SPN23F12470 gene affects transcription of the 
ply, lytA and comA genes, it was observed that BOX-type repeat regions were 
present in the neighbouring intergenic regions beside each of these genes. BOX 
repeat regions are a family of short repetitive fragments of DNA between 45-59 
base pairs in length that are present at over 100 different positions within the 
pneumococcal genome and have been shown to affect transcription of 
neighbouring genes (Knutsen et al., 2006). They usually consist of a combination 
of boxA (59bp), B (45bp) and C (50bp) repeat sequences, which can overlap, be 
in different orientations and in different combinations throughout the genome. 
Generally, boxA and boxC flank the boxB region, which can be repeated more 
than once and be in different orientations to the flanking repeat regions. Regions 
containing boxA and boxC elements are also known to form stable stem-loop 
structures, which could be involved in modulating the expression of neighbouring 
genes (Knutsen et al., 2006). 
In the case of the ply gene, BOX repeats are found immediately downstream in 
the neighbouring intergenic region. They are also found 5-7 genes upstream, 
however these upstream repeat regions are only one gene distant from the start 
of the ply operon, as annotated in strain D39V in the online programme 
PneumoBrowse (Slager et al., 2018). The downstream BOX repeat regions which 
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immediately neighbour ply are found in the order AB1CB2, with all repeat 
sequences in the same orientation as the two neighbouring genes, encoded on 
the lagging strand (see figure 5.15). 
 
Figure 5.15. BOX repeat regions downstream of the ply gene in strain ATCC 700669 
(SPN23F). A screenshot of the ply gene from the FM211187.1 annotation of the genome 
on the National Centre for Biotechnology Information website and its downstream 
intergenic region in which four BOX repeat regions can be found in the combination 
AB1CB2. All are encoded on the lagging strand like the two neighbouring genes. 
 
Based on the presence of a helicase region and two nuclease domains within the 
UvrD-like protein encoded by SPN23F12470, and based on the down-regulation 
of ply in the mutant as shown by qRT-PCR, it was hypothesised that the UvrD-
like protein could be affecting transcription of the ply gene. Furthermore, it is 
known that Cas proteins, to which the nuclease domains of this UvrD-like protein 
have homology, bind to repeat sequences which guide the protein to a target 
region of DNA; therefore it was thought that interactions between the 
SPN23F12470 protein and the BOX repeat regions could be mediating the effect 
on transcription of ply. To investigate this, an electrophoretic mobility shift assay 
(EMSA) was conducted in which specific binding of a protein to small regions of 
DNA can be visualised. For this assay, wild type UvrD-like protein was purified by 
Oliver Wilkinson in the Dillingham lab (see chapter 2, section 2.3.5.8 for method 
details). 
Firstly, the intergenic region downstream of ply containing the BOX repeats was 
amplified through PCR, yielding a product size of 882bp, and a region of 
corresponding size was amplified from the ply gene itself for use as a control. 
The downstream repeat region was chosen initially because of the closer 
proximity of these repeat regions to the ply gene. An EMSA was then conducted 
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using a range of protein concentrations and a fixed DNA concentration of 10nM 
to determine whether the wild type protein would bind to either section of DNA. 
Further details of this method can be found in chapter 2 section 2.3.5.8. 
Results shown in figure 5.16 indicate binding of the UvrD-like protein to the 
intergenic region containing BOX repeats downstream of ply at the lower protein 
concentrations of 31.25nM and 62.5nM, as demonstrated by a shift in size of the 
DNA band at these concentrations, to which protein is bound. High-affinity 
binding is visualised by a distinct, clear band at a higher position on the gel than 
the no protein control, while smeary bands indicate non-specific binding, as is 
observed at higher protein concentrations and for the ply region of DNA. 
 
Figure 5.16. EMSA showing high-affinity binding of the UvrD-like protein to the 
intergenic region containing BOX repeats. A range of protein concentrations from 0-
1µM were used initially to determine at what concentration range, if any, the protein 
would bind to DNA. Results show high-affinity binding of the protein to the intergenic 
region downstream of ply containing BOX repeats, at a concentration range of 31.25-
62.5nM protein, as demonstrated by the presence of a distinct band of bigger size than 
the no protein control at these concentrations. 
 
To further clarify this result, the EMSA was repeated with a smaller, more 
focused range of protein concentrations and a lower concentration of DNA (5nM 
compared to 10nM in the previous experiment). Figure 5.17 shows a clear shift of 
the intergenic region containing BOX repeats at all concentrations, but most 
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distinctly at concentrations of 2.5-10nM protein, while the ply control shows non-
specific shifting from 20-80nM protein. 
 
Figure 5.17. EMSA repeat using lower range of protein concentrations. Results 
demonstrate clear, specific binding of the UvrD-like protein to the region of DNA 
containing BOX repeats, while there is mostly no binding or some non-specific binding of 
the protein to the ply DNA. 
 
Results of these EMSAs show high-affinity binding of the UvrD-like protein to the 
intergenic region downstream of ply containing BOX repeats. However, the 
concentration of DNA used in both experiments (10nM and 5nM respectively) 
was higher than the lowest concentration of protein used (2.5nM). This means 
the protein is saturated at this point, and as such substrate binding at this 
concentration cannot be accurately determined. To address this, DNA was 
radiolabelled with phosphorous-32 and the EMSA repeated, such that a DNA 
concentration of 2nM could be used to obtain an accurate picture of substrate 
binding at the lowest protein concentration of 2.5nM. For this assay, an 882bp 
region of DNA was included from the region 2,758bp upstream of ply which also 
contains BOX repeats. The up- and down-stream BOX repeat regions used as 
substrates here correspond to the regions either side of the ply operon, as 
annotated in strain D39V in the online programme PneumoBrowse (Slager et al., 
2018). Figure 5.18 shows the result of the first of two repeats of this assay using 




Figure 5.18. EMSA repeat using 2nM DNA labelled with phosphorous-32. 882bp 
regions of DNA from the ply gene, the BOX repeat region downstream of ply and an 
additional BOX repeat region upstream of ply were radiolabelled and added to a final 
concentration of 2nM in this EMSA repeat. Protein concentrations were 0, 2.5, 5, 10, 20, 
40 and 80nM.  
 
Following a second repeat of this assay, disappearance of the lowest band 
(corresponding to the size of the no protein control) as protein concentration 
increases was quantified using ImageJ and converted to represent percentage 
substrate to which the protein is bound. The bands which were quantified are 
indicated by the red rectangle in the inset image of figure 5.19. This data is then 
presented in figure 5.19 as a substrate binding curve from 0-20nM protein, at 
which point 99-100% of each substrate is bound to the protein. 
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Figure 5.19. Substrate binding curves. Percentage substrate binding for each region of 
DNA was quantified by measuring the reduction in intensity of the bands corresponding in 
size to the no protein control, as indicated in the inset figure here. This measurement was 
then converted to represent the percentage of substrate bound to the protein. Data is 
shown for protein concentrations from 0-20nM, as 99-100% of each substrate was bound 
to the protein at a concentration of 20nM.  
 
These results demonstrate a physical interaction between the UvrD-like protein 
encoded by SPN23F12470 and regions of the genome either side of the ply 
operon that contain BOX repeats, suggesting that it may be through interactions 
with these repeat regions that the UvrD-like protein exerts its effect on 
transcription of the ply gene.  
 
5.2.9 The ICESp23FST81 element is present in higher 
quantities in circularised form in the ΔSPN23F12470 mutant 
After demonstrating a physical interaction between the UvrD-like protein encoded 
by SPN23F12470 and regions of the genome neighbouring the ply gene 
containing BOX repeats, it was observed (using the FM211187.1 annotation of 
the genome on the National Centre for Biotechnology Information website) that 
BOX repeat regions are present two genes upstream of the rplL gene at the end 
of the ICESp23FST81 element. It was therefore hypothesised that the UvrD-like 
protein could be involved in mobilisation of the ICESp23FST81 element via an 
interaction with these BOX repeat regions. To test this hypothesis, PCR was 
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conducted to the junction of the circularised form of the element where the two 
linear ends join, using a forward primer for gene SPN23F12410 and a reverse 
primer for gene SPN23F13160 as shown in figure 5.20 below (see chapter 2, 










Figure 5.20. Primers used to amplify circularised ICESp23FST81. A forward primer 
for gene SPN23F12410 was used along with a reverse primer for gene SPN23F13160 to 
amplify the junction where the two linear ends of ICESp23FST81 join.  
 
Sequencing of this PCR product for the junction of the circularised 
ICESp23FST81 element (extracted from the ATCC 700669 SPN23F wild type) 
where the two linear ends meet revealed that it starts within an intergenic region 
at the 3’ end of gene SPN23F12410, which is 6 genes distant from 
SPN23F12470, and ends 9 base pairs into the 3’ end of the rplL gene, which is 
70 genes distant from SPN23F12470. Figure 5.21 below shows the sequence 
where the two linear ends join. 
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Figure 5.21. Sequencing results for the region where the linear ends of 
ICESp23FST81 join. Sequencing of the junction of the circularised ICESp23FST81 
element shows the two linear ends join at an intergenic region 57 bases downstream of 
the 3’ end of the SPN23F12410 gene and 9 bases into the 3’ end of the rplL gene. 
 
After establishing that the circularised form of the element was present in both 
the wild type ATCC 700669 (SPN23F) strain and the ΔSPN23F12470 mutant, 
PCR was conducted on three separate plasmid extractions from each strain to 
determine whether there was a difference in quantity of the circularised element. 
DNA concentration was standardised such that the final concentration in each 
PCR reaction was 20ng. Figure 5.22 shows consistently higher quantities of the 
circularised form of this ICESp23FST81 element in the ΔSPN23F12470 mutant 




Figure 5.22. PCR to detect the circularised form of ICESp23FST81. Circularised 
ICESp23FST81 is present in higher quantities in the ΔSPN23F12470 mutant, as 
demonstrated by PCR to the junction where the two linear ends of the element join, using 
plasmid extractions from three biological repeats for each strain. 
 
These results suggest that the circularised form of the ICESp23FST81 element is 
present in higher quantities in the ΔSPN23F12470 mutant compared to the 
isogenic wild type; this could be either due to increased excision of the ICE 
element from the chromosome in the mutant or decreased uptake of the 
circularised element into the chromosome of the mutant.  
5.3 Discussion 
Results presented here demonstrate a clear link between activity of the UvrD-like 
protein encoded by the SPN23F12470 gene and production of the pneumolysin 
toxin of S. pneumoniae in strain ATCC 700669 (SPN23F). Toxicity assays show 
a significant reduction in in vitro toxicity of the ΔSPN23F12470 mutant compared 
to its isogenic wild type and Western blotting confirms reduced production of the 
pneumolysin protein. Autolytic activity of the mutant was assayed in comparison 
to the isogenic wild type and an autolysis-deficient strain, confirming that loss of 
toxicity in the mutant was not related to a deficiency in autolytic activity, which is 
corroborated by qRT-PCR data to the major autolysin gene lytA. qRT-PCR data 
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further demonstrates that the loss in production of pneumolysin is due to a 
reduction in transcript expression of the ply gene in ΔSPN23F12470. Up-
regulation of the comA gene is also shown through qRT-PCR, implying an 
increase in expression of competence machinery in ΔSPN23F12470, although 
this has not been confirmed phenotypically.  
Analysis of the UvrD-like protein encoded by SPN23F12470 revealed that the 
gene encodes a DNA helicase domain homologous to the uvrD gene found in E. 
coli, with two tandem repeat active nuclease domains at the N-terminus with 
homology to the Cas4 nuclease of the CRISPR-Cas system. From 
communication with collaborator Mark Dillingham at the University of Bristol, it 
was suggested that the SNP change observed in clinical strain McGeeDG104 
from leucine to phenylalanine (table 5.1) is within a highly conserved locus, 
positioned just outside the amino acid region which would normally be defined as 
helicase motif VI, which is important for ATP hydrolysis and coupling hydrolysis to 
DNA translocation. The change from aspartate to asparagine in strain 
McGee1789 is suggested to occur within a somewhat conserved region close to 
helicase motif IV, but asparagine can be found at this locus in some cases 
anyway. The change from alanine to threonine in strain HKP1 takes place in an 
insert region that is only present in extremely similar proteins, so the level of 
conservation of this sequence cannot be established. The change from threonine 
to methionine in strains 11923, 11919 and 11924 is within a poorly conserved 
locus, but is close to the Q motif, otherwise known as motif 0, which is important 
for ATP binding and nucleotide hydrolysis specificity. All these insights have 
come from personal communication with Mark Dillingham, who also suggested 
that it is likely some of these mutations lead to problems in ATPase function.  
However, as shown in figure 5.1, clinical isolates with a polymorphism in the 
SPN23F12470 gene have on average higher toxicity than those with the 
reference SPN23F12470 gene. This could mean that these polymorphisms are 
instead hyper-activating and lead to an improvement in the function of the UvrD-
like protein; toxicity data indicates that in the absence of this protein toxin 
production is significantly reduced, suggesting that it normally serves to promote 
toxin production in the wild type strain. 
Based on the observation of the presence of BOX repeat regions neighbouring 
the ply, lytA and comA genes, for which transcript expression is affected, a 
potential interaction between the UvrD-like protein and regions of the genome 
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containing BOX repeats was investigated, with a specific focus on the ply gene to 
elucidate whether it via this interaction that the UvrD-like protein is exerting its 
effect on toxicity. It was demonstrated that the protein interacts with high affinity 
with the regions either side of ply containing BOX repeat regions. BOX repeat 
regions have been shown in work by Knutsen et al. (2006) to influence 
expression of their neighbouring genes. They are considered parasitic mobile 
genetic elements that appear to have inserted randomly and at regular intervals 
throughout pneumococcal genomes in which they are present (Croucher et al., 
2009). It is also known that BOX repeat regions containing both boxA and boxC 
elements can form secondary stem-loop structures (Knutsen et al., 2006).  
In the wild type strain ATCC 700669 (SPN23F), BOX repeat regions downstream 
of ply are present in the intergenic region between the stop codon of ply and the 
start codon of its downstream neighbour. They are encoded on the lagging strand 
in the same orientation as the two flanking genes and they are in the combination 
AB1CB2. BOX repeats are also found 5-7 genes upstream of the ply gene prior to 
the start of the ply operon (as annotated in strain D39V in the programme 
PneumoBrowse [Slager et al., 2018]).  
Based on the high-affinity binding of the UvrD-like protein to regions of DNA 
containing these BOX repeats, while a control region of the ply gene does not 
show the same degree of affinity, it is possible that in the wild type ATCC 700669 
(SPN23F) strain, the UvrD-like protein serves to unwind and/or degrade the 
secondary structures formed by these repeats through the action of its helicase 
and nuclease domains. This interaction with BOX repeat regions up- and 
downstream of ply could be important for normal expression of the wild type ply 
gene, which could explain how this protein affects toxin production in this S. 
pneumoniae strain.  
To test this hypothesis, further work would be needed to investigate the direct link 
between the UvrD-like protein, the BOX repeat regions and expression of the ply 
gene. This could be done by deleting the BOX repeat regions upstream and 
downstream of ply in the ΔSPN23F12470 mutant. As this mutant contains an 
intact ply gene but lacks the UvrD-like protein, it would be expected that deletion 
of the BOX repeat regions either side of ply would remove this physical block to 
transcription, allowing normal expression of pneumolysin to proceed. Single 
deletions of the upstream and downstream BOX repeat regions could be done 
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alongside a double deletion of both repeat regions to characterise whether one 
region alone or both regions in tandem are affecting transcription of the ply gene. 
Interestingly, a region of BOX repeats is also found upstream of the comA gene, 
for which an increase in transcription is observed in the ΔSPN23F12470 mutant. 
It could be the case that in the wild type strain, SPN23F12470 serves to increase 
expression of the pneumolysin gene through its interaction with the neighbouring 
BOX repeat regions, while simultaneously inhibiting expression of competence 
machinery. The upregulation of competence machinery in ΔSPN23F12470 could 
also be related to the observed increase in mobilisation of the mobile genetic 
element ICESp23FST81, on which the SPN23F12470 gene is located. 
ICESp23FST81 is an integrative conjugative element present in strains of the 
SPN23F ST81 lineage, although it has regions of homology to transposons found 
in other strains. From a clinical perspective, acquisition of this element provides 
several benefits to the host, as it contains both chloramphenicol and tetracycline 
resistance cassettes, and based on the findings presented here, a gene which 
serves to promote pneumolysin production in its host. The absence of any BOX 
repeat regions within the ICESp23FST81 element, in spite of their otherwise 
regular appearance on average every 17.3kb in this strain, implies this element 
integrated into the genome of ATCC 700669 (SPN23F) after the BOX repeat 
regions. Therefore, it is particularly interesting that the ICE element encodes a 
gene which interacts with regions of the genome containing BOX repeats to the 
apparent benefit of the host.  
The presence of higher quantities of circularised ICESp23FST81 element within 
the ΔSPN23F12470 mutant in comparison to the isogenic wild type also implies 
that loss of this gene causes either greater excision of the ICE element from the 
chromosome or reduced ability to reintegrate the element back into the 
chromosome. This could be a direct result of the disruption of the SPN23F12470 
gene, or it could be an indirect consequence whereby loss of SPN23F12470 
affects other genes involved in excision or reintegration of the element into the 
chromosome or its transmission out of the cell.  
Interestingly, recent work from several groups has identified a link between 
CRISPR-Cas systems and bacterial virulence (Louwen et al., 2014; Faure et al., 
2019; Ratner et al., 2019). Clustered regularly interspaced short palindromic 
repeats (CRISPR) and CRISPR-associated (Cas) genes have been identified as 
a bacterial system of adaptive immunity, whereby small CRISPR RNA sequences 
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guide Cas nucleases towards a complementary nucleic acid target sequence of 
invasive genetic elements such as viruses and plasmids. Cas nucleases then 
work to degrade the invading DNA to prevent infection of the chromosome by 
potentially harmful genetic elements. Mobile genetic elements have been shown 
to contribute to the origin and evolution of CRISPR-Cas systems, which are 
thought to have evolved from a specific type of transposon described as a 
‘casposon’, which encodes a transposase enzyme with homology to the Cas1 
nuclease (Faure et al., 2019). Transposase enzymes catalyse the integration of 
mobile genetic elements into the genome, and one of the best characterised 
classes of transposase enzymes is the DD(D/E) transposases, so named based 
on the amino acid residue of their catalytic domain (Faure et al., 2019; Guérillot et 
al., 2014). Examination of the amino acid sequence for the UvrD-like protein 
revealed a highly conserved DDD residue at amino acid positions 388-390, which 
could imply a potential role for this protein as a transposase. Indeed, there is a 
possibility that the nuclease activity of this protein is causing the difficulty in 
complementing the whole gene deletion mutant, as it may be fatal to the E. coli 
host that is used to passage the vector containing the wild type gene. Attempts 
were made to clone the wild type gene directly into the pneumococcus, but these 
were unsuccessful. 
Faure et al. (2019) suggest that the casposon transposase has been co-opted for 
use in bacterial adaptive immunity, and further highlight that some casposons 
encode a Cas4 nuclease, to which the two tandem repeat nuclease domains of 
the UvrD-like protein have homology. It is therefore tempting to speculate that the 
protein encoded by SPN23F12470 is involved in transposition of the 
ICESp23FST81 element, and furthermore that it is involved in mediating the 
effects of the parasitic BOX repeat elements in strain ATCC 700669 (SPN23F) 
through degradation of the secondary structures that they form via the Cas4-like 
nuclease domains. This could be a form of adaptive immunity against these 
invasive genetic elements that have integrated throughout the genome.  
5.3.1 Further work 
Time constraints prevented this work being taken further, however, detailed 
mechanistic characterisation of the link between the UvrD-like protein and 
pneumolysin production could be done by looking in more detail at the 
connection between the protein, the BOX repeat regions and the ply gene. For 
example, it would be interesting to investigate whether the protein is binding BOX 
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repeat regions all over the genome and if this is how it affects, for example, 
competence gene expression. Interactions between the protein and other areas 
of the genome could be investigated using chromatin immunoprecipitation-
sequencing assays (ChIP-seq), in which, briefly, cells containing a tagged UvrD-
like protein would be grown to a desired stage, then the protein and any regions 
of DNA to which is it bound would be extracted and the bound DNA purified and 
sequenced. This would elucidate specific regions of DNA to which the wild type 
UvrD-like protein binds. Further biochemical analysis of the function of the UvrD-
like protein would also help to elucidate whether this protein is in fact acting as a 
transposase comparable to the bacterial CRISPR-Cas adaptive immunity system.  
Complementation of the ΔSPN23F12470 mutant with the wild type 
SPN23F12470 gene has thus far been unsuccessful. Attempts to complement 
the mutant will be continued, to show that toxicity in ΔSPN23F12470 can be 
restored with re-introduction of the wild type gene. Work is ongoing to do this in 
the ΔSPN23F12470 mutant, and in parallel, attempts will be made to introduce 
the wild type SPN23F12470 into strain D39, to see if an increase in toxicity is 
observed in a strain that does not contain this protein, but does contain BOX 
repeats downstream of the ply gene. 
It would also be of interest to further investigate the relationship between the 
UvrD-like protein and competence, with a focus on how the protein affects 
mobilisation of ICESp23FST81. It would be particularly interesting to investigate 
whether there is a direct link between competence and toxicity in this strain which 
is mediated by the UvrD-like protein, since much is known about the relationship 
between competence and autolysis, and likewise autolysis and toxicity. There 
could be a direct link between competence and toxicity, which have thus far been 
indirectly linked via the mechanism of autolysis.  
5.4 Conclusions 
To conclude, loss of the SPN23F12470 gene causes a significant reduction in 
toxicity in S. pneumoniae strain ATCC 700669 (SPN23F) as shown using whole 
cell culture, supernatant and contact-dependent haemolytic activity assays. A 
6.8-fold reduction is observed in transcript expression of the ply gene in the 
ΔSPN23F12470 mutant, causing a significant reduction in pneumolysin 
production which is confirmed by Western blotting. The ΔSPN23F12470 mutant 
is not deficient in autolytic activity, as shown through a phenotypic assay and 
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qRT-PCR, the latter of which also shows that transcript expression of the comA 
gene is increased 4.9-fold. Perhaps related to this, presence of the mobile 
genetic element ICESp23FST81 in circularised form is increased in the 
ΔSPN23F12470 mutant in comparison to its isogenic wild type. These results are 




Figure 5.23. Summary of findings. In the presence of the wild type SPN23F12470 
gene, via interactions with neighbouring BOX repeat regions, transcript expression of 
pneumolysin is upregulated while transcript expression of autolysin and competence 
machinery is downregulated and the ICESp23FST81 element remains more stably 
integrated in the genome. In the absence of the SPN23F12470 gene, toxicity is reduced 
due to downregulation of ply, while transcript expression of autolysin and competence 
machinery is upregulated, and the ICESp23FST81 element is found in its circularised 
form at comparably higher quantities relative to the wild type.  
It is shown that the UvrD-like protein encoded by the SPN23F12470 gene binds 
with high affinity to the intergenic region immediately downstream of ply which 
contains BOX repeats and the region upstream of ply also containing BOX 
repeats. Research by Knutsen et al. (2006) has illustrated that BOX repeat 
regions can affect the transcription of neighbouring genes, and that they form 
stable secondary stem-loop structures. A possible explanation therefore for the 
relationship between the UvrD-like protein encoded by SPN23F12470 and 
toxicity in this strain could be that under normal circumstances the protein 
interacts with the BOX repeat regions neighbouring ply to promote its 
transcription by unwinding and degrading the structures formed by these repeat 
regions. In the absence of this protein, the BOX repeats may form a physical 
block to transcription of ply, preventing successful expression of the gene and 
resulting in the subsequent reduction in toxicity. There is a possibility the UvrD-
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like protein is acting as a form of adaptive immunity against these invasive BOX 
repeat elements that have integrated throughout the pneumococcal genome.  
These results demonstrate the important role mobile genetic elements can play in 
bacterial virulence, and how spread of such elements can have a dramatic effect 
on hosts into which they integrate. Identification of this UvrD-like protein as a 
genetic contributor to toxicity is a novel finding which contributes to the body of 
knowledge regarding the genetic effectors of pneumolysin production in 
Streptococcus pneumoniae. It also demonstrates how the top-down GWAS 
approach to identifying novel effectors of a phenotype can be successful, and 
how this approach can help to expand our knowledge of individual gene function 


















6.  Conclusions 
The overarching aim of this work was to investigate the genetic basis for bacterial 
toxicity using functional genomics. Toxicity is an important aspect of virulence 
which is often responsible for the symptoms of bacterial disease in a patient. It is 
regulated by a complex network of genetic interactions which is not yet fully 
understood. The work presented here has focussed on identifying and 
characterising novel toxicity-affecting loci in two clinically important pathogens; 
Staphylococcus aureus and Streptococcus pneumoniae. By further elucidating 
genetic contributors to the toxic phenotype in these bacteria, this work adds to 
the body of research which looks to better understand a key aspect of bacterial 
virulence. 
In S. aureus, follow-up work was conducted from a prior genome-wide 
association study (GWAS) to characterise the involvement of the cyoE gene in 
staphylococcal toxicity. This identified the protoheme IX farnesyltransferase 
enzyme encoded by cyoE as a critical component in toxicity, without which the 
cell down-regulates TCA cycle activity, respires as if growing in microaerobic 
conditions and reduces toxin production and secretion through down-regulation 
of the global toxicity regulator agr. 
This work has highlighted the important link between bacterial metabolism and 
virulence, demonstrating how disruption of a gene which plays a crucial role in 
electron transport can have a profound downstream effect on the energetically 
costly process of toxin production. The fact that single nucleotide polymorphisms 
in the cyoE gene in clinical S. aureus strains exhibit reduced toxicity also 
corroborates the importance of metabolic processes to toxin production in vivo. 
As such, identification of genes such as cyoE and its resulting protein product 
protoheme IX farnesyltransferase, which is not in itself a virulence factor yet 
contributes to the phenotype, may provide an avenue for the development of 
future therapies against S. aureus.  
Following the successful identification of a novel toxicity-associated gene in S. 
aureus, the functional genomics approach was applied to a collection of clinical 
S. pneumoniae isolates. In this work, three different genome-wide association 
methods were applied to the same dataset to aid prioritisation of genes for further 
investigation. Of a total of 181 genes and intergenic regions that were identified 
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by the three methods, 8 genes were identified by more than one method. Due to 
difficulties encountered in the mutant construction process, functional verification 
was not possible for each of these 8 genes, however, 2 were identified as false 
positive associations; priA and trcF. A further 6 genes which were each identified 
by only one GWAS method were also identified as false positive associations.  
However, despite the small number of individual loci which were identified by 
more than one method as significantly associated with toxicity, neighbouring 
genes within clusters of the genome were picked up by combinations of the three 
different methods. For example, the SNP-based GWAS method and Bugwas 
identified genes in the region from agaD to clpL as significant associations, while 
the SNP-based method and SEER overlapped in identification of genes on the 
ICESp23FST81 element, and all three methods identified genes around the priA 
locus.  
Problems encountered with the process of functional verification, due in part to 
the background strain chosen for mutant construction, have limited the extent to 
which loci can be verified as false positive or true positive associations with the 
phenotype. Therefore, firm conclusions as to which method, or combination of 
methods, is most accurate in predicting genetic associations with toxicity cannot 
be drawn at this stage. Differences in the initial data filtration steps, controlling of 
population structure, and significance thresholds are likely to account for the 
differences in results obtained by the three methods, however it is particularly 
interesting that no single gene has been identified as a significant association 
with toxicity by all three methods.  
Nonetheless, one gene was confirmed to be a true association with 
pneumococcal toxicity; this was the SPN23F12470 gene, encoding a UvrD-like 
protein with one helicase and two tandem-repeat nuclease domains. Further 
investigation of the contribution of this protein to toxicity has illustrated its 
importance in transcription of the pneumolysin gene and has suggested a role for 
the protein in competence and mobilisation of ICESp23FST81 in strain ATCC 
700669 (SPN23F). Initial data implies a physical interaction between the UvrD-
like protein and the BOX repeat regions neighbouring the pneumolysin gene 
which may be affecting expression of the toxin. In the absence of the UvrD-like 
protein, these BOX repeat regions may form a physical block to transcription of 
the operon on which ply is encoded, which would otherwise be unwound and 
degraded through the action of SPN23F12470.  
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Investigation of the differences in quantity of circularised ICESp23FST81 
between the wild type strain and the ΔSPN23F12470 mutant demonstrate a 
higher quantity of the circularised mobile genetic element in ΔSPN23F12470, 
suggesting either increased excision of the element in the mutant or reduced re-
integration into the chromosome. This observation, in combination with both the 
observed interaction of the UvrD-like protein and the BOX repeat regions 
neighbouring ply and the homology of its two tandem repeat nuclease domains 
with Cas4 proteins, could imply a role for SPN23F12470 similar to the CRISPR-
Cas system of bacterial adaptive immunity. The UvrD-like protein could be using 
BOX repeat regions to guide its activity of unwinding and degrading target 
sections of DNA. It could also be important in this capacity for transposition of the 
ICESp23FST81 element either out of or into the host chromosome, in which case 
this protein may be important in mediating transmission of ICESp23FST81 
between hosts.  
Given the observed positive effect of the UvrD-like protein on toxin expression, 
and therefore virulence, in the wild type strain ATCC 700669 (SPN23F), it is 
interesting that the ICESp23FST81 element on which this protein is located has 
not propagated throughout other pneumococcal lineages; perhaps there is a 
fitness cost to incorporation of this element into the host genome. It is also 
interesting that SPN23F12470 is shown here to interact with regions of the 
genome containing BOX repeats, which integrated into the chromosome prior to 
the integration of ICESp23FST81. Furthermore, whilst interactions with specific 
regions containing BOX repeats neighbouring ply are investigated here, it would 
be of interest to investigate whether the UvrD-like protein also interacts with BOX 
repeat regions throughout the genome of this strain to mediate other aspects of 
bacterial behaviour.  
Both S. aureus and S. pneumoniae are commensal organisms with the ability to 
transition to opportunistic pathogens within the human host. Whilst the genes 
encoding specific toxins produced by these two organisms have been 
characterised, the work presented here illustrates how complex the genetic 
regulation of toxicity can be, with identification of a metabolic gene in S. aureus 
and a gene encoded on a mobile-genetic element in S. pneumoniae which have 
both been observed to significantly impact toxin production when disrupted. 
Despite the stark differences in the number of different toxins employed by these 
bacteria, this work has emphasised that regardless of species, toxin production in 
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bacteria is affected by a wide-ranging network of genetic contributors for which 
our understanding is very much incomplete.  
The functional genomics approach used to investigate the genetic basis for toxin 
production, whilst it has limitations, has proven successful in identification of a 
novel effector of toxicity in both species studied here. Without the statistical 
associations made in the GWAS analyses used, both the cyoE and 
SPN23F12470 loci may have gone unnoticed as significant contributors to the 
toxic phenotype. Furthermore, this approach is useful in the first instance to 
establish which genes are involved in bacterial toxicity, but it is also useful to 
understand how SNP changes in these genes in clinical isolates can impact toxin 
production in vivo. Understanding the impact these loci have on toxicity in 
isolates causing disease may allow for better interpretation of genetic information 
should it ever come to be used in diagnosis of bacterial infections. For example, 
the ability to predict the likely severity of disease caused by an infecting isolate 
will allow for tailored treatment to the needs of the individual patient. 
The use of three different GWAS methods on the same dataset showed that, 
unexpectedly, there was very little crossover of loci that were identified as 
statistically significantly associated with toxicity between the three methods. Due 
to the small number of results that could be functionally verified it is not possible 
at this stage to say whether one method is more accurate in its prediction of 
toxicity-associated loci than the other two. Nonetheless, this approach led to the 
identification of a second novel association with toxicity; the SPN23F12470 gene. 
Whilst this gene is annotated as a putative DNA helicase II with homology to 
UvrD, the results presented here suggest that this is not a complete picture of the 
protein’s function. Work is ongoing to elucidate this function, with a specific focus 
on the role of the protein in pneumococcal toxicity, which like cyoE, had not been 
previously identified.  
In the long term, it is hoped that research such as this will collectively lead to 
improved prevention and treatment of disease caused by S. aureus and S. 
pneumoniae through a better understanding of pathogenesis in these bacteria. 
With the substantial advances made in genome sequencing technology over 
recent years, and the increased availability of genome sequence data, work such 
as this demonstrates how a genomic approach can be used to study one of the 




I.I Primers used to construct whole gene deletion mutants in the 
background strain ATCC 700669 (SPN23F): 
Primer Sequence Tm 
ply F1 CCCTTGCTCTGGTTAAAAAAAGAAGC 61.6 
ply R1 ATATTTTTGTTCATATTTGCCATCTTCTACC 60.2 
ply F2 GGTAGAAGATGGCAAATATGAACAAAAATATAAAA 61.3 
ply R2 CTACCTGAGGTTATTTCCTCCCGTT 63 
ply F3 GAGGAAATAACCTCAGGTAGAAGATAAG 62.2 
ply R3 GATCACCTTTTTTAGCTGCTACATAG 60.1 
nanA F1  CTAATTTAGAGAATGAAATATAGAG 53.1 
nanA R1 ATTTTTGTTCATCAGATTTCTCCTTTATATTG 59.2 
nanA F2 GAAATCTGATGAACAAAAATATAAAATATTCTC 58.3 
nanA R2 TATTTATTATTATTTCCTCCCGTTAAATAATAG 58.3 
nanA F3 GAGGAAATAATAATAAATAAAATCAATATG 54.5 
nanA R3  ATGCAATAAAGTACATAAAGATTTG 53.1 
priA F1 CTGGTCCTTCAGGGGTTGGAAAAGG 66.3 
priA R1 ATTTTTGTTCATTAGGGCCATCGTCTCAC 63.9 
priA F2 GATGGCCCTAATGAACAAAAATATAAAATATTC 60.8 
priA R2 CATGGTCAATGCTTTATTTCCTCCCGTTA 63.9 
priA F3 GAGGAAATAAAGCATTGACCATGAGCCGC 66.7 
priA R3 CACAAAAACATCCTCTAGCACTGCTAGAG 65.3 
SPN23F12470 F1 TGCCCACTATTTTTATCTAGTTGCTTACC 62.4 
SPN23F12470 R1 ATTTTTGTTCATTGTTGTCATCGTTTTACCTC 61.8 
SPN23F12470 F2 CGATGACAACAATGAACAAAAATATAA 55.9 
SPN23F12470 R2 CTTTTCCGGATTCTTATTTCCTCCC 61.3 
SPN23F12470 F3 GGAGGAAATAAGAATCCGGAAAAG 59.3 
SPN23F12470 R3 AATTAATTCCTGAATACAAGTTAACAAAATAG 58 
SPN23F01610 F1 ATCACAGCGGTTAAGGATGTGAC 60.6 
SPN23F01610 R1 ATTTTTGTTCATTGATTCCATCTTACTGTAC 60.2 
SPN23F01610 F2 GATGGAATCAATGAACAAAAATATAAAATATTCTC 60.1 
SPN23F01610 R2 GTCAAGAAATCTTATTTCCTCCCGT 59.7 
SPN23F01610 F3 GGGAGGAAATAAGATTTCTTGACTAAG 60.4 
SPN23F01610 R3 ACCATAGGTCAAAACTAGACCCAC 61 
SPN23F01620 F1 TAAAGTATTTAT AGA TTC CCT CAA TAC GAG 59.9 




SPN23F01620 R2 TTACTCAAGGCTTATTTCCTCCCG 61 
SPN23F01620 F3 GGGAGGAAATAAGCCTTGAGTAAAA 59.7 
SPN23F01620 R3 CGAGAAGCAAGAAATCGTGGAAC 60.6 
SPN23F02870 F1 GCGTTGCTCCGGTATGACG 61 
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SPN23F02870 R2 CATTTCCAACAATTATTTCCTCCCG 59.7 
SPN23F02870 F3 GGAGGAAATAATTGTTGGAAATGATATTTAC 60.2 
SPN23F02870 R3 GTCATATAATGGTTTAATAAAAATCCTGATAAAAC 60.1 










SPN23F15290 F3 AACGGGAGGAAATAAGTAGAGCCAGATGGC 68.1 
SPN23F15290 R3 TCAAGGTATCCATCATTCCTCAATCTATATAAC 63.3 
SPN23F12470 

















trcF F1 CTGAATTGGATGATGAAGATAAAAAAGAGTT 60.2 
trcF R1 ATTTTTGTTCATGGTCACCATTTATCCG 60.7 
trcF F2 TAAATGGTGACCATGAACAAAAATATAAAATATTC 60.1 
trcF R2 CTTAAACTCTTTTATTTATTTCCTCCCGTTAA 60.5 
trcF F3 GGAGGAAATAAATAAAAGAGTTTAAGGAAG 59.9 
trcF R3 AATCTTCATTCGCATAAACAGGAACC 60.1 







gidB R2 CATACCAGCCTTTTATTTCCTCCCGTTAAATAATAG 66 
gidB F3 GGGAGGAAATAAAAGGCTGGTATGCCAAATAAAC 67.1 
gidB R3 ACCAGTTGGCTTTAAGAACTGGTGTAAAGTC 65.5 
 
**The ΔSPN23F12470 mutant was reconstructed with the spectinomycin resistance 





I.II Primers used to verify successful mutant construction: 
Primer name Sequence Tm 
ply FW GCAGTAAATGACTTTATACTAGCTATGATAAAC 62 
ply RV GAGAGTTGTTCCCCAAATAGAAATCG 61.6 
ply mutant check FW ATCTCTTCAAAAGTGGTACGCTGAACACTAAC 65.6 
ply mutant check RV GTGTTCGGTGAATATCCAAGGTACGCTTG 66.7 
nanA FW ATGAAAGATTTAACTAAATACAAAGGCG 57.8 
nanA RV TTATAAAAATTCTTTTCGTGCTTGTTG 55.9 
nanA mutant check 
FW 
TCTTGCGCAATGAAGCTCATCTTTCCCTTTG 66.8 
nanA mutant check 
RV 
GTGTTCGGTGAATATCCAAGGTACGCTTG 66.7 
priA FW GCTAAGATTATCGTAGATGTGCCCTTGATG 65.4 
priA RV GAGTCAAGGCCAAGACCTGGTTGAGGGTC 70.9 
priA mutant check FW GTCGATGTGATTATCGACGATACACCAG 65.1 
priA mutant check RV GTGTTCGGTGAATATCCAAGGTACGCTTG 66.7 
SPN23F12470 FW GATTTTAAAACTTTATTTAAAGAAGAATATG 54.9 









SPN23F01610 FW GATTCAAACCTATTTACCAAATGTCTAT 57.8 







SPN23F01620 FW ATCTATCTTAACTACACTGCTTTTTGCAG 61 







SPN23F02870 FW GGGAGAGTTTTATCGAATCTCTG 58.9 







SPN23F15290 FW TCGATAGAAACAGACTACGTACAGGCTTG 65.3 
















mutant check FW 
ATAAAAGAGCAACAAACTTTACAAATCTAC 58.6 
SPN23F12470 (aad9) 
mutant check RV 
GAATATCAGGTAGTAATTCCTCTAAGTC 60.7 
trcF FW ATGGTGACCTTATTAGATTTATTCTCAG 59.3 
trcF RV TCAAATGGAATTTTCTTCCTTAAACTCTTTTATC 61 
trcF mutant check FW ATCACACGCTTGTACAATCAAGTCGACTGG 66.8 
trcF mutant check RV GTGTTCGGTGAATATCCAAGGTACGCTTG 66.7 
gidB FW CATTTTACAACTTGCTTGCCGAGCAGAATC 65.4 
gidB RV CCACTGTGATATAGCGCGGATCTCTATTC 66.7 
gidB mutant check 
FW 
AGTCTCAATTTCAGTTATCCAGAAATGCAGCATC 65.9 
gidB mutant check RV GTGTTCGGTGAATATCCAAGGTACGCTTG 66.7 
 
Primers designated *gene_name FW/RV* are to amplify the wild type allele of the 
corresponding gene. 
Primers designated *gene_name mutant check FW/RV* are to amplify the region 
from 1kb upstream of the transformed 3kb insert to within the antibiotic resistance 
cassette. 
ply FW and RV primers to the wild type ply gene were used for all mutants, 
except Δply, to verify that the mutant was S. pneumoniae and not a 
contaminating organism. For the Δply mutant primers were used for the 
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